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Androgens are steroid hormones that have sex-specific effects on regulation of metabolic and 
reproductive physiology. Androgens primarily act upon nuclear hormone receptors, including 
androgen receptors (AR), or estrogen receptors (ERs) after conversion to estradiol by aromatase. 
Adult males typically have higher levels of circulating androgens. However, imbalance of 
androgens outside the homeostatic range has both reproductive and metabolic deficits for both 
sexes. For example, hypoandrogenism in males and hyperandrogenism in females can result in 
infertility, obesity, and increased risk of diabetes. While many tissues express AR and are sensitive 
to the effects of androgens, the brain is a key androgen responsive organ. In adults, AR is expressed 
in many brain regions, including those that are involved in regulation of reproduction, metabolism, 
behavior, cognition, mood, and autonomic processes. Yet, characterization of AR expression has 
been lacking in the female and prepubertal brain. Here, we present a comprehensive 
neuroanatomical characterization of Ar mRNA expression in the mouse brain of both sexes, and 
compare adult and prepubertal expression. We found that expression of Ar undergoes dynamic 
change during a critical window of prepubertal development in male and female mice. 
Furthermore, we describe brain regions that may preferentially respond to androgens, rather than 
estrogens. For example, the ventral premammillary nucleus (PMv) shows dense expression of AR-
immunoreactivity in both sexes, yet it is relatively low in ERs and aromatase. To identify neuronal 
populations that are targets of androgen action, we compared areas of dense AR expression, 
including the PMv and arcuate nucleus (ARH), with known neuronal populations in these nuclei. 
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AR was found to be coexpressed in PMv and ARH leptin receptor (LepRb) neurons, which are 
crucial in regulation of energy homeostasis and exert permissive effects on fertility. We 
hypothesized that androgens acting via AR in LepRb cells contribute to the regulation of 
reproduction and metabolism at the hypothalamic level, and that loss of AR from LepRb cells 
would disrupt reproductive and metabolic homeostasis. We found that deletion of AR from LepRb 
cells (LepRbΔAR) results in sex-specific changes in the neuroendocrine reproductive axis, 
locomotor activity, and body composition. We observed that loss of negative feedback actions of 
sex steroids induces an exaggerated rise in luteinizing hormone in LepRbΔAR male mice and in 
follicle stimulating hormone in LepRbΔAR female mice. Furthermore, female LepRbΔAR mice show 
increased lean mass, while male LepRbΔAR mice display increased ambulatory activity. 
Subsequently, we tested if deletion of AR from LepRb neurons would protect female mice from 
hyperandrogenism-induced reproductive deficits. Female mice exposed to androgen excess during 
late prenatal development exhibit disrupted estrous cycles, infertility, and mild metabolic changes 
during adulthood. This phenotype replicates many features of polycystic ovary syndrome (PCOS), 
which is also partly characterized by androgen excess. We found that female mice with deletion 
of AR in LepRb neurons had improved estrous cycles with prenatal androgenization compared to 
their AR-intact littermates. Our findings highlight that LepRb neurons represent an important 
target of androgen action in the brain, and contribute to sex-specific differences in the 
neuroendocrine reproductive axis and some aspects of metabolic regulation. Furthermore, LepRb 
neurons may be involved in the pathogenesis of PCOS. These studies further elucidate the specific 
targets of androgens in the brain, and open the possibility of additional mechanistic study into the 













Biology of androgens   
Androgens are a class of steroid hormones that are traditionally known for their role as male sex 
hormones which promote male traits, including development of male reproductive organs, 
secondary sex characteristics, and reproductive physiology. However, a contemporary 
understanding of androgens includes important roles in female physiology as well. Hormones 
classified as androgens include testosterone (T) and dihydrotestosterone (DHT), while 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), and 
androstenedione (A4) are considered as androgenic pro-hormones. The predominant circulating 
androgen in males is testosterone (T), which is primarily produced in Leydig cells. Testicular T 
production is responsible for relatively higher levels of circulating androgens in males compared 
to females.  
 
Androgens are also produced by the ovary and adrenal gland (1). Ovarian androgens are 
synthesized by theca cells, with A4 and T serving as precursors for estrogen synthesis in granulosa 
cells (17β-estradiol, or E2, and estrone, or E1)(2). In humans, the adrenal gland is responsible for 
production of androgenic precursors, including DHEA, DHEA-S, and A4, with minor production 
of T and 11-oxyandrogens (11-OH-testosterone and 11-OH-androstenedione)(3,4). Peripheral 
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tissues also contribute to androgen synthesis. For example, adipose tissue expresses steroidogenic 
enzymes capable of steroid conversion, androgen synthesis, and inactivation (5,6).  
 
Androgens in circulation 
Androgens in circulation are primarily bound to sex-hormone binding globulin (SHBG), which in 
humans, is primarily produced by the liver (7,8). A majority of T and DHT are transported while 
bound to SHBG (~45-80%), which binds testosterone with high affinity, albeit at low capacity. A 
smaller fraction of T is bound to lower affinity, but higher capacity, serum proteins, including 
albumin, corticosteroid-binding globulin, and orosomucoid (9-11). The rodent liver does not 
produce SHBG past the prenatal period, however, androgen binding protein (ABP), an SHBG 
homologue, is produced by the testes (12,13). Only approximately 1-2% of T in circulation remains 
unbound (9,10). It has been traditionally thought that when bound to carrier proteins in circulation, 
androgens are unable to exert biologic effects via hormone receptors, and were considered 
biologically inactive. This so called “free hormone hypothesis” predicted that once reaching target 
tissues, T would dissociate from binding proteins, and become bioavailable for binding to receptors 
or enzymes for conversion (14,15). However, this hypothesis is disputed. Multiple mechanisms of 
bound-T uptake and intracellular signaling have been described (11). SHBG-bound T can be 
internalized via endocytosis mediated by membrane proteins such as megalin. Upon 
internalization, vesicles containing SHBG-bound T fuse with lysosomes, and T dissociates from 
SHBG. Free T can then diffuse to the cytoplasm, and interact with androgen receptors (AR) 
(16,17). In addition to hormone binding sites, SHBG has a binding site that interacts with 
membrane SHBG-receptors. The ligand-bound SHBG and membrane receptor complex can then 
activate G-protein coupled intracellular signaling (18,19). Additionally, extracellular matrix 
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associated proteins, including fibulins, can interact with ligand-bound SHBG. Matrix proteins may 
provide scaffolding to facilitate interaction with other membrane receptors, or may sequester 
ligand-bound SHBG extracellularly (20). Each of these mechanisms provides additional 
complexity to regulate tissue access to androgens and their bioavailability to AR.  
 
Levels of circulating androgens are dependent on sex and age. Following testis differentiation and 
maturation in fetal humans, T peaks at 11-17 gestational weeks, then decreases until term (21). 
Following birth, males experience a surge in luteinizing hormone (LH) which triggers a peak in T 
lasting up to 12 hours in humans (22). The post-natal hypothalamic-pituitary-gonadal (HPG) axis 
is transiently reactivated during a short period of time called the “mini-puberty of infancy”, that 
occurs following the removal and inhibitory actions of placental and maternal hormones with birth. 
Increasing gonadotropin releasing hormone (GnRH) from the hypothalamus results in raised LH, 
leading to elevated T in male infants between 1 and 3 months of age (23,24). The HPG axis remains 
quiescent in both sexes through the rest of childhood, until the pubertal transition begins. In 
humans, circulating T typically reaches adult levels in males by Tanner stage IV or V (25,26), 
while in adult females, T will remain only a fraction of male levels (adult male range ~222-848 
ng/dL total T, adult female T range ~3-52 ng/dL total T) (27,28). Small but significant rises in T 
have been detected during the mid-follicular and luteal phases of the ovarian cycle (29,30). Male 
total and free T decline progressively with age (31,32), and lower levels of T are observed post-
menopause (30,33) 
 
Steroidogenesis of androgens  
Androgens, like other steroid hormones, consist of a four ring, carbon structure backbone derived 
from cholesterol. Cholesterol is intracellularly synthesized via acetate, stored in intracellular lipid 
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droplets, or is taken up by circulating lipoproteins (34). Free cholesterol is transported between the 
outer and inner mitochondrial membranes by steroid acute regulatory protein (StAR). Cholesterol 
side-chain cleavage enzyme (cytochrome P450 side-chain cleavage enzyme 11a, CYP11A) 
converts cholesterol to pregnenolone in the first and rate-limiting step of steroidogenesis (35). 
Pregnenolone is then released to the smooth endoplasmic reticulum to undergo 17α-hydroxylation 
via 17α-hydroxylase (cytochrome P450c17, CYP17, also performs 17,20 lyase activity) to form 
17α-hydroxypregnenolone. CYP17 then converts 17α-hydroxypregnenolone to DHEA, which is 
then converted to androstenediol (A5) via 17β-hydroxysteroid dehydrogenase (17βHSD), and 
finally from A5 to T via 3β-hydroxysteroid dehydrogenase (3βHSD) (36). T is primarily 
synthesized via the so called Δ5 pathway (Δ5 indicating the double bond at carbon 5 in 
pregnenolone, 17α-hydroxypregnenolone, DHEA, and A5). Alternatively, T may be synthesized 
via the Δ4 pathway, which proceeds from pregnenolone being converted to progesterone via 3β-
hydroxysteroid dehydrogenase (3βHSD). Progesterone is subsequently converted to 17α-
hydroxyprogesterone, then to androstenedione (A4) via 17α-hydroxylase/17,20-lyase. A4 is then 
converted to T via 17βHSD (Figure 1.1).  
 
Differences in expression of steroidogenic enzymes in endocrine tissues results in diverse 
production of hormones, including androgens. A good example is the adrenal gland, where in 
humans, only the zona reticularis is capable of producing androgenic precursors (DHEA and 
DHEA-S) (37). The zona glomerulosa does not express CYP17 (17α-hydroxylase/17,20-lyase), so 
steroidogenesis proceeds towards corticosteroid and aldosterone production. The zona fasciculata 
expresses CYP17, but has little 17,20-lyase activity, so progesterone and 17-hydroxyprogesterone 
are shuttled toward corticosteroid production rather than producing DHEA. The zona reticularis 




Figure 1.1: Steroidogenesis of Androgens. Synthesis of androgens by key steroidogenic enzymes, 
beginning with cholesterol. 
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DHEA. Due to low 3βHSD expression, only small amounts of A4 and T are synthesized by the 
zona reticularis (35). 
 
Intermediate hormones in the synthesis of T, such as DHEA, have weak androgenic effects and 
binding to androgen receptors (AR). They are therefore better considered as pro-androgens or 
androgenic precursors rather than “weak androgens” (37). Notably, the adrenal gland of mice and 
rats does not express CYP17, and therefore is not capable of producing adrenal androgens (38). 
 
The gonads in mice and rats are the main organ responsible for production of bioactive androgens, 
such as T and A4. In the testis, 3βHSD and 17βHSD are highly expressed in Leydig cells, ensuring 
that available DHEA is converted to A4 and T (35). Ovarian androgen production occurs primarily 
in theca cells, which express all enzymes needed to complete steroidogenesis up to T (1,39). Theca 
steroidogenic enzymes are regulated via LH, which upon binding to its receptor, initiates a G-
protein coupled signal transduction cascade that stimulates CYP11A, CYP17, 3βHSD, and 
17βHSD expression (40-43). Theca cells produce A4 and T, which are used as estrogen precursors 
by granulosa cells (44). This reaction is catalyzed by the enzyme aromatase (cytochrome P450aro, 
CYP19A1), which eliminates the methyl group (carbon #19, thus forming 18-carbon estrogens) 
and aromatizes the A ring (45) (Figure 1.2). Aromatase in the granulosa cell is under regulation of 
follicle-stimulating hormone (FSH) (46,47), and converts T to E2 and A4 to E1. Other tissues also 
express aromatase, including the placenta, certain brain regions, adipose tissue, and bone (48).  
 
T can be further metabolized to the highly potent androgen DHT via 5α-reductase (5α-R) (Figure 
1.2). Three isozymes of 5α-R have been described, each transcribed by three separate genes, i.e., 
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type I 5α-reductase encoded by SRD5A1, type II 5α-reductase by SRD5A2, and type III by SRD5A3 
(49). Tissue expression of each isozyme differs. Type I 5α-R is mostly expressed in the liver, skin 
(scalp, torso, sebaceous glands), adrenal gland, and kidney, and type II 5α-R is expressed in 
reproductive tissues (prostate, seminal vesicles, epididymis, testes), skin (face, chest, external 
genitalia), liver and hair follicles (50). Type III 5α-R has a more ubiquitous expression pattern in 
a wider variety of tissues, but it rather participates in lipid metabolism, not steroidogenesis (51). 
DHT is primarily an intracellular metabolite and does not widely circulate in blood. Although, 
high production of DHT in tissues such as prostate can lead to spillover of DHT into circulation. 
A key feature of DHT is its inability to be aromatized to estradiol. However, DHT can be converted 
to estrogenic metabolites, including 3β-androstanediol (3β-diol) via 3βHSD and 3α-androstanediol 
(3α-diol) via 3αHSD (52,53). Notably, DHT is a potent androgen and binds with high affinity to 
androgen receptors. 
 
Figure 1.2: Amplification and Diversification of Testosterone. Conversion of testosterone to 
dihydrotestosterone via 5-alpha-reductase (5α-reductase) to amplify androgenic signaling via androgen 






Androgens exert biologic actions by binding to either androgen receptors (AR) or to estrogen 
receptors (ERs) after aromatization. AR belongs to a super family of steroid hormone nuclear 
receptors and is encoded by a single gene (Ar) located on the X chromosome. Ar is composed of 
8 exons which encode 3 functional domains (54,55) (Figure 1.3). The N-terminal domain (exon 1) 
has transactivation properties, and is required for AR-induced transcription of target genes (56,57). 
The DNA-binding domain (exons 2 and 3), along with the N-terminal domain, facilitates binding 
of the receptor to DNA androgen-response elements (ARE) (58), located within promoter or 
enhancer regions up or downstream of androgen target genes (59). AREs consist of a pair of 
inverted repeated palindromic sequences separated by three nucleotide spacer (60), which 
facilitates binding of an AR dimer. The DNA-binding domain is separated from the ligand-binding 
domain by a hinge region, encoded by part of exon 4. The C-terminal ligand-binding domain (part 
of exon 4, and exons 5-8) is responsible for ligand interaction and confers specificity of AR for 
androgens (61). Within the ligand-binding domain is the C-terminal activation function 2 (AF2) 
sequence, that provides transactivation function in a ligand-dependent manner.  
 
Figure 1.3: Androgen Receptor Gene and Protein Organization. The androgen receptor (Ar) gene 
consists of 8 exons (upper figure). Androgen receptor (AR) protein consists of N-terminal (NTD), DNA 
(DBD), and ligand-binding domains (LBD), with a hinge region in between the DBD and LBD. 
 
AR shares sequence conservation with progesterone (PR), glucocorticoid (GR), and 
mineralocorticoid receptors (MR) in the DNA-binding and C-terminal ligand binding domains, yet 
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relative binding assays demonstrate a high-affinity of AR to endogenous androgens (55). DHT 
binds much more strongly to AR than T, with a relative binding affinity of 94-180% of T (62,63). 
However greater concentrations of T can achieve greater AR binding (64). 
 
When in the ligand-unbound state, AR remains in the cytoplasm forming complexes with heat-
shock proteins (Hsp). Binding of androgens to the ligand-binding domain induces a conformational 
change in the receptor, causing dissociation of Hsp and allowing for AR to homodimerize. 
Homodimeric AR may be phosphorylated and translocated to the nucleus, a process enabled by 
the nuclear localization signal region spanning between the hinge and DNA-binding region (55). 
AR then binds to ARE and recruits additional transcriptional co-regulators, either co-activators or 
co-repressors of gene transcription. Included in the recruited transcriptional machinery are histone 
acetyltransferases (HAT) that remodel chromatin to an open, accessible state to facilitate 
transcription of target genes, steroid receptor co-activators (SRC-1), and RNA polymerase II (65). 
The AF2 region enables the formation of the transcriptional machinery complex at a promoter and 
enhancer region, allowing for the transcription of AR target genes. Androgens acting on AR may 
also repress gene expression via the recruitment of a transcriptional repressive complex, consisting 
of the nuclear receptor corepressor (NCoR) and silencing mediator of retinoid and thyroid 
receptors (SMRT), and histone deacetylases (HDAC) which causes chromatin to become tightly 
packed and inaccessible for transcription (66).  
 
In addition to the canonical genomic, transcriptional activity of AR, non-genomic actions of AR 
signaling have been described. Rapid effects of androgens on cells that cannot be attested to the 
slower transcription of target genes and translation of proteins have been demonstrated. Ligand-
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bound AR can trigger intracellular signaling cascades, such as the PI3K/Akt pathway (67), or the 
MAPK pathway, by interacting with cellular-Src tyrosine kinase at the inner face of the plasma 
membrane (68). Membrane-associated AR can also activate G-protein coupled signaling to open 
membrane calcium channels which increase intracellular calcium, leading to activation of PKC, 
PKA, and/or MAPK/ERK pathways (69). It has also been suggested that DHT when converted to 
3α-diol can bind to γ-aminobutyric acid type A receptors (GABAAR), triggering influx of chloride 
into cells resulting in hyperpolarization (70,71). Additionally, DHEAS can allosterically 
antagonize GABAAR, resulting in reduction in GABAAR currents (72-74). Crosstalk between AR 
and other signaling pathways have also been described, including growth factor receptor (insulin-
like growth factor 1 and epidermal growth factor) signaling (75), MAPK signaling, and cytokine 
(TNFα , IL-6) signaling pathways (76). 
 
Androgens may also signal via non-AR membrane bound receptors that are unrelated to steroid 
hormone nuclear receptors. Several multi-functional membrane proteins have been proposed to act 
as membrane-AR, including transient receptor potential cation channel M8 (TRPM8), G-protein 
coupled receptors OXER1 and GPCR6A, and the zinc-transporter Zrt Irt-like protein ZIP9 (77,78). 
While novel membrane androgen receptors are an interesting development, the work in this 
dissertation focuses only on the classic nuclear AR, whose effects on gene expression have been 
better described. Additionally, the majority of characterized and validated experimental models of 
AR deletion involves loss of the classic AR nuclear receptor.  
  
Androgens auto-regulate AR, and depending on the tissue or cell type, may either up or down 
regulate Ar mRNA expression. Castration-induced androgen deprivation results in increased Ar 
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mRNA in the ventral prostate, seminal vesicles, epididymis, kidney (79-81), pre-optic area and 
pituitary (82) of adult male rats. In contrast, Ar mRNA decreases in the hippocampus (83), and 
shows no change in testis with castration (81). Studies focused on androgen regulated expression 
of AR protein have also shown increases in AR in prostate and seminal vesicles (79), and decreased 
AR in efferent ductules and brain (84) with gonadectomy (85,86). The cause for these differences 
is not yet clear but may reflect differences in tissue-specific regulation of AR expression.  
 
Experimental approaches to investigate actions of androgens on AR 
Androgens have a variety of physiologic effects via AR in both male and female tissues. Distinct 
roles of AR have been elucidated by examining mutation or deletion of androgen steroidogenic 
enzymes or AR in clinical cases and preclinical animal models. Loss of function mutations in AR 
lead to either complete or partial androgen insensitivity syndrome (AIS), depending on the location 
and type of mutation. Features of AIS are replicated in the testicular feminization (Tfm) mouse 
(87) and rat models (88,89), including feminization of external genitalia and intra-abdominal testes 
in XY males, and resistance to the effects of androgens. Global loss of AR function due to mutation 
is useful for examining the overall effect of AR on phenotype, but does not necessarily provide 
organ, tissue, or cell specificity of AR action. Additionally, AR dysfunction can be induced by a 
variety of different mutations with differing degrees of severity in phenotype. Experimental female 
offspring are also extremely difficult to produce, as ArTfm males are infertile, and only possess one 
copy of the mutated AR. Molecular genetic approaches have been utilized to generate global-, 
tissue-, or cell-specific deletion of AR, or AR “knockouts” (ARKO), to overcome the difficulties 




The Cre/loxP technology is the most common method to generate genetically-modified animal 
models in a conditional fashion. It uses the P1 bacteriophage-derived enzyme cyclization 
recombination (Cre), which recognizes a pair of inverted 34 base pair loxP (locus of crossing over 
in P1) sites, resulting in recombination of the “floxed” sequence of DNA (90) (Figure 1.4). Several 
AR-flox mouse lines have been generated, with loxP sites flanking exon 1 (91-93), exon 2 (94,95), 
or exon 3 (96,97). Recombination of the floxed sequence in exons 1 or 2 results in premature stop 
codons in Ar mRNA, and lack of transcription of remaining exons, leading to loss of AR protein 
expression (98). The AR-flox model recombining exon 3, however, results in an in-frame mutation 
where AR protein is expressed, can bind to ligand, but does not express a portion of the DNA-
binding domain, and therefore is unable to induce gene transcription but can still elicit non-
genomic actions (96). Of note, excision of exon 2 does not eliminate AR signaling via novel 
membrane bound AR (77,78). Therefore, rapid membrane effects via androgens may still be 
possible.  
 
Figure 1.4: Cre-mediated Recombination of Exon 2 of the Mouse Androgen Receptor. Exon 2 of Arflox 
mouse is flanked by two loxP sites, which are recognized by the enzyme Cre recombinase. Presence of Cre 
results in recombination, and excision of the target gene plus one loxP site.   
 
To drive tissue- or cell-specific deletion of target floxed genes, Cre can be conditionally expressed 
by insertion of the Cre transgene under control of tissue or cell-specific promoters. Global, or 
body-wide ARKO are generated using strong, widely-expressed promoters to drive Cre 
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expression, including the human cytomegalovirus (CMV), beta-actin, or phosphoglycerate kinase 
1 (PGK) promoters. Tissue-specific Cre expression and subsequent ARKO have been generated 
for many tissues, including testes (Leydig and Sertoli cells), ovary (granulosa and theca cells), 
pituitary, brain, muscle, adipose, bone, liver, and skin. Effects of ARKO in various tissues will be 
discussed further below. 
 
Physiologic effects of androgens 
Development and Sexual differentiation:  
Sex differentiation of the reproductive tract is one of the earliest effects of androgens acting on 
AR. Prior to sex differentiation, embryos contain two undifferentiated duct systems, Wolffian and 
Müllerian, which give rise to either the male or female reproductive tract, respectively (99,100). 
After differentiation of testes from bipotential gonads, fetal Leydig cells begin secreting A4, which 
is converted to T by fetal Sertoli cells (101,102). T then diffuses to nearby AR-expressing Wolffian 
ducts, where it promotes differentiation into seminal vesicles, vas deferens, and epididymis 
(103,104). Anti-Müllerian hormone (AMH) produced by Sertoli cells promotes regression of 
Müllerian ducts so that only Wolffian ducts will be present in differentiated males (105-107). 
Conversion of T to DHT via 5αR is required for virilization of the external genitalia, including 
penis and scrotum development, urogenital sinus development into prostate, and male-typical 
urethra (108,109). The requirement of androgens for the development of the male-typical 
reproductive tract and external genitalia has been clearly demonstrated by studies using mutations 
in AR. For example, Tfm rodents and 46,XY patients with complete AIS display feminized 
external genitalia, with a short, blind-ended vagina, small phallus, absence of epididymis, vas 
deferens, seminal vesicles, and prostate. Global ARKO males display similar phenotype to Tfm 
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males, with overall feminized appearance of external genitalia and lack of secondary and accessory 
reproductive organs (94,96).  
 
Male Reproductive Function: 
The role of androgens and AR are crucial for male reproductive physiology, especially in the testes 
where androgenic actions are critical for proper spermatogenesis and androgen production. 
Overall, with mutation of AR (Tfm) or global ARKO, testes are small and remain intra-abdominal, 
leading to infertility (94,96). However, androgens acting via AR play different roles in cells of the 
testes, including Sertoli and Leydig cells. Sertoli cells are the nurse cells of the testis, whose 
primary role is to nourish and provide support for developing germ cells, maintaining the blood-
testis barrier, making up part of the seminiferous tubules along with peritubular myoid cells, and 
secreting AMH during sex differentiation. AR expression in Sertoli cells is stimulated by FSH and 
androgens produced in nearby Leydig cells (110). Transgenic AMH-Cre mice have been used to 
drive Sertoli cell-specific ARKO (SCARKO), as AMH is expressed early in testicular 
development and is exclusive to immature Sertoli cells. SCARKO mice display reduced testis mass 
and are infertile due to arrest of spermatogenesis during meiosis at the pachytene spermatocyte 
stage (94,111,112). The blood-testis barrier is also disrupted in SCARKO mice, due to decreased 
expression of tight junction related components (113,114). However, the ability for Sertoli cells to 
secrete AMH and trigger sexual differentiation of the reproductive tract is not impaired, and 
SCARKO mice develop a male typical reproductive tract, accessory organs, external genitalia, 




Androgens are also important for Leydig cell function. Leydig cells are interspersed throughout 
the interstitial space surrounding the seminiferous tubules and are the primary cell responsible for 
producing T. LH stimulates T production by the Leydig cell, which feeds back to AR expressed in 
Leydig cells in an autocrine manner (115,116). AR is essential for promoting maturation and 
development of Leydig cells in adult males (117,118), but is dispensable for fetal Leydig cells, 
whose function is androgen independent. Leydig cell-specific ARKO (LCARKO) mice that have 
been generated using Cre-driven by the AMH-receptor 2 (Amhr2) promoter display infertility, 
decreased mass of testes and epididymis, arrested spermatogenesis at the spermatocyte stage, and 
reduced levels of T (119,120). However, Amhr2 is expressed in cells other than Leydig (121,122), 
limiting the conclusions that can be drawn from this line.  
 
Androgens acting via AR are required for the maintenance and homeostasis of adult male 
accessory glands, including the epididymis, vas deferens, seminal vesicles and prostate, which are 
highly androgen dependent (123). Loss of androgens via castration or pharmacologic blockade of 
AR results in decreased mass of seminal vesicles (124), and atrophy and deterioration of prostate 
gland structures via apoptosis (125,126).  
 
Sufficient levels of androgens are required to maintain male reproductive function and secondary 
sex characteristics. Hypoandrogenism in males, or androgen deficiency, is generally defined as 
total T levels below the lower end of the reference range in eugonadal males (below ~300-350 
ng/dL)(127,128). While male androgen levels naturally decline with age (129), primary 
hypogonadism (defect in testicular T production) or secondary hypogonadism (defect in 
hypothalamic GnRH or pituitary LH/FSH production) can result in clinical androgen deficiency. 
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Androgen deprivation therapy for the treatment of androgen-dependent cancers (i.e., prostate 
cancer) will also result in hypoandrogenism, and can be achieved via orchidectomy, GnRH 
agonists or antagonists, or AR antagonists (130). Hypoandrogenism in males can cause decreased 
sperm production and infertility, regression or lack of development of secondary sex 
characteristics, and reduced libido or sexual dysfunction, (127,131,132).  
 
Since males typically have a high concentration of circulating androgens, symptoms of elevated 
androgens beyond the typical male range may not be readily apparent (133). Endogenous androgen 
excess in males is uncommon and may be attributed to androgen-secreting adrenal or testicular 
tumors, or congenital adrenal hyperplasia. It may manifest as precocious puberty, increased body 
and muscle mass, gynecomastia, or acne (134-136). Male androgen excess may also be attributed 
to abuse of anabolic steroids or misuse of T prescriptions. Supraphysiologic doses of T may be 
used for their desired anabolic effects in skeletal muscle, to stimulate erythropoiesis, and gain 
advantage in competitive sports. However, long-term exogenous androgen excess in males leads 
to suppression of the HPG axis due to constant negative feedback, causing decreased 
spermatogenesis and infertility (137).  
 
Female Reproductive Function: 
Androgens also play an important role in female reproduction, including ovarian folliculogenesis, 
particularly during early follicle growth (138). In ovaries, AR is expressed in granulosa, theca, 
stromal cells, and oocytes (139-142). Developing follicles begin expressing AR at the primary 
stage, with expression increasing during transition to secondary and pre-antral, reaching a peak in 
small antral follicles. Androgens acting via AR reduce atresia and enhance expression of FSH 
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receptors, which promotes growth of pre-antral follicles (143). Mouse models of ARKO have been 
useful in dissecting the populations of AR expressing cells required for these effects. Female Tfm 
and global ARKO mice display reduced fertility, which is attributed to decreased ovarian follicle 
counts and premature ovarian insufficiency (92,95,97,144). Ovaries from granulosa cell-specific 
ARKO (GCARKO) mice show an increase in preantral and unhealthy atretic follicles, leading to 
subfertility and premature ovarian insufficiency (145,146). The phenotype of GCARKO mice 
closely mimics that of the global ARKO, indicating that many of the negative effects on fertility 
are due to loss of AR in granulosa cells. Contrarily, loss of AR specific to theca cells (ThARKO) 
does not result in any changes to fertility, pubertal onset, or serum T or E2 (147). 
 
AR is expressed throughout the female reproductive tract, including the Fallopian tube epithelium 
(148,149), uterine endometrium and myometrium (150), vaginal stroma and epithelium (151,152). 
Cyclic changes in ovarian estradiol levels induce changes in AR expression in the female 
reproductive tract. For example, estradiol upregulates AR in the uterus and vagina (153,154). 
Experimental reduction in estradiol via ovariectomy results in decreased Ar mRNA in the mouse 
uterus and vagina, which is restored with administration of estradiol (151). In the uterus, androgens 
modulate proliferation of the myometrium and endometrium (155). Global loss of AR in mice 
results in altered uterine morphology, with elongated and smaller diameter uterine horns (156). 
Androgens also have physiologic effects on vaginal physiology, often in synergy with estrogens. 
They regulate epithelial function (157), mucin production (158,159), maintenance of innervation 
(160,161), and local blood flow (162,163). Additionally, vaginal tissues express steroidogenic 
enzymes needed to synthesize androgens, and can convert DHEA to T and/or DHT, indicating 
intracrine androgen actions (164). Vestibular glands (major or Bartholin’s glands, and minor or 
18 
 
Skene’s glands) of the female vulva, which are the equivalent of the male bulbourethral gland, also 
depend on androgens and AR for proper mucous production and vaginal lubrication (165). 
 
In contrast to the stimulatory role in some tissues of the reproductive tract, androgens negatively 
impact mammary gland development in an age-specific manner. During embryonic development, 
androgens acting via AR promote the regression of primordial mammary tissues in males (166), 
while development of mammary tissue continues in females that do not produce androgens during 
embryogenesis. Postnatally, AR is expressed in epithelial and stromal cells of the mammary glands 
(167). Androgens inhibit mammary gland maturation by suppressing E2-induced epithelial 
proliferation and breast development during puberty (168,169).  
 
While androgen levels in females are typically much lower than males, hypoandrogenism can have 
negative effects on female fertility and sexual health (170). Female androgen insufficiency can be 
caused by age (menopause), primary or secondary hypogonadism, adrenal insufficiency (leading 
to loss of androgenic precursors DHEA and DHEAS), oral contraceptive pills, premature ovarian 
insufficiency, or oophorectomy (171). However, since accurate female androgen levels are 
difficult to obtain without liquid chromatography and mass spectrometry (LC/MS)-based methods 
(172,173), there is no set of clinical guidelines to define female androgen deficiency. Nonetheless, 
supplementation of DHEA for those with low functional ovarian reserve undergoing in vitro 
fertilization treatments has proven beneficial for some patients (174). 
 
Elevated androgens, however, prove much more consequential for female reproductive health. 
Androgen excess in females can be a result of androgen-secreting adrenal or ovarian tumors, 
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Cushing’s syndrome, adrenal hyperplasia, pregnancy, or drug induced androgen excess, but most 
commonly, polycystic ovary syndrome (PCOS) (175,176). Consequences of hyperandrogenism in 
females include excessive male pattern body and facial hair growth (hirsutism), androgenic 
alopecia, increased acne, oligo or anovulation, subfertility or infertility, insulin resistance, 
abdominal obesity, increased risk of type 2 diabetes, dyslipidemia, increased risk of cardiovascular 
disease, and increased depression and anxiety. Levels of total T in female hyperandrogenism are 
elevated relative to the typical range of female values, but usually do not reach that of the typical 
adult male range, i.e., male total T = ~222 – 848 ng/dL, female total T = ~3 – 52 ng/dL, PCOS 
total T = ~23 – 138 ng/dL (28). In certain cases of severe biochemical hyperandrogenism caused 
by androgen producing tumors, female total T may overlap with the typical adult male range, i.e., 
androgen producing tumor average female total T range = ~185 – 410 ng/dL (177). Androgenic 
precursors such as DHEA/DHEA-S and A4 may also be elevated, depending on the origin of 
hyperandrogenism (ovarian vs adrenal), and pre vs post-menopausal status. For example, post-
menopausal patients with PCOS may show greater relative elevations in A4, rather than T (176). 
 
Figure 1.5: Adult serum testosterone levels. Range of typical total testosterone for adult males and 
females, and female polycystic ovary syndrome (PCOS) and androgen producing tumor (APT).  
 
Since AR is expressed in multiple reproductive and HPG axis tissues, increases in female 
androgens can have diverse physiologic outcomes. For example, despite being a heterogeneous 
syndrome, many patients with PCOS exhibits similar neuroendocrine and ovarian changes. GnRH 
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neurons display continuous increased pulse frequency (178-181), which preferentially drives 
pituitary LH over FSH production (182,183). Increased LH pulse frequency and amplitude drives 
increased ovarian androgen production by theca cells. Excessive androgen action on AR drives 
proliferation of preantral follicles and depletes the primordial follicle pool (184,185). Smaller, 
non-dominant follicles also inappropriately respond to LH and undergo premature luteinization 
(186). Without a rise in FSH during the follicular phase, no dominant follicle is selected, resulting 
in early antral follicle arrest. Without ovulation of a mature follicle, no corpus luteum is formed 
and progesterone remains low. Lack of a drop in progesterone during the late luteal phase needed 
to trigger shedding of the endometrium, along with chronic E2 stimulation, results in a buildup of 
endometrial tissue (187,188). Elevated androgens also reduce hypothalamic sensitivity to 
progesterone, decreasing progesterone-mediated negative feedback action on GnRH pulses (189). 
These effects together lead to a vicious cycle of increased GnRH, LH, and ovarian androgens. 
 
Effects in metabolic regulation 
Androgens have notable effects on the regulation of energy balance and body composition through 
sex-specific actions on a variety of metabolic tissues. Male ARKO mice develop obesity later in 
life due to decreased energy expenditure and reduced brown adipose tissue thermogenesis, insulin 
resistance, impaired glucose tolerance, and accumulation of triglycerides in skeletal muscle and 
liver (190-192). Male global ARKO mice replicate phenotypes seen in human males with 
hypoandrogenism, including increased adiposity, and decreased muscle mass and bone density 
(193).  
 
Interestingly, elevated androgens in females usually promote metabolic dysfunction similar to 
androgen deficiency in males. Female hyperandrogenism can decrease insulin sensitivity in 
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muscle, liver, and adipose tissue, diminish liver glycogen synthesis, promote visceral adipose 
accrual by increasing adipocyte size and inhibiting lipolysis, and cause beta cell dysfunction via 
increased basal hypersecretion of insulin, and inadequate or exaggerated glucose-induced insulin 
secretion (194-197). Overall, these impairments increase the risk of type 2 diabetes and metabolic 
syndrome.  
 
The metabolic changes seen in hypoandrogenic males and hyperandrogenic females highlights the 
impact of sex-specific changes in androgen levels in multiple organs (197,198). To dissect out the 
role of androgens acting via AR on different metabolic organs, several tissue-specific ARKO 
models have been generated. For example, liver-specific ARKO results in hepatic steatosis and 
insulin resistance in high-fat diet fed male mice (199), indicating that androgens prevent excess 
lipid accumulation under normal physiologic conditions. Lack of AR in white adipose tissue, 
results in decreased body weight and hyperinsulinemia early in life in male mice. Eventually, these 
mice develop deficiencies in insulin secretion and become hyperglycemic (200).  
 
Skeletal muscle is a major target of androgenic action, with general anabolic effects. Certain 
skeletal muscles display greater dependence on androgens than others. For example, muscles 
responsible for control of the penis (e.g., levator ani) that are innervated by the sexually-dimorphic 
spinal nucleus of the bulbocavernosus (SNB) are highly androgen dependent  (201-203). AR is 
expressed in myofibers, satellite cells (muscle stem cells), fibroblasts, and mesenchymal stem cells 
(204,205). Deletion of AR from satellite cells results in decreased grip strength, decreased mass 
of androgen-dependent muscles (levator ani), and fiber type switching in the soleus muscle in male 
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mice (206). Additionally, decreased muscle strength and maximal force production in the 
hindlimbs was also observed in male myofiber-specific ARKO mice (207).  
 
Androgens also contribute to pancreatic endocrine function. Beta cells, the endocrine component 
of the pancreas responsible for producing insulin, express AR, and DHT can enhance glucose-
stimulated insulin secretion (GSIS) in beta cell cultures (208). Loss of androgens or AR in male 
rodents can lead to impaired glucose homeostasis, as castration and/or ARKO in male rodents 
leads to a reduction in beta cell mass, impaired insulin secretion, and glucose intolerance 
(209,210). Furthermore, male mice with deletion of AR from beta cells display impaired glucose 
tolerance and reduced insulin secretion in response to glucose (208).  
 
Brain as a Link for Sex-Specific Androgen Actions in Reproduction and Metabolism 
While the effects of androgens acting on AR are important for homeostasis of peripheral tissues, 
androgens can impact reproduction and energy homeostasis via direct actions in the brain. The 
brain is a highly androgen-sensitive organ. AR is expressed throughout the hypothalamus, 
telencephalon, thalamus, and brainstem of both sexes (211-216). In males, T during a critical 
window of prenatal brain development is necessary for permanent organizational changes which 
masculinize and defeminize the brain, leading to male-typical behaviors and physiology later in 
life (217). However, in rodents, the majority of these effects is attributed to androgens acting via 
estrogen receptors (ERα, ERβ) after aromatization, as mice with deletion of both ERα and ERβ 
fail to display male-typical sexual behavior (mounting) during adulthood (218). Loss of aromatase 
expression also results in reduced male-typical behavior (219). While estrogens play a dominant 
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role in the organization of a male-typical brain, loss or mutation of AR also results in reduction or 
abolition of male-typical sexual behavior and aggression (220-223).  
 
While AR may not play a significant role in the organizational programming of the brain, it is 
required for executing male-typical behaviors in mature rodents. Interestingly, primates do not 
show the same dependence on estrogens for brain sexual differentiation as do rodents, and 
androgens acting via AR are the dominant mechanism driving male-typical differentiation in 
primates (224,225). In addition to deficits in behaviors, neuron-specific ARKO (NARKO) mice 
show disruption in growth, with decreased body mass and serum insulin-like growth factor 1 
(IGF1), and disrupted HPG axis (226). Female NARKO mice show altered ovarian follicle 
dynamics due to dysregulated kisspeptin and LH release (227).   
 
AR contributes to negative feedback regulation of the HPG axis. GnRH neurons located in the 
hypothalamus release GnRH at the median eminence, which is transported through the pituitary 
portal vessels to gonadotropes in the anterior pituitary gland. GnRH stimulates gonadotropes to 
release LH and FSH, which in turn stimulate Leydig and Sertoli cells, respectively. T produced by 
Leydig cells circulates back to the hypothalamus and pituitary gland and exerts negative feedback, 
which maintains levels of gonadotropins and T within homeostatic range.  
 
At the level of the hypothalamus, T decreases GnRH pulse frequency, which in turn results in 
decreased LH pulse frequency, amplitude, and mean serum LH (228,229). These effects are 
demonstrated through castration, which removes negative feedback from the gonads. Castration 
leads to increased GnRH neuron firing rate, increased GnRH release at the median eminence, and 
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increased LH pulse frequency, which can be reversed by treatment with T (230-233). Negative 
feedback actions of androgens are mediated via both androgenic and estrogenic pathways (AR and 
ER), as both DHT and estradiol reduce serum LH and increase LH interpulse-interval in castrated 
male sheep (234,235). However, only estradiol reduces GnRH neuron firing in castrated male mice 
(236). The contribution of both AR and ER in the hypothalamus and pituitary in HPG axis negative 
feedback likely represents redundant mechanisms to ensure proper control. However, GnRH 
neurons themselves do not express detectable levels of either AR or ERα (237-239), so the negative 
feedback effect of T is likely via neurons upstream of GnRH neurons. 
 
Kisspeptin is one of the most potent stimulators of GnRH release via signaling through the G-
protein coupled receptor GPR54 (aka, Kiss1R) (240). Kisspeptin neurons are located in the 
forebrain, including the anteroventral periventricular nucleus (AVPV) and the arcuate nucleus of 
the hypothalamus (ARH), where kisspeptin is coexpressed with neurokinin and dynorphin (KNDy) 
(241). Notably, kisspeptin neurons are sensitive to sex steroids, and express ERα and/or AR 
(242,243). Androgens influence Kiss1 mRNA expression in both the AVPV and ARH. For 
example, castration of male mice leads to increased Kiss1 in the ARH (242). In addition to 
influencing gene expression, androgens can modulate kisspeptin neuronal activity. In male mice, 
DHT inhibits long-term episodic activity in ARH kisspeptin neurons (244). Although the role of 
estrogens in both negative and positive feedback actions is well described in females, the role of 
androgens acting upon AR is poorly understood. Nonetheless, female mice with neuron-specific 
ARKO display reduced Kiss1 mRNA in the AVPV, but increased Kiss1 in the ARH during 
proestrus (227), indicating that androgens acting via AR may regulate Kiss1 expression in females 
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as well. These studies reflect the importance of neuronal AR in regulating neuroendocrine output 
upstream of GnRH neurons.  
 
In addition to kisspeptin-expressing neurons, multiple other pathways converge upon GnRH 
and/or kisspeptin neurons in HPG axis regulation. One of such critical inputs is the melanocortin 
system. The hypothalamic melanocortin system consists mainly of two distinct groups of neurons 
in the ARH, i.e., neurons that coexpress pro-opiomelanocortin (POMC) and cocaine- and 
amphetamine-regulated transcript (CART), and those that coexpress neuropeptide Y (NPY) and 
agouti-related peptide (AgRP) (245-247). POMC/CART and NPY/AgRP neurons are the first 
order neurons that sense metabolic signals, including leptin, insulin, and ghrelin. Leptin increases 
activity of POMC/CART neurons, but inhibits NPY/AgRP neurons, resulting in an overall 
anorectic effect which decreases food intake and increases energy expenditure (248-250). In 
addition to regulating energy homeostasis, melanocortin neurons also modulate the reproductive 
axis via direct actions in kisspeptin neurons (251-255). Activation of NPY/AgRP neurons or fibers 
results in inhibition of kisspeptin neurons (256), and decreased LH pulse frequency (257). 
Conversely, kisspeptin stimulates POMC neurons, and indirectly inhibits NPY/AgRP neurons 
(258).  
 
While metabolic cues have well-described effects on the reproductive neuroendocrine axis, 
gonadal hormones can act to modulate overall hypothalamic sensitivity to metabolic hormones, 
including leptin and insulin. For example, gonadal hormones modulate patterns of food intake and 
energy expenditure in a sex-specific manner (259-261). These effects are mediated in part through 
direct actions on POMC and/or NPY/AgRP neurons, as a subset of each neuronal population 
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coexpress AR. Castration-induced loss of androgens results in decreased Pomc mRNA in the male 
rodent and primate ARH, which is restored by T treatment (262-264). Additionally, treatment of 
neonatal female mice with DHT results in decreased POMC immunoreactivity and reduced 
projections from the ARH, resulting in increased food intake (265). However, species differences 
are conspicuous. Whereas sheep display a high coexpression of AR in POMC and NPY/AgRP 
neurons (266), only a small subset of POMC neurons (~3%) coexpress AR in the rat (267). 
Exposure to prenatal androgen excess increases the proportion of NPY/AgRP-AR positive neurons 
in female mice, and the number and projections of NPY/AgRP neurons in ewes (266,268). This 
suggests that, at least in rodents, the effects of androgens on energy expenditure via melanocortin 
neurons is mediated by estrogens after aromatization, as POMC neurons express ERs (269,270). 
Moreover, androgens can influence POMC and/or NPY/AgRP neurons via upstream AR-
expressing neurons. For instance, leptin exerts sexually dimorphic trophic effects on NPY/AgRP 
fiber innervation during postnatal development (271). Yet, NPY/AgRP neurons express virtually 
no detectable AR or ERα (260,271), indicating that other AR-positive neurons mediate these 
effects.  
 
The ventral premammillary nucleus (PMv) is another key site for the metabolic control of 
reproduction. Interestingly, the PMv shows dense expression of AR in both sexes, but is relatively 
low in ERs (211,272). Furthermore, the PMv has virtually no aromatase expression (273), 
suggesting preferential regulation by androgens acting via AR. In addition to receiving signals 
conveying reproductive status, the PMv also integrates signals conveying energy balance, and 
environmental cues, such as pheromones (274), and photoperiod in seasonal breeders (275). PMv 
neurons express a variety of receptors, including receptors for leptin, insulin, ghrelin, sex steroids, 
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and melanocortins (272,276-279). Neurons of the PMv project directly to GnRH neuronal cell 
bodies and terminals in the median eminence (280-283), as well as to kisspeptin neurons (281,284-
286). The PMv facilitates leptin’s permissive actions on puberty and fertility, as re-expression of 
the leptin receptor (LepRb) in LepRb-null mice is sufficient for pubertal progression and fertility 
in females (283). AR is coexpressed in LepRb PMv neurons of male mice (287), but the role of 
androgen actions in PMv neurons has not been determined. 
 
Current Gap in Knowledge 
Despite the wealth of knowledge on the physiologic effects of androgens in various organs and 
tissues, the action of androgens via AR in the brain has remained largely unexplored. The brain is 
a highly heterogeneous tissue, therefore, the neuronal-specific AR knockout models cannot 
distinguish the effects of androgens on different brain nuclei, cell types, and function. Furthermore, 
many studies investigating the role of androgens in the brain have either neglected to include 
female subjects, examined only adult animals, or focused on the role of aromatized T acting on 
ERs.  
 
AR is highly expressed in the hypothalamus, particularly in the ARH and PMv (211). These 
hypothalamic nuclei contain key neuronal populations associated with the neuroendocrine 
reproductive axis and the metabolic control of reproduction, such as LepRb (277). LepRb neurons 
respond to leptin, which signals the amount of energy stored in the form of lipids (288,289). 
Therefore, leptin indicates that enough energy is available to conduct energetically-demanding 
processes, such as pregnancy and lactation, territoriality in males, and gametogenesis in both sexes 
(290,291). Lack of either leptin or LepRb results in obesity, diabetes, and infertility (292). This 
phenotype is reminiscent of global or neuronal ARKO mice, which develop increased adiposity 
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later in life, glucose intolerance, and insulin resistance (192,293). Whether AR/LepRb neurons 
mediate the sex-specific actions of androgens in reproduction and/or metabolism remains 
unknown. 
 
Hypothesis and Objectives 
I hypothesize that subpopulations of hypothalamic LepRb neurons coexpressing AR play a crucial 
role in androgenic actions in reproductive and metabolic regulation, and mediate the deficits 
caused by hyperandrogenism in female mice.  
 
The overall objective of this dissertation is to examine the role of androgens acting on AR in the 
brain, and to determine whether LepRb neurons relay the androgenic actions in reproductive and/or 
metabolic function. To accomplish this objective, we performed three independent studies 
described in separate chapters.  
 
In chapter 2, we present a systematic evaluation of AR distribution in the brain of prepubertal and 
adult mice of both sexes. We found high expression of Ar mRNA in multiple brain regions, 
including the hypothalamus. Of interest are areas which are also dense in LepRb, such as the ARH 
and PMv (Cara et al, J Neuroendocrinol, 2021, re-submitted following revision). 
 
In chapter 3, we assessed if the direct actions of androgens via AR in LepRb cells impact 
metabolism and/or reproduction. We generated a LepRb-specific ARKO mouse model, and 
performed a comprehensive analysis of the reproductive and metabolic phenotype of male and 




In chapter 4, we assessed if deletion of AR from LepRb cells protects female mice from the 
consequences of exposure to androgen excess during late embryonic development. We used a well-
characterized mouse model of prenatal androgen excess that replicates many features of PCOS 
(Cara et al, in preparation).  
 
Finally, in the fifth chapter, I discuss the findings in an integrative perspective, highlighting the 
strengths and weaknesses, and proposing future studies needed to further advance the 
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Androgens are steroid hormones that play a critical role in brain development and sexual 
maturation by acting upon both androgen receptors (AR), and estrogen receptors (ERα/β) after 
aromatization. The contribution of estrogens from aromatized androgens in brain development and 
the central regulation of metabolism, reproduction, and behavior is well defined, but the role of 
androgens acting on AR has been unappreciated. Here we map the sex specific expression of Ar 
in the adult and developing mouse brain. Postnatal days (PND) 12 and 21 were used to target a 
critical window of prepubertal development. Consistent with previous literature in adults, sex-
specific differences in Ar expression were most profound in the bed nucleus of the stria terminalis 
(BST), medial amygdala (MEA), and medial preoptic area (MPO). Ar expression was also high in 
these areas in PND 12 and 21 of both sexes. In addition, we describe extra-hypothalamic and extra-
limbic areas which show moderate, consistent, and similar Ar expression in both sexes at both 
prepubertal time points. Briefly, Ar expression was also observed in olfactory areas of the cerebral 
cortex, in the hippocampus, several thalamic nuclei, and cranial nerve nuclei involved in 
autonomic sensory and motor function. To characterize areas that are preferably responsive to 
androgens, we mapped the coexpression of AR-immunoreactivity (AR-ir) and aromatase-Cre or 
ERα-Cre dependent eGFP expression. We found that only BST, MEA, and part of the ventrolateral 
subdivision of the ventromedial hypothalamus (VMHvl) coexpress AR-ir and aromatase-
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Cre;eGFP. Coexpression of AR-ir and ERα-Cre;eGFP was more penetrant, but still restricted to 
hypothalamic and limbic sites. Our findings indicate that in various brain areas androgens, rather 
than neuroestrogens or circulating estrogens, play an important role in female neuronal 
development and physiology.  
 
Introduction 
Gonadal steroids, including androgens and estrogens, play a dominant role in the development of 
sex differences in the brain. During male embryonic development, expression of the Sry gene 
located on the Y chromosome leads to differentiation of bipotental gonads into testes, which begin 
secreting testosterone (1-4). Embryonic testosterone is locally converted to estradiol by the enzyme 
P450 aromatase (CYP19A1) (5-7), which acts to masculinize and defeminize specific brain nuclei 
via estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) (8-11). Both effects take place 
during the organizational window of development (12-14), when the bipotential brain is most 
sensitive to the organizational effect of gonadal steroids. Developing females, which lack Sry, do 
not develop testes or produce testosterone, and are protected from maternal estradiol by the 
presence of alpha-fetoprotein in utero, and therefore differentiate toward a feminized brain (15,16). 
As a result, several adult brain sites display gonadal steroid-dependent sexual dimorphism (17-
20). 
 
During puberty, increased activity of hypothalamic gonadotropin releasing hormone (GnRH) 
neurons drives pituitary synthesis and release of gonadotropins, which induce gonadal steroid 
secretion and production of mature gametes (21). Testosterone activates developmentally 
programmed brain circuits to generate male specific behaviors, while cyclical ovarian steroids 
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have a similar role in females (22). Circulating levels of androgens are higher in males during and 
after completion of puberty (23-25), while very low levels of androgens are detected during the 
prepubertal stage in both sexes. In the hypothalamus, however, androgen receptor 
immunoreactivity (AR-ir) is observed throughout postnatal development. AR-ir is higher in males 
at postnatal day 5, but comparable at 15 days of age, when increasing numbers of female neurons 
show AR-ir (26). This is highly relevant as the prepubertal window between postnatal days 12 and 
22 accounts for the greatest differences in temporal gene expression (27,28) indicating that active 
neurodevelopmental changes occur prior to puberty and the activation of the hypothalamic-
pituitary-gonadal (HPG) axis, when circulating gonadal steroids are low, particularly in females.  
 
The requirement of gonadal steroids and sexual dimorphism in specific brain nuclei for 
reproduction has been widely demonstrated (29,30), but the same cannot be said of 
nonreproductive sex-dependent or sex-associated brain responses and function. Among them, 
emotion, motivation, addiction, and energy balance are well-defined (31). Notably, sex is one of 
the most relevant risk factors for a variety of psychiatric and neurologic disorders, most of which 
show clinical onset in peripubertal stages (32). Whether this is a direct effect of developmental 
testosterone is not clear. In both sexes many adult brain areas outside reproductive centers are 
androgen sensitive and express AR (33), but the distribution of Ar expression in male and female 
brain during the prepubertal time window has been poorly defined. 
 
In this study, we performed a comprehensive analysis of Ar expression in the mouse brain, 
expanding upon previous descriptions (26,34-37) to include all main subdivisions (e.g., neocortex, 
thalamus, brainstem, circumventricular organs) in both sexes. In addition, we mapped the 
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distribution of Ar expression in the developing brain, specifically at postnatal days 12 and 21, 
which frame a critical window of pubertal development (27,28). Finally, we identify regions that 
are preferentially responsive to androgens in females, i.e., those that lack the enzyme aromatase 
and do not express ERα. Our data provides a greater in-depth anatomical map of reproductive and 
non-reproductive sites of androgen action in the male and female mouse brain, particularly during 




All research animals were acquired, used, and maintained in accordance with the National 
Research Council Guide for the Care and Use of Laboratory Animals (38), the US Public Health 
Service’s Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use 
of Laboratory Animals, as well as federal, state, and local laws. Procedures and protocols were 
approved by the University of Michigan Committee on Use and Care of Animals (IACUC, Animal 
Protocol: PRO8712).  
 
Animals 
C57BL/6J (JAX® mice, stock #000664), aromatase-Cre (aroCre, JAX® mice, B6.129S(SJL)-
Cyp19a1tm2.1(cre)Shah/J, stock #027038, provided by Dr. Nirao Shah, Stanford University, (39)), 
ROSA26-loxSTOPlox-eGFP-L10a (JAX® mice, B6;129S4-Gt(ROSA)26Sortm9(EGFP/Rpl10aAmc/J, 
stock #024750, (40)), and ERαCre (JAX® mice, B6N.129S6(Cg)-Esr1tm1.1(cre)And/J,  stock #017911, 
(41)) mice were housed in an Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) accredited facility at the University of Michigan Medical School. Mice were 
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housed in a 12:12 light/dark cycle environment with controlled temperature (21-23°C) and 
humidity (30-70%). Mice were provided water ad libitum and were fed a phytoestrogen-reduced 
diet (16% protein, 4.0% fat, 48.5% carbohydrate, Teklad 2916 irradiated global rodent diet, 
Envigo) or a phytoestrogen-reduced, higher protein and fat diet (19% protein, 9% fat, 44.9% 
carbohydrate, Teklad 2919 irradiated global rodent diet, Envigo) for breeding and lactating 
females. Phytoestrogen-reduced diets were used to avoid any effects of exogenous dietary 
estrogens on AR or aromatase expression in experimental mice. Primers used for genotyping are 
listed in Table 2.1. Adult male mice were single housed at least one week prior to euthanasia to 
control for housing status, which may impact testosterone levels (42), and androgen-regulated AR 
expression (36,37). Adult female mice (group housed) were euthanized during diestrus, after 
completing at least two estrous cycles. Cycle stage was determined by vaginal lavage with 
predominately leukocytes (43) and confirmed by uterine weight below 100 mg (44).  
Table 2.1: Primers used for genotyping 
Mice Primer Sequence Size (bp) 
aroCre 
WT FOR 5’ AAA TGA GGA CAG GCA CCT TG 3’ 
MUT FOR 5’ GAA ACA GGG GCA ATG GTG 3’ 





FOR 1 5’ GAG GGG AGT GTT GCA ATA CC 3’ 
FOR 2 5’ TCT ACA AAT GTG GTA GAT CCA GGC 3’ 




COMM FOR 5’ AAC AAA GGC ATG GAG CAT CT 3’ 
WT REV 5’ CCA CAG TGT ACG CAG GAG AC 3’ 




The aromatase-Cre (aroCre) mouse line, which contains an IRES-Cre transgene knocked into the 
3’ UTR region of the Cyp19a1 locus (39) was crossed with reporter mice that express eGFP-L10a 
in a Cre-dependent manner to obtain aroCre;eGFP mice. AroCre mice were bred to homozygosity for 




The ERαCre mouse line, which contains an attP-flanked 2A oligopeptide and Cre recombinase 
knocked into the 3’ UTR region of the Esr1 gene (41), was crossed with reporter mice that express 
eGFP-L10a to obtain ERαCre;eGFP mice. ERαCre mice were heterozygous for the Cre allele. 
 
Sample size was 3-4 animals per sex and per age group (PND 12, PND 21, and adult) for C57BL/6J 
mice, and 3-4 adult females/group for aroCre;eGFP and ERαCre;eGFP mice.  
 
Tissue preparation  
Adult (postnatal day (PND) 56-70) and PND 21 mice were deeply anesthetized with isoflurane 
and transcardially perfused with diethyl pyrocarbonate (DEPC)-treated 0.1M PBS until liver and 
lungs cleared (about 1 minute), followed by 10% neutral buffered formalin (NBF) for 10 minutes. 
Brains were dissected and postfixed for 2 h, then transferred to 20% sucrose in DEPC-treated 0.1M 
PBS overnight for cryoprotection. PND 12 mice were anesthetized with isoflurane and euthanized 
by decapitation. Brains were dissected and fixed in 10% NBF for 4 h, then transferred to 20% 
sucrose in 10% NBF for 48-72 h at 4°C. PND 12 and PND 21 brains were embedded in optimal 
cutting temperature (OCT) compound, frozen on dry ice, and stored at -80°C. Brains from PND 
12 and 21 mice were sectioned at 30 µm thickness on the frontal plane into 4-5 series on a cryostat 
(Leica CM 3050S). Sections were directly collected onto SuperFrost Plus slides (Fisher Scientific) 
and stored at -20°C. Adult brains were sectioned at 30 µm thickness on the frontal plane into 5 






AR immunoreactivity was visualized using a modified tyramide signal amplification (TSA) 
method previously described (45). Brain sections were rinsed with 0.1M PBS, incubated in 0.6% 
hydrogen peroxide for 30 min, rinsed with 0.1M PBS, then blocked with 3% normal donkey serum 
with 0.25% Triton-X-100 for 1 h at room temperature. Sections were incubated overnight with 
rabbit anti-AR antibody (1:200, AbCam [EPR1535(2)], Cat #ab133273, RRID: AB_11156085). 
Sections were rinsed with 0.1M PBS and then incubated for 1 h with biotinylated donkey anti-
rabbit IgG (1:500, Jackson ImmunoResearch Laboratories, Cat #711-065-152, RRID: 
AB_2340593), followed by incubation in avidin-biotin (AB) solution in 0.1M PBS (1:1000, Vector 
Laboratories) for 1 h. Next, sections were incubated in biotinylated tyramide (1:250, Perkin Elmer) 
with 0.009% hydrogen peroxide for 10 min, followed by incubation with streptavidin-conjugated 
AlexaFluor 594 (1:1000, Invitrogen, ThermoFisher) for 1 h. Sections were mounted onto gelatin-
coated slides and coverslipped with ProLong Gold Antifade mounting medium (Invitrogen, 
ThermoFisher).  
 
In situ hybridization  
Adult brain sections were mounted onto Superfrost Plus slides (Fisher Scientific) in DEPC-treated 
0.1M PBS, air dried overnight at room temperature, and stored at -20°C. For pretreatment, slides 
were thawed at room temperature for 15-20 min, then fixed with 10% NBF for 15 min. Slides were 
rinsed with DEPC-treated PBS, then dehydrated with increasing concentrations of ethanol and 
cleared with xylene. Slides were rehydrated, boiled in sodium citrate (0.01M sodium citrate, pH 





To generate a 35S-labelled Ar cRNA riboprobe, a cDNA template was first generated by RT-PCR 
amplification using cDNA obtained from whole mouse hypothalamic RNA (TRIzol Reagent, 
Ambion, Life Technologies) and the primer pairs FOR 5’ CAACCAGATTCCTTTGCTGCC 3’ 
and REV 5’ GAGCTTGGTGAGCTGGTAGAA 3’ (NCBI accession number NM_013476.4, M. 
musculus androgen receptor (Ar), mRNA, target region 3042-3551, product length 510 bp). Linear 
template PCR products were gel purified according to the manufacturer’s protocol (QIAquick Gel 
Extraction Kit, 28706, Qiagen). To generate an antisense cRNA 35S-Ar riboprobe by in vitro 
transcription, the linear template was incubated with 35S-UTP (UTPαS, Perkin Elmer) and T7 RNA 
polymerase according to the manufacturer’s protocol (Promega). Riboprobes were diluted to 106 
cpm/mL in hybridization buffer (50% formamide, 10mM Tris-HCl, pH 8.0 (Invitrogen), 5mg 
tRNA, 10mM dithiothreitol (DTT), 10% dextran sulfate, 0.3M NaCl, 1mM EDTA, 1x Denhardt’s 
Solution, 0.1% SDS, 0.1% sodium thiosulfate). Hybridization solution was applied to slides, which 
were coverslipped and incubated overnight at 57°C. The following morning, slides were treated 
with RNAse A (Roche Applied Bioscience) for 30 min, then treated with a series of high stringency 
washes in sodium chloride-sodium citrate buffer (SSC). Slides were dehydrated, air dried, then 
placed into an X-ray film cassette with Biomax MR film (Carestream) for 1-2 days. Slides were 
dipped in NTB autoradiographic emulsion (Kodak, VWR), dried, and stored at 4°C in foil-wrapped 
slide boxes for 5 days per 1 day of film exposure. Slides were developed with GBX (Carestream 
Dental) developer and fixer, then dehydrated with graded ethanol, cleared with xylene, and 
coverslipped with DPX mounting media (Electron Microscopy Sciences).  
 
To generate neuroanatomical references, slides with adjacent sections of PND 12 and 21 male and 
female brains were dipped in 0.25% thionin for 45 s, quickly rinsed in water, dehydrated in 
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increasing concentration of ethanol, and cleared in xylene. Slides were coverslipped with DPX 
mounting media.  
 
Microscopy and Image Acquisition  
Digital images were acquired using an Axio Imager M2 (Carl Zeiss) with a digital camera 
(AxioCam, Zeiss) using Zen Pro 2 software (Zeiss). Photomicrographs of films were acquired 
using a SteREO Discovery.V8 stereomicroscope with a digital camera (AxioCam, Carl Zeiss), 
using the same magnification, illumination, and exposure time for each image. Dark field 
photomicrographs for silver grains (hybridization signal) were acquired using the same 
illumination and exposure time for each section, at 10× magnification.  
 
Illustration 
Adobe Photoshop software (Adobe Creative Cloud) was used to prepare digital images, including 
adjusting resolution to 300 dpi, adjustment of image size, addition of annotation and labels, 
conversion to greyscale, unsharp mask, and levels. Uniform adjustments were made to every 
image. Mouse brain coordinates were estimated from Paxinos and Franklin’s Mouse Brain in  
Stereotaxic Coordinates atlas (46). Abbreviations are based on the Allen Mouse Brain Atlas 




Estimation of hybridization signal was obtained by analysis of integrated optical density (IOD) 
using ImageJ software (NIH, http://rsb.info.nih.gov/ij) as previously described (47,48). Briefly, 
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IOD values were calculated as the total IOD of a constant region of interest (ROI) after subtracting 
background intensity. Quantification of Ar silver grain IOD was performed in one 30-µm thick 




Data are reported as mean ± standard error of the mean (SEM). Analysis was performed using 
GraphPad Prism software (Version 8). Normal distribution of data was analyzed using Shapiro-
Wilk test (significance alpha 0.05). Unpaired t test with Welch’s correction and Mann-Whitney 
nonparametric test was used to analyze IOD. Exact P values are reported and statistical 
significance is defined as P < 0.05.  
 
Results 
Distribution of AR mRNA in adult mouse brain 
Ar mRNA expression was visualized using in situ hybridization histochemistry. Hybridization 
signal on autoradiographic film was evaluated in male and female brain sections (n = 3-4/sex, 
Figure 2.1A). Adult brains were systematically examined and compared with published data as an 
initial control (26,36,37). Analysis of AR immunoreactivity was also performed as a control for 







Table 2.2: Qualitative expression of Ar mRNA distribution by nuclei in postnatal and adult mouse 
brain. -, +/-, +, ++, +++, and ++++ represent not detected, very low, low, moderate, high, and very high 
expression of silver grain deposits corresponding to Ar mRNA. The Allen Mouse Brain Atlas was used as 
a reference for names, abbreviations, and location of nuclei. 
 Adult Prepubertal 
 PND 56-70 PND 12 PND 21 
Brain areas and nuclei Male Female Male Female Male Female 
Cerebral Cortex       
Motor (MO) +/- +/- +/- +/- +/- +/- 
Olfactory nucleus (Anterior) (AON) - - ++ ++ ++ ++ 
Taenia tecta (TT) + +/- + + + + 
Piriform (PIR) + + + + + + 
Cingulate (Anterior) (ACA) + + + + + + 
Endopiriform (EP) +/- +/- +/- +/- + +/- 
Hippocampal Formation       
Induseum griseum (IG) + + + + + + 
Field CA1 (CA1) +++ +++ +++ +++ +++ +++ 
 Field CA2 (CA2) +++ +++ +++ +++ +++ +++ 
Field CA3 (CA3) + + + + + + 
Dentate gyrus (DG) + + +/- +/- + + 
Entorhinal area (ENT) +/- +/- + + +/- +/- 
Presubiculum / Subiculum 
(PRE/SUB) + + + + + + 
Cortical subplate and cerebral 
nuclei   
    
Septohippocampal nucleus (SH) + + + + + + 
Lateral septal nucleus, caudodorsal 
(LSc) +++ + + + + + 
Lateral septal nucleus, rostroventral 
(LSr) +++ + + + + + 
Bed nucleus of stria terminalis, 
principal nucleus (BSTpr) ++++ +++ + + ++++ +++ 
Cortical amygdalar area (COA) +++ +++ + + +++ +++ 
Medial amygdalar nucleus, 
posterodorsal (MEApd) +++ + + + +++ +++ 
Posterior amygdala (PA) +++ + +++ + +++ + 
Thalamus and Subthalamus       
Ventral posterior complex of the 
thalamus (VP) + + + + + + 
Paraventricular nucleus of the 
thalamus (PVT) + + + + + + 
Nucleus of reuniens (RE) +/- +/- + + ++ + 
Subthalamic/ Parasubthalamic, caudal 
(STN/PSTN) ++ + + + ++ ++ 
Medial geniculate complex (MG) + + + + ++ + 
66 
 
Hypothalamus       
Medial preoptic area, anterior 
(MPOa) + + + + + + 
Medial preoptic area, posterior 
(MPOp) ++++ ++++ ++++ ++++ ++++ ++++ 
Suprachiasmatic nucleus (SCH) ++ + +/- +/- + +/- 
Paraventricular hypothalamic nucleus 
(PVH) +/- +/- - - - - 
Periventricular hypothalamic nucleus 
(PV) + +/- - - - - 
Subparaventricular zone (SBPV) + + ++ ++ + + 
Lateral hypothalamic area (LHA) +/- +/- - - - - 
Arcuate hypothalamic nucleus (ARH) ++ + +/- +/- + + 
Ventromedial hypothalamic nucleus, 
ventrolateral (VMHvl) + ++ + + ++ + 
Tuberal nucleus (TU) + + - - + + 
Dorsomedial nucleus of the 
hypothalamus (DMH) + - - - +/- - 
Dorsal premammillary nucleus (PMd) + + ++ ++ ++ ++ 
Ventral premammillary nucleus 
(PMv) ++++ ++++ +++ +++ +++ ++ 
Supramammillary nucleus (SUM) + +/- + + + +/- 
Midbrain       
Periaqueductal gray, ventrolateral 
(PAGvl) +/- +/- +/- +/- + + 
Ventral tegmental area (VTA) +/- - - - - - 
Red nucleus (RN) +/- - - - +/- - 
Dorsal nucleus raphe (DR) +/- +/- +/- +/- + + 
Pons and Medulla       
Pontine reticular nucleus (PRN) +/- +/- +/- +/- +/- +/- 
Superior olivary complex (SOC) - - + + + + 
Principal sensory nucleus of the 
trigeminal (PSV) - - + +/- + - 
Parabrachial nucleus (PB) +/- +/- - - - - 
Dorsal tegmental nucleus (DTN) + + + + + + 
Facial motor nucleus (VII) + +/- + + + + 
Cochlear nuclei (CN) +/- - + + + + 
Vestibular Nucleus (VNC) +/- - + + + + 
Nucleus ambiguus (AMB) +/- +/- ++ ++ ++ ++ 
Hypoglossal nucleus (XII) + + + + ++ ++ 
Nucleus of the solitary tract (NTS) +/- +/- +/- +/- +/- +/- 
Dorsal motor nucleus of vagus nerve 
(DMX) + + + + ++ ++ 
Circumventricular Organs       
Subfornical organ (SFO) +/- + + + +/- +/- 
Area postrema (AP) +/- +/- +/- +/- + + 
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Patterns of hybridization signal were similar between sexes in several subdivisions of the cerebral 
cortex, including the motor (MO), piriform (PIR), and anterior cingulate (ACA) (Table 2.2). In the 
hippocampal formation, highest expression was observed in Field CA1 and CA2 (Figure 1A, 
Bregma -1.34 through -3.52mm), and lowest expression in the entorhinal area (ENT). As 
previously described for AR-ir (35-37), several cortical subplate and cerebral nuclei displayed 
apparent sex differences. The lateral septal nucleus (caudodorsal and rostroventral subdivisions, 
LSc and LSr) (Figure 2.1A, Bregma +0.62, +0.14, -0.22mm), bed nucleus of the stria terminalis 
(principal, BSTpr) (Figure 1A, Bregma -0.22mm), posterodorsal medial amygdalar nucleus 
(MEApd, Figure 1A, Bregma -1.34mm), and posterior amygdala (PA, Figure 2.1A, Bregma -
2.46mm) showed higher Ar mRNA levels in males. The cortical amygdalar area (COA) displayed 
high Ar mRNA in both sexes (Table 2.2).  
 
The thalamus and subthalamus contained low to moderate Ar hybridization signal. Conspicuous 
expression was observed in the paraventricular (PVT), medial geniculate (MG), and subthalamic 
nuclei (STN) in both sexes (Figure 2.1A, Bregma -1.34 to -3.52, Table 2.2).  
 
Hypothalamic AR-ir expression is fairly well characterized in adult mice, and Ar hybridization 
signal was consistent with previous descriptions (26,34,35,37). In brief, highest expression was 
seen in the medial preoptic area (MPO, Figure 1A, Bregma +0.14mm), arcuate nucleus (ARH), 
ventrolateral subdivision of the ventromedial hypothalamic nucleus (VMHvl, Figure 2.1A, 
Bregma -1.34mm), and ventral premammillary nucleus (PMv, Figure 2.1A, Bregma -2.46mm). 
Sex differences were apparent in the suprachiasmatic nucleus (SCH) and ARH, with expression 
higher in male mice. Higher Ar hybridization signal was also apparent in the periventricular (PV) 
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and dorsomedial (DMH) nuclei of the hypothalamus in males. The tuberal nucleus (TU) displayed 
low Ar expression, and the paraventricular hypothalamic nucleus (PVH) displayed very low 
expression in both sexes (Table 2.2). The supramammillary nucleus (SUM) was observed to have 
an apparent sex difference, with females exhibiting very low expression, and males with higher 
but still low Ar mRNA (Table 2.2).  
 
In the midbrain, Ar mRNA was low in both sexes, and mainly observed in the periaqueductal gray 
(ventrolateral column, PAGvl) and dorsal raphe nucleus (DR, Figure 2.1A, Bregma -3.52 and -
5.02mm). Very low expression was also observed in the ventral tegmental area (VTA) and red 
nucleus (RN) (Table 2.2).  
 
In the pons and medulla, low Ar mRNA expression was observed in the dorsal tegmental (DTN), 
facial motor (VII), hypoglossal (XII), and dorsal motor nucleus of the vagus nerve (DMX) in both 
sexes (Figure 2.1A, Bregma -5.02mm). Very low hybridization signal was observed in the 
parabrachial nucleus (PB) and pontine reticular nucleus (PRN, Table 2.2). Ar mRNA was also 
detected in the nucleus ambiguus (AMB, Figure 2.1A, Bregma -7.08mm), and nucleus of the 
solitary tract (NTS, Figure 2.1A, Bregma -7.48mm) of both sexes, while the cochlear (CN) and 
vestibular nuclei (VNC) displayed very low signal in males, but not in females (Table 2.2).  
 
In circumventricular organs, we observed very low to low Ar hybridization signal in the 





AR-immunoreactivity in adult mouse brain 
In the adult brain, our findings thoroughly replicate previous reports by different groups 
(26,34,36,37). In brief, high AR-ir was observed in the BSTpr, MPO, VMHvl, PMv, and MEApd. 
In addition, and in agreement with Ar mRNA distribution, we found moderate to low AR-ir in the 
PIR, ACA (Figure 2.2A), CA1 and CA2 (Figure 2.2B), septohippocampal nucleus (SH), LSc 
(Figure 2.2C), PVT (Figure 2.2D), subparaventricular zone (SBPV, Figure 2.2E), PA, PAGvl 
(Figure 2.2F), DTN (laterodorsal), and many nuclei of the cranial nerves, including the principal 
sensory nucleus of the trigeminal nerve (PSV), VII, and medial vestibular nucleus (MV, Figure 
2.2G). Scattered AR-ir was also observed in the SFO (Figure 2.2H) and AP.  
 
Prepubertal distribution of Ar mRNA 
Ar mRNA expression was analyzed in two developmental prepubertal stages, PND 12 and 21 (n = 
3-4/sex/age, Figure 2.1B-C). In the cerebral cortex, both male and female mice at PND 12 and 
PND 21 showed consistent and similar expression between sexes (Table 2.2). The anterior 
olfactory nucleus (AON) displayed moderate Ar hybridization signal, while the taenia tecta (TT), 
PIR, and ACA displayed low Ar hybridization signal (Figure 2.3A-D). The endopiriform (EP) and 
MO showed very low Ar hybridization signal in PND 12 and PND 21 mice (Table 2.2).  
 
In the hippocampal formation, expression level of Ar mRNA in prepubertal mice was similar to 
that observed in adults. Briefly, expression of Ar mRNA in both male and female mice was 
detected in the induseum griseum (IG, Figure 2.3E-F), CA1, CA2 (Figure 2.3G-H), and 
presubiculum/subiculum (PRE/SUB). Higher expression was observed in CA1 and CA2, while 
lower expression was found in Field CA3 (CA3, Table 2.2). In the dentate gyrus (DG), lower 
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expression was observed in PND 12 of male and female mice. The ENT displayed moderate 
expression at PND 12 in male and females, but expression decreased by PND 21.  
 
Cortical subplate and cerebral nuclei also exhibited consistent Ar hybridization signal in 
prepubertal mice in the SH (Figure 2.3E-F) and PA. The LSc displayed moderate expression in 
PND 12 (Figure 2.4A-C), and PND 21 (Figure 2.4D-F). Ar hybridization signal was higher in PND 
12 males compared to females, (Figure 2.4C), and was not different between sexes at PND 21 
(Figure 2.4F). The BSTpr showed sex differences at PND 12 (Figure 2.4G-I) with higher Ar levels 
in males, and similar levels between sexes at PND 21 (Figure 2.4J-L), whereas the MEApd showed 
similar pattern of Ar expression in between sexes at PND 12 and PND 21 (Table 2.2). Ar mRNA 
in the COA was similar between sexes, with low expression at PND 12, increasing to high 
expression by PND 21 (Table 2.2).  
 
In thalamic nuclei, moderate to high levels of Ar hybridization signal was observed in the PVT 
(Figure 2.5A-B), the nucleus of reuniens (RE, Figure 2.5C-D), the ventral posterior complex nuclei 
(VP, Figure 2.5E-F), the STN (Figure 2.5G-H) and the MG (Table 2.2). No difference between 
sexes and prepubertal ages was apparent.  
 
In the hypothalamus, the MPO and anteroventral periventricular nucleus (AVPV) showed similar 
levels of Ar in both sexes at PND 12 and PND 21 (Table 2.2). The SCH had similar levels of Ar 
at PND 12 in both sexes (Figure 2.6A-C, E-G), however, expression increased in male mice at 
PND 21 (Figure 2.6G). The SBPV, although apparently higher in males, did not reach statistical 
significance when comparing sexes at both prepubertal ages (Figure 2.6D, H). The PMv showed 
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no difference between sexes at PND 12 and PND 21 (Figure 2.6I-K, M-O), however expression 
was higher in PND 12 (Figure 2.6K) compared to PND 21 mice (Figure 2.6O). In the dorsal 
premammillary nucleus (PMd), Ar mRNA levels were low to moderate, and no difference between 
sexes or ages was observed (Figure 2.6L, P). The SUM displayed low Ar mRNA expression in 
both sexes at PND 12, and low expression in males and very low expression in females at PND 21 
(Table 2.2). The TU exhibited no detectable Ar hybridization signal at PND 12, but low signal was 
detected at PND 21 (Table 2.2). The PVH had no detectable Ar hybridization signal at either PND 
12 or 21 (Table 2.2).  
 
In the midbrain, expression of Ar hybridization signal was low to very low. The PAG showed low 
expression which was consistent between sexes, particularly in the caudal ventrolateral column 
(PAGvl, Figure 2.7A-B, Table 2.2). The DR also showed a low to very low level of Ar mRNA 
expression in PND 12 and PND 21 mice (Table 2.2). 
 
In the pons and medulla, the DTN showed consistent, moderate expression in both sexes and in 
both prepubertal ages (Figure 2.7A-B, Table 2.2). Low Ar mRNA expression was detected in the 
superior olivary complex (SOC, Figure 2.7C-D), the VII (Figure 2.7E-F), the VNC, and the CN 
(Table 2.2) in both prepubertal stages of both sexes. Low to moderate Ar expression was observed 
in the AMB (Figure 2.7G-H), the DMX and the XII (Figure 2.7I-J) in males and females. Very 
low to low levels of Ar mRNA were detected in the PRN and the PSV (Table 2.2).  
 
In circumventricular organs, Ar mRNA expression was low to very low in the SFO and AP of both 




Brain sites selectively responsive to androgens 
Because this study is focused on brain sites that are selective targets of androgens, we further 
mapped the areas that express AR, but not the enzyme aromatase or ERα. We chose to examine 
areas expressing ERα due to the well described role of estrogens in masculinization of the male 
brain during development (49,50), as well as the major role that estrogens play in female pubertal 
development (51). We used mouse models of Cre-induced reporter gene expression (aroCre and 
ERαCre), previously validated (39,41), to allow well-defined labelling of the neuronal soma. Only 
adult female mice were assessed for colocalization between Cre-induced reporter expression and 
AR-ir (n = 3-4/group). 
 
Distribution of aroCre dependent eGFP-L10a reporter expression was consistent with previous 
literature (52-55). Briefly, eGFP was mostly restricted to forebrain sites, particularly cerebral 
nuclei and hypothalamus. Virtually no eGFP-positive neurons were detected in the neocortex, 
hippocampal formation, thalamus, midbrain, or hindbrain. Highest number of eGFP-positive 
neurons were observed in the BSTpr and the MEApd (Figure 2.8A-D), and a moderate number in 
the MPO and the VMHvl (Figure 2.8E-H). Colocalization between aroCre induced eGFP and AR-
ir was mostly observed in the BSTpr and the MEApd. The MPO showed virtually no coexpression 
of AR-ir and eGFP, whereas the VMHvl showed partial co-localization (Figure 2.8E-H). In the 
VMHvl, three distinct populations were apparent; those co-expressing AR-ir and aroCre;eGFP, 
those expressing only AR-ir, and those expressing only aroCre;eGFP.  Notably, in the LSc and 
PMv, two sites of high AR-ir, very few eGFP positive neurons and no colocalization between AR-
ir and aroCre-eGFP was observed (Table 2.3). 
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Table 2.3: Subjective analysis of colocalization of AR-ir and eGFP in aroCre and ERαCre mouse 
models. +, high colocalization; +/-, partial colocalization; -, virtually no or very few colocalization. Areas 
not represented had no colocalization. 
 Adult Female (PND 56-70) 
Brain areas and nuclei 
AR-ir 
aroCre;eGFP ERαCre;eGFP 
Cortical Subplate and Cerebral Nuclei  
Lateral septal nucleus, caudodorsal (LSc) - - 
Lateral septal nucleus, rostroventral (LSr) - +/- 
Bed nucleus of stria terminalis, principal nucleus 
(BSTpr) + + 
Medial amygdalar nucleus, posterodorsal (MEApd) + + 
Hypothalamus  
Medial preoptic area, anterior (MPOa) - +/- 
Medial preoptic area, posterior (MPOp) - + 
Periventricular nucleus, anterior (PVa) - +/- 
Arcuate hypothalamic nucleus (ARH) - +/- 
Ventromedial nucleus, dorsomedial (VMHdm) - - 
Ventromedial nucleus, ventrolateral (VMHvl) +/- + 
Tuberal medial nucleus (TU) - +/- 
Dorsomedial nucleus of the hypothalamus (DMH) - +/- 
Lateral hypothalamic area (LHA) - +/- 
Ventral premammillary nucleus (PMv) - +/- 
Dorsal premammillary nucleus (PMd) - - 
Brainstem  
Periaqueductal gray, ventrolateral (PAGvl) - +/- 
Area Postrema (AP) - +/- 
 
We next assessed if brain sites that are direct targets of androgens are also responsive to circulating 
estrogens via ERα. Here, we also used Cre-induced eGFP-L10a expression driven by the ERα 
promoter (41) to allow for better cellular definition and to potentially identify cells that express 
ERα in distinct phases of development. As described before (9,26,56,57), and as expected due to 
the role of ERα in the organization of sex differences in the brain, eGFP was widespread and 
densely expressed in multiple brain areas of male and female brains. This was particularly evident 
in forebrain nuclei, including both sexually dimorphic and non-dimorphic sites. The entire female 




In cerebral nuclei, we found that virtually all AR-ir neurons in the BSTpr and most of the MEApd 
coexpress ERαCre;eGFP (Figure 2.9A-D, Table 2.3). In the LS, we found that most dual labeled 
AR-ir and eGFP neurons were distributed in the rostroventral subdivision, whereas the caudodorsal 
subdivision showed segregated populations. In the hypothalamus, the posterior MPO has near 
complete colocalization, whereas about half of AR-ir neurons in the anterior MPO colocalized 
with eGFP. We also found clear differences in the VMH, where most of AR-ir neurons in the 
ventrolateral subdivision co-express eGFP, but not those in the dorsomedial subdivision, which 
are almost exclusively AR-ir (Figure 2.9E-F). There was also moderate co-expression of eGFP 
and AR-ir in the PMv, and distinct groups of AR-ir or eGFP positive neurons were observed 
(Figure 2.9G-H). 
 
In the brainstem, partial colocalization was observed in the PAGvl and in the AP. In cranial nerve 
nuclei, including VII, VNC, DMX (Figure 2.9I-J) and AMB (Figure 2.9K-L), there were two 
distinct populations; neurons that expressed AR-ir, or those that expressed ERαCre-eGFP. 
 
Discussion 
 In this study, we characterized the expression of Ar mRNA in the brain of adult and two 
prepubertal time points of male and female mice. We show that at PND 12 and 21, before the 
activation of the HPG axis, many brain nuclei express high levels of Ar in both sexes. Additionally, 
we highlight specific nuclei and subpopulations of neurons that are selectively responsive to 
androgens. Mouse models carrying Cre-induced reporter genes for aromatase and ERα were used 
to allow for better cellular (cytoplasmic boundaries) delimitation and to take advantage of the 
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possibility of identifying cells that express aromatase or ERα in different phases of development. 
We focused on ERα due to the well described role of estrogens in masculinization of the male 
brain during prenatal development (49,50), and in female pubertal development and fertility 
(51,58). Further studies will be necessary to evaluate if the identified brain sites are responsive to 
alternative estrogens receptors. 
 
Systematic characterization of AR expression during prepubertal development is essential for 
understanding how androgens can shape brain organization and activation of neural circuits. While 
circulating androgens are low in the prepubertal period, we show that AR is highly expressed in 
many areas of the brain in both sexes during this time window. The exact role of AR in brain 
development in general, and in specific neuronal subpopulations is not well described. It has been 
demonstrated that gonadal hormones during puberty can further organize and refine neural circuits 
(59,60). During adolescence, pruning and remodeling of synapses, morphology, density, and 
sexual dimorphism of dendritic spines occurs throughout the brain. In many brain sites, this fine 
remodeling is orchestrated by gonadal hormones, particularly androgens (61-65). Thus, increased 
AR expression during the prepubertal window in both sexes plays a key role in the continuous 
developmental process towards the adult brain. Sex differences in circulating steroids during 
pubertal transition would ultimately determine the circuitry, morphology, and neurochemical fate 
of the subpopulations of neurons.  
 
Sex differences in AR expression are most apparent in areas related to male sexual behavior and 
reproduction, including the well characterized BSTpr, MPO, MEApd, and LS (26,35,66,67).  
Differences were also observed during development, with similar Ar expression at PND 12 
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between males and females (e.g., BSTpr and LS), and higher Ar in males at PND 21, in agreement 
with previous reports showing greater hypothalamic AR-ir in prepubertal male mice (26). 
Nonetheless AR is still prevalent in the female brain and is expressed in a multitude of different 
brain nuclei.  
 
While the role that AR plays in the prepubertal and adult female brain is not fully understood, 
models of female androgen excess demonstrate that prenatal and prepubertal androgen exposure 
has the potential to heavily impact female physiology. For example, polycystic ovary syndrome 
(PCOS) is partly characterized by female androgen excess, and can significantly impact fertility, 
body weight and insulin sensitivity (68-70). PCOS-like features can be replicated in mice, with 
one prepubertal model inducing androgen excess beginning at PND 19 (71) and another at PND 
21 (72). This peripubertal androgenization model induces changes upon multiple tissues, including 
the brain, eliciting well described effects on reproduction and metabolism (73,74). The exact brain 
sites associated with the consequences of hyperandrogenism in females have not been fully 
determined. Defining selective and non-selective brain sites responsive to androgens is an 
important first step for a better mechanistic understanding of the pathological origins of diseases 
of androgen excess.  
 
Brain AR expression and distribution have been previously characterized in the rat (67,75), 
hamster (76), musk shrew (77), and monkey (78). These findings, however, are not directly 
translatable to the mouse due to species differences. For example, AR is abundant in the 
dorsomedial VMH (VMHdm) of adult male rats (20,67,75), but much less so in adult male mice. 
It is important to be aware of species differences, particularly in the mouse, which is a frequently 
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used model organism in studies using genetic and molecular tools. Furthermore, because the 
number of neurons necessary for a specific function may not be determined a priori, moderate and 
low AR expression in extra-hypothalamic and extra-limbic areas is not irrelevant or less important. 
Consistent with this concept, Ar expression in cranial nerve nuclei of both sexes during pre-
pubertal development is particularly interesting. Many nuclei along the olfactory and auditory 
pathways express AR, but studies exploring the role of androgenic signaling in cranial nerve nuclei 
have been limited (79,80). Androgens promote neuronal survival and axon regeneration in cranial 
nerve motor nuclei in male and female rats (81,82). In the spinal cord, however, androgens acting 
on AR protect against motor neuron death in the spinal nucleus of the bulbocavernosus (SNB) 
during postnatal development in males, resulting in a male-biased sex difference in cell number 
and morphology (83,84). It remains to be determined as to why circulating androgens induce 
sexual dimorphism in some areas of the brain, but not others, and why specific nuclei preferentially 
respond to androgens, rather than estrogens, to promote neuronal survival, and if these events occur 
before puberty when androgens are low but AR expression is present in many nuclei of both sexes. 
Answers to these questions may require a closer look into the regulation of AR signaling 
complexity, including the role of alternative ligands and ligand-independent signaling properties 
(85).  
 
While this study examines the distribution of AR in male and female prepubertal mice, we have 
not systemically mapped ERα or other estrogen receptors in the same experimental groups. 
Instead, we have examined AR immunoreactivity in neurons coexpressing an ERαCre reporter 
gene. The advantage of this model is that cells are labelled permanently from the time of promoter 
expression, allowing for the visualization of all neurons that have expressed Cre during 
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development. It is highly possible however, that subpopulations of cells only transiently express 
ERα, inflating the number of cells expressing the reporter gene in adult mice. Additional studies 
will be necessary to define specific time points of postnatal development in which subpopulations 
of neurons are engaged by selective gonadal steroids.  
 
Gonadal hormones are not the only factor that contribute to sex differences in the brain. Sex 
chromosome genes, autosome genes whose expression are mediated by sex-steroid receptors, 
epigenetics, environmental factors and exposures, factors which regulate the sensitivity of a brain 
region to sex steroids, and brain immune cells all contribute to brain sex differentiation (86). Yet, 
it is clear that androgens play a very important, arguably dominant role in sex differentiation in 
rodents, and their unknown role in female brain remains to be fully determined. In the attempt to 
decrease this gap, we focused our analysis on the female brain. Our findings indicate that in various 
brain areas androgens, rather than neuroestrogens or circulating estrogens, play an important role 
in female neuronal development and physiology. They also highlight the need for greater 
investigation into the variety of actions of androgens throughout the male and female brain, 
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Figure 2.1: Ar mRNA hybridization signal expression in male and female postnatal and adult brain. 
Images from scanned autoradiographic film of adult (postnatal day/PND 56-70, A), and prepubertal (PND 
12, B, and PND 21, C) male and female mouse brain. Select coronal sections are shown in rostral to caudal 
order. Darker signal indicates higher expression of Ar mRNA. Approximate distance from bregma (left 









Figure 2.2: AR immunoreactivity (AR-ir) in adult mouse brain. A-H, fluorescent images showing AR-
ir in the adult female mouse brain (postnatal day/PND 56-70). AR-ir was observed in virtually all areas 
where we observed Ar mRNA. Selected areas from (A) cerebral cortex (dorsal and ventral anterior cingulate 
area, ACAd, ACAv), (B) hippocampal formation (pyramidal layer or sp field CA1 and CA2), (C) cerebral 
nuclei (lateral septal nucleus, caudodorsal, LSc), (D) thalamus (paraventricular nucleus of the thalamus, 
PVT), (E) hypothalamus (subparaventricular zone, SBPV), (F) midbrain (periaqueductal gray, PAG), (G) 
pons/medulla (medial vestibular nucleus, MV), and (H) circumventricular organs (subfornical organ, SFO) 
are shown. Abbreviations: AHN, anterior hypothalamic nucleus, alv, alveus, AQ, cerebral aqueduct, IG, 
induseum griseum, MS, medial septal nucleus, PRP, nucleus prepositus, PT, parataenial nucleus, V3, third 


















Figure 2.3: Ar mRNA expression in cerebral cortex in prepubertal male and female mice.  Images 
showing thionin staining for neuroanatomical reference (left column), silver grains corresponding to Ar 
mRNA (right column). Low AR expression was observed in the piriform area (PIR, A-B), dorsal and ventral 
anterior cingulate area (ACAd and ACAv, C-D), induseum griseum, septohippocampal nucleus (IG and 
SH, E-F), and CA3, and high in field CA1 and CA2 (G-H). Abbreviations: ACB, nucleus accumbens, ccg, 
genu of corpus callosum, DG, dentate gyrus, lot, lateral olfactory tract, LS, lateral septal nucleus, MOs, 




Figure 2.4: Ar mRNA expression in cerebral nuclei of male and female prepubertal mice. Silver grain 
deposition corresponding to Ar mRNA hybridization signal in prepubertal (postnatal day (PND) 12 (A-B, 
G-H), and PND 21 (D-E, J-K) male (A, D, G, J) and female (B, E, H, K) mice. (A-F) Lateral septal nucleus, 
caudodorsal (LSc) and (G-L) bed nucleus of the stria terminalis, principal nucleus (BSTpr). Bar graphs 
showing mean ± SEM integrated optical density (IOD) of silver grains (C, F, I, L). IOD was analyzed by t-
test with Welch’s correction for LSc male vs female PND 12 (P = 0.04, n = 3-4/sex), PND 21 (P = 0.46, n 
= 3-4/sex), BST male vs female PND 12 (P = 0.03, n = 3/sex), and Mann-Whitney nonparametric test for 
BST male vs female PND 21 (P = 0.68, n = 4/sex). Abbreviations: cc, corpus callosum, LSr, lateral septal 
nucleus, rostral (rostroventral), MS, medial septal nucleus, PVT, paraventricular nucleus of the thalamus, 




Figure 2.5: Ar mRNA expression in thalamic nuclei of male and female prepubertal mice. Images 
showing thionin staining for neuroanatomical reference (left column), silver grains corresponding to Ar 
mRNA (right column). (A-B) Low silver grain deposition in the paraventricular nucleus of the thalamus 
(PVT), (C-D) low to moderate in the nucleus of reuniens (RE), (E-F) ventral posterolateral and 
posteromedial nuclei of the thalamus (VPL and VPM), (G-H) subthalamic and parasubthalamic nuclei 
(STN and PSTN). Abbreviations: AD, anterodorsal nucleus of the thalamus, AV, anteroventral nucleus of 
the thalamus, cpd, cerebral peduncle, DG, dentate gyrus, em, external medullary lamina of the thalamus, 
fr, fasciculus retroflexus, ml, medial lemniscus, PF, parafascicular nucleus, RH, rhomboid nucleus, sm, 




Figure 2.6: Ar mRNA expression in hypothalamic nuclei of male and female prepubertal mice. Silver 
grain deposition corresponding to Ar mRNA hybridization signal in prepubertal (postnatal day (PND) 12 
(A-B, I-J), and PND 21 (E-F, M-N) male (A, E, I, M) and female (B, F, J, N) mice. (A-H) Suprachiasmatic 
nucleus (SCH) and subparaventricular zone (SBPV), and (I-P) dorsal and ventral premammillary nuclei 
(PMd and PMv). Note higher expression of Ar in the SCH of males at PND 21 (E). Bar graphs showing 
mean ± SEM integrated optical density (IOD) of silver grains (C-D, G-H, K-L, O-P). IOD was analyzed by 
t-test with Welch’s correction for SCH male vs female PND 21 (P = 0.01, n = 3-4/sex), SBPV male vs 
female PND 12 (P = 0.18, n = 3/sex) and PND 21 (P = 0.23, n = 3-4/sex), PMv male vs female PND 12 (P 
= 0.47, n = 3-4/sex) and PND 21 (P = 0.30, n = 3-4/sex), PMd male vs female PND 12 (P = 0.81, n = 4/sex) 
and PND 21 (P = 0.37, n = 3-4/sex), and Mann-Whitney nonparametric test for SCH male vs female PND 




Figure 2.7: Ar mRNA expression in brainstem nuclei of prepubertal male and female mice. Images 
showing thionin staining for neuroanatomical reference (left column), silver grains corresponding to AR 
mRNA (right column). (A-B) Very low to low silver grain deposition in the periaqueductal gray (PAG), 
and low in the dorsal tegmental nucleus (DTN). (C-D) Low expression in the superior olivary complex 
(SOC), (E-F) facial motor nucleus (VII). (G-H) Moderate expression in the nucleus ambiguus (AMB). (I-
J) Low to moderate expression in the dorsal motor nucleus of the vagus nerve (DMX) and hypoglossal 
nucleus (XII). Abbreviations: VIIn, facial nerve, AP, area postrema, AQ, cerebral aqueduct, c, central canal 
of the spinal cord/medulla, DR, dorsal nucleus raphe, IRN, intermediate reticular nucleus, LRN, lateral 
reticular nucleus, MARN, magnocellular reticular nucleus, PRNc, pontine reticular nucleus, caudal part, 





Figure 2.8: Brain areas expressing AR immunoreactivity (AR-ir) and aroCre;eGFP in adult female 
mice. A-L, fluorescent images showing aroCre;eGFP-L10a reporter mice (green) and AR-ir (purple). B, D, 
F, and H are higher magnification of highlighted area in A, C, E, and G. Areas with high aroCre;eGFP and 
AR-ir coexpression include the bed nucleus of the stria terminalis, principal nucleus (BSTpr ,A-B) and 
medial amygdalar nucleus, posterodorsal (MEApd, C-D). Areas with moderate aroCre;eGFP expression, but 
high AR expression include the medial preoptic area (MPO, E-F), and ventrolateral ventromedial 
hypothalamic nucleus (VMHvl, G-H). B, D, F, and H are higher magnification of highlighted areas. Solid 
white arrows indicate cells that express both AR-ir and aroCre;eGFP, hollow arrows indicate cells that 
express only AR-ir. Abbreviations: ARH, arcuate hypothalamic nucleus, AVPV, anteroventral 
periventricular nucleus, cpd, cerebral peduncle, fx, fornix, MPN, medial preoptic nucleus, opt, optic tract, 
PMv, ventral premammillary nucleus, sm, stria medularis, st, stria terminalis, VMHc, ventromedial 














Figure 2.9: Brain areas expressing AR immunoreactivity (AR-ir) and ERαCre;eGFP in adult female 
mice. A-L, fluorescent images showing AR-ir (purple) and ERαCre;eGFP-L10a expression (green). Areas 
with high ERαCre;eGFP and AR-ir colocalization include the bed nucleus of the stria terminalis, principal 
nucleus (BSTpr, A-B) and medial amygdalar nucleus, posterodorsal (MEApd, C-D). Areas with partial 
ERαCre;eGFP and AR-ir colocalization include the ventrolateral ventromedial hypothalamic nucleus 
(VMHvl, E-F) and ventral premammillary nucleus (PMv, G-H). The dorsal motor nucleus of the vagus 
nerve (DMX, I-J) and nucleus ambiguus (AMB, K-L) show distinct AR-ir and ERαCre;eGFP positive cells. 
B, D, F, H, J, L are higher magnification of highlighted areas. Solid white arrows indicate cells that express 
both AR-ir and ERαCre;eGFP, hollow arrows indicate cells that express only AR-ir. Abbreviations: AP, area 
postrema, ARH, arcuate nucleus, c, central canal of the spinal cord/medulla, fx, fornix, IG, induseum 
griseum, IRN, intermediate reticular nucleus, opt, optic tract, SCH, suprachiasmatic nucleus, sm, stria 
medularis, st, stria terminalis, V3, third ventricle, VMHdm, ventromedial hypothalamic nucleus, 














Lack of AR in LepRb Cells Disrupts Ambulatory Activity and Neuroendocrine Axes in a 




Disorders of androgen imbalance, such as hyperandrogenism in females or hypoandrogenism in 
males, increase risk of visceral adiposity, type 2 diabetes, and infertility. Androgens act upon 
androgen receptors (AR) which are expressed in many tissues. In the brain, AR are abundant in 
hypothalamic nuclei involved in regulation of reproduction and energy homeostasis, yet the role 
of androgens acting via AR in specific neuronal populations has not been fully elucidated. Leptin 
receptor (LepRb) expressing neurons co-express AR predominantly in hypothalamic arcuate and 
ventral pre-mammillary nuclei (ARH and PMv, respectively), with low colocalization in other 
LepRb neuronal populations, and very low colocalization in the pituitary gland and gonads. 
Deletion of AR from LepRb expressing cells (LepRbΔAR) has no effect on body weight, energy 
expenditure, and glucose homeostasis in male and female mice. However, LepRbΔAR female mice 
show increased body length later in life, whereas male LepRbΔAR mice show an increase in 
spontaneous ambulatory activity. LepRbΔAR mice display typical pubertal timing, estrous cycles, 
and fertility, but increased testosterone levels in males. Removal of sex steroid negative feedback 
action induced an exaggerated rise in LH in LepRbΔAR males and in FSH in LepRbΔAR females. 
Our findings show that AR can directly affect a subset of ARH and PMv neurons in a sex-specific 





Androgens are steroid hormones that play a role in reproductive and metabolic physiology in males 
and females (1-4). Androgens primarily act upon nuclear hormone receptors to induce gene 
transcription, resulting in sex-specific differences in reproductive and metabolic physiology. 
Androgens can act on either estrogen receptors (ERα/β) after conversion to estradiol via the 
enzyme aromatase, or on androgen receptors (AR) as testosterone or dihydrotestosterone via 5α-
reductase (5,6). Many tissues express AR, including gonads, reproductive tract, skeletal muscle, 
adipose tissue, and the brain. The role of AR in reproductive physiology has been demonstrated 
using models which lack AR (3) or express a non-functional AR mutant (testicular feminization, 
Tfm) (7). Global deletion of AR (ARKO) in mice results in male infertility due to lack of proper 
testicular descent and impaired spermatogenesis (8). These models replicate dysfunctions 
observed in men with low levels of androgens who experience sexual and reproductive deficits 
(9). Additionally, female ARKO mice display a subfertile phenotype, with disrupted uterine 
morphology, fewer corpora lutea, abnormal estrous cycles, and defective folliculogenesis (10). 
ARKO and Tfm females also display accelerated reproductive senescence (11,12).  
 
In addition to the role that AR plays in the reproductive axis, AR signaling is also required for 
typical metabolism. Global ARKO male mice display increased body weight, increased adiposity, 
and glucose intolerance (13,14). Furthermore, liver-specific ARKO males on a high-fat diet show 
increased body weight and insulin resistance (15), while deletion of AR in beta cells or adipocytes 




Androgens via AR exert many effects on peripheral tissues, yet the brain regulates many metabolic 
and reproductive processes, and abundantly expresses AR. Neuronal deletion of AR has produced 
controversial data, potentially due to distinct mouse models and different Cre lines used in each 
study with varying degrees and pattern of AR deletion (18-20). Neuronal ARKO male mice display 
reduced insulin sensitivity, increased body weight and adiposity later in life in one study (18), and 
no changes or decreased body weight and length in different studies (19,20). AR is widely 
expressed in many different areas of the brain, yet the role of AR in specific neuronal populations 
has not been clearly defined, and it is unclear which populations of neurons mediate androgenic 
effects.  
 
Several hypothalamic nuclei associated with the control of reproduction and metabolism express 
leptin receptors (LepRb). Leptin is primarily secreted by white adipocytes in proportion to adipose 
tissue mass, which signals peripheral energy stores via binding to LepRb (21,22). LepRb 
expressing neurons in the brain are crucial targets for converging metabolic and reproductive 
signals, and are required for the central control of metabolism and reproduction (23-28). States of 
low leptin or leptin resistance are associated with infertility, diabetes, and obesity (29-34). We and 
others have shown that LepRb cells in the ventral pre-mammillary nucleus (PMv) and in arcuate 
agouti-related peptide (AgRP) neurons, which co-express LepRb (35), integrate metabolic and 
reproductive signals required for timing of puberty and fertility (36-40). Therefore, we 
hypothesized that AR in LepRb cells contributes to the regulation of reproduction and metabolism 
at the hypothalamic level, and that loss of AR from LepRb cells would disrupt reproductive and 
metabolic homeostasis. We initially made a whole-body evaluation of LepRb and AR 
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colocalization and used a Cre-loxP approach to systematically assess the metabolic and 
reproductive phenotype generated by lack of AR signaling in LepRb cells in male and female mice.  
 
Materials and Methods 
Animal Ethics 
All research animals were acquired, used, and maintained in accordance with the National 
Research Council Guide for the Care and Use of Laboratory Animals (41), as well as federal, state, 
and local laws. Procedures and protocols were approved by the University of Michigan Committee 
on Use and Care of Animals (IACUC, Animal Protocol: PRO00008712).  
 
Animals 
LepRb-Cre (LepRbCre, JAX®  mice, B6.129-Leprtm3(cre)Mgmj/J, stock #032457 (42,43)), AR-flox 
(ARflox, 129-Artm1Verh/Sv, provided by Dr. S. Marc Breedlove, Michigan State University, with 
permission from Dr. Karel De Gendt, Catholic University of Leuven, Belgium, UFA ID: 16-
UFA03327 (8)), ROSA26-loxSTOPlox-eGFP-L10a (JAX® mice, B6;129S4-
Gt(ROSA)26Sortm9(EGFP/Rpl10aAmc/J, stock #024750, (44)), C57BL/6J (JAX® mice, stock # 000664), 
and FVB/NJ (JAX® mice, stock #001800) mice were housed in an Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) accredited facility at the University of 
Michigan Medical School. Mice were housed in a 12:12 light/dark cycle environment with 
controlled temperature (21-23°C) and humidity (30-70%). Mice were provided water ad libitum 
and were fed a phytoestrogen-reduced diet (16% protein, 4.0% fat, 48.5% carbohydrate, Teklad 
2916 irradiated global rodent diet, Envigo) or a phytoestrogen-reduced, higher protein and fat diet 
(19% protein, 9.0% fat, 44.9% carbohydrate, Teklad 2919 irradiated global rodent diet, Envigo) 
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for breeding and lactating females. Phytoestrogen-reduced diets were used to avoid any effects of 
exogenous dietary estrogens on reproductive or metabolic physiology of experimental mice.  
 
LepRb-specific deletion of AR (LepRbΔAR) 
A Cre-loxP approach was used to generate mice with deletion of AR in LepRb expressing neurons. 
LeprCre mice, which contain an IRES element plus the coding sequences for Cre-recombinase 
knocked into the LepRb-specific exon of Lepr  (42) were crossed with mice expressing lox-P sites 
flanking exon 2 of the Ar gene, located on the X chromosome (ARflox mice) (8). Mice were bred 
to homozygosity or hemizygosity for Arflox (Arfl/fl females and Arfl/Y males), and homozygosity for 
LeprCre, as complete Cre-mediated excision of floxed alleles is only accomplished with two copies 
of Cre under the Lepr promoter (45-47). No metabolic or reproductive phenotypes are observed in 
mice homozygous for LeprCre (46). Experimental mice (LepRbΔAR mice = LeprCre/Cre; Arfl/fl females 
or Arfl/Y males) were compared to littermates homozygous for the wild-type allele of Lepr (ARflox 
mice = Leprwt/wt; Arfl/fl females or Arfl/Y males). For scientific rigor and reproducibility, we 
performed the same experiment in at least two independent cohorts. Experimental animals were 
derived from multiple breeding pairs (a minimum of 5, but up to 10 breeding pairs per data set). 
Each graph shown includes animals derived from different pairs of breeders to account for 
differences in vivarium conditions. Genotyping was performed on DNA extracted from ear 
samples or tail tips obtained prior to weaning and at termination of experiments (RED Extract-N-





Table 3.1: Primers used for genotyping 
 
Immunohistochemistry  
To assess where AR and LepRb colocalize, we crossed LepRbCre mice with reporter mice that 
express eGFP-L10a in a Cre-dependent manner to obtain LepRbCre reporter mice (48). Adult male 
(n = 5/genotype) and female (n = 4/genotype) LepRbCre and LepRbΔAR reporter mice were deeply 
anesthetized with isoflurane and trans-cardially perfused with 10% neutral buffered formalin for 
10 min. Brains were dissected and post-fixed for 2 h, then transferred to 20% sucrose in 0.1M PBS 
overnight for cryoprotection. Brains were sectioned at 30 µm on a freezing microtome (Leica SM 
2010R) into 4-5 series and stored at -20°C in cryoprotectant. AR immunoreactivity was labelled 
using a modified tyramide signal amplification method previously described (49). Brain sections 
were rinsed with 0.1M PBS, incubated in 0.6% hydrogen peroxide for 30 mins, rinsed with 0.1M 
PBS, then blocked with 3% normal donkey serum with 0.25% Triton-X-100 for 1 h at room 
temperature. Sections were incubated overnight with rabbit anti-androgen receptor antibody 
(1:200, AbCam [EPR1535(2)], Cat # ab133273, RRID: AB_11156085). Sections were rinsed with 
0.1M PBS and then incubated for 1 h with biotinylated donkey anti-rabbit IgG (1:500, Jackson 
ImmunoResearch Laboratories, Cat # 711-065-152, RRID: AB_2340593), followed by incubation 
in avidin-biotin (AB) solution in PBS (1:1000, Vector Laboratories) for 1 h. Next, sections were 
Mice Primer Sequence Size (bp) 
LepRbCre  
Comm FOR 5’ TCC AAG AAG CCT CAA GGT TCC A 3’ 
Wt REV 5’ TCG TGT TGA AAT TTC TTC TTT CCA GA 3’ 
Cre REV 5’ ACG CAC ACC GGC CTT ATT CC 3’ 
Wt: 300 
Mutant: 200 






FOR 1 5’ GAG GGG AGT GTT GCA ATA CC 3’ 
FOR 2 5’ TCT ACA AAT GTG GTA GAT CCA GGC 3’ 





incubated in biotinylated tyramide (1:250, Perkin Elmer) with 0.009% hydrogen peroxide for 10 
mins, followed by incubation with streptavidin-conjugated AlexaFluor 594 (1:1000, Invitrogen, 
ThermoFisher) for 1 h. Sections were mounted onto gelatin-coated slides and coverslipped with 
ProLong Gold Antifade mounting medium (Invitrogen, ThermoFisher). The eGFP-L10a reporter 
did not require additional immunostaining to amplify fluorescent signal.  
To assess potential deletion of AR in neuroendocrine tissues, testes, ovaries, and pituitary gland 
were examined for LepRbCre mediated eGFP-L10a and AR expression. Fixed frozen gonads and 
pituitary were cryoprotected and embedded in optimal cutting temperature (OCT) compound 
(Electron Microscopy Systems). They were sectioned at 30 µm for testes, 12 µm for ovaries, and 
14 µm for pituitary on a cryostat (Leica CM 3050S) into 3-5 series on SuperFrost Plus slides 
(Fisher Scientific) and stored at -20°C. AR staining was performed as described above.  
To assess potential compensation of sex steroid receptors in LepRbΔAR cells, brain sections from 
male LepRbCre and LepRbΔAR reporter mice (n = 4/genotype) were stained for ERα 
immunoreactivity. Brain sections were rinsed with 0.1M PBS, then blocked with 3% normal 
donkey serum with 0.25% Triton-X-100 for 1 h at room temperature. Sections were incubated 
overnight in rabbit anti-estrogen receptor α antibody (1:5000, Millipore, Cat # 06-935, RRID: 
AB_310305). Sections were rinsed with 0.1M PBS and then incubated for 1 h with donkey anti-
rabbit AlexaFluor 594 Plus (1:500, Invitrogen ThermoFisher, Cat # A32754, RRID: AB_2762827) 
for 1 h. Sections were mounted onto gelatin-coated slides and coverslipped with ProLong Gold 





Table 3.2: Antibodies 
 
Metabolic phenotyping 
Body weight of experimental and control mice was measured weekly beginning at weaning (post-
natal day 21). Body composition (fat and lean mass) was quantified at 15-week old male (n = 10-
13 mice/genotype), and female (n = 8-9 mice/genotype) LepRbΔAR and ARflox mice using an NMR-
based device (Minispec LF 90II, Bruker Optics). Comprehensive Laboratory Monitoring System 
(CLAMS, Columbia Instruments) unit was used as an indirect calorimeter to measure O2 
consumption (VO2), CO2 production (VCO2), as well as food intake and spontaneous motor 
activity via photo beam sensors. Body composition and CLAMS analysis was performed at the 
Michigan Mouse Metabolic Phenotyping Center (MMPC). Male (15 weeks of age, n = 10-11 
mice/genotype) and female (19-21 weeks of age, n = 8-9 mice/genotype) LepRbΔAR and ARflox 
mice were transferred to the MMPC for CLAMS analysis. Mice were weighed before 
measurements and individually placed into the sealed chambers with free access to food and water. 























































were sampled in 10 min intervals and the motor activity was recorded every second in X and Z 
dimensions. Total energy expenditure was calculated respectively based on the values of VO2 and 
VCO2. Indirect calorimetry data was normalized to lean body mass (LBM) recorded at the end of 
the CLAMS run using an NMR-based device (Minispec LF 90II, Bruker Optics). Total energy 
expenditure was calculated using the following formula: Energy Expenditure = 3.91 x [(VO2LBM) 
+ 1.1 x (VCO2LBM)]/1000.  
 
Glucose levels were measured in blood samples obtained from tail-tip bleeding in male (n = 5-8 
mice/genotype, 11-15 weeks of age) and female (n = 7 mice/genotype, 20-21 weeks of age, after 
estrous cycle analysis was completed) LepRbΔAR and ARflox mice after an overnight fast 
(approximately 16 h) using a glucometer (OneTouch Ultra, LifeScan Inc). Males were single 
housed up to 2 weeks prior to and during GTT. After fasting blood glucose was measured, mice 
received an intraperitoneal bolus of D-glucose in sterile saline (2 mg D-glucose/g body weight) at 
0 min, and tail tip blood was collected for glucose levels at 15 min intervals for the first hour, and 
30 min intervals for the second hour (2 h total).  
 
An additional group of male (n = 9-10/genotype) and female (n = 7-8/genotype) LepRbΔAR and 
ARflox mice were fed high-fat diet (HFD, Teklad TD.88137, 42% fat, 15.2% protein, 42.7% 
carbohydrate, Envigo) for 12 weeks beginning at weaning. Mice were weighed weekly, and GTT 




Body length was measured as snout to anus distance in isoflurane (Fluriso, VetOne) anesthetized 
LepRbΔAR and ARflox male (n = 10-12 mice/genotype) and female (n = 14-15 mice/genotype) mice 
at 15 weeks of age, and at 20 weeks of age as a follow-up for females. 
 
Tissue collection and organ weight 
Adult LepRbΔAR and ARflox mice were deeply anesthetized with isoflurane and euthanized via 
decapitation. Females were euthanized during diestrus, as confirmed by the presence of 
predominantly leukocytes in vaginal smear and a uterine weight of less than 100 mg (50). Trunk 
blood was collected and allowed to clot for 45 min at room temperature, then centrifuged at 4°C 
for 20 min at 3,000 x g, followed by collection of serum which was stored at -20°C. Testes and 
seminal vesicles were dissected and weighed. Femurs were collected from LepRbΔAR and ARflox 
female mice at 20 weeks of age, fixed in 10% neural buffered formalin for 48 h, then transferred 
to 70% ethanol. Tissue was removed from bone, and femur length was measured using digital 
calipers. Pituitary gland and whole hypothalamus were quickly collected, frozen on dry ice, and 
stored at -80°C until RNA extraction. 
 
Reproductive Phenotyping 
Timing of pubertal onset was monitored daily beginning at weaning (post-natal day 21) in male (n 
= 14-17 mice/genotype) and female (n = 10-12 mice/genotype) LepRbΔAR and ARflox mice. Female 
mice were checked for day of vaginal opening (VO) and day of first estrus, defined by the presence 
of keratinized epithelial cells in vaginal lavage for two consecutive days following presence of 
predominantly leukocytes or one day preceded by proestrus (51-53). Male mice were checked 
daily for completion of balanopreputial separation (BPS) by applying gentle pressure to the 
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prepuce (54). Estrous cyclicity was analyzed in female mice beginning at 8-10 weeks of age. 
Vaginal lavage was performed daily for 35 consecutive days and estrous cycle stage determined 
based on the proportion of leukocytes, epithelial, and keratinized epithelial cells (55). Estrous cycle 
length was determined by counting the number of days between the first day of estrous in each 
cycle, and averaged for each female. Percentage of days in each estrous cycle stage was calculated 
as number of days in each cycle (diestrus, proestrus, or estrus) divided by 35 total days. Number 
of cycles over the total sampling period were counted as the number of complete estrous cycles in 
35 days.  
 
One female LepRbΔAR and one ARflox mouse (n = 6 mice/genotype) at 10 weeks of age were trio-
mated with a sexually-experienced male C57BL/6J (8-10 weeks of age) mouse. Male LepRbΔAR 
and ARflox mice (n = 7-8 mice/genotype) at 8 weeks of age were trio-bred with two FVB/NJ 
females (8-10 weeks of age). FVB/NJ female mice were chosen for their high fecundity and high 
percent of productive matings (56). Trios were allowed to breed until delivery of two consecutive 
litters per female. Time to first litter and inter-litter interval (latency to birth), and number of pups 
per litter for females were recorded.  
 
Sex steroid and gonadotropin assays  
To assess response of the HPG axis to negative feedback, male LepRbΔAR and ARflox mice (n = 7-
11 per group) were orchidectomized (ORX), and female LepRbΔAR and ARflox mice (n = 5-13) 
ovariectomized (OVX) under isoflurane anesthesia. One week after gonadectomy, mice were 
deeply anesthetized with isoflurane, and euthanized via decapitation. Intact female LepRbΔAR and 
ARflox mice were euthanized during diestrus. Trunk blood was collected as described above, and 
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serum samples were sent to the University of Virginia Ligand Core for the following assays: 
mouse/rat LH/FSH multiplex (LH reportable range = 0.24 – 30.0 ng/mL, FSH reportable range  = 
0.48 – 300.0 ng/mL, intra-assay %CV = 4.0-5.4, inter-assay %CV = 8.6 - 8.9), mouse/rat 
testosterone IBL ELISA (IBL, Cat# IB79174, RRID#: AB_2784504, reportable range = 10.0 - 
1600.0 ng/dL, assay sensitivity = 6.6 ng/dL, intra-assay %CV = 5.4 - 6.0, inter-assay %CV = 7.8 
- 9.4). ORX LepRbΔAR and ARflox males were compared to intact LepRbΔAR and ARflox males (n = 
11-15 per group). An additional group of LepRbΔAR and ARflox males (n = 8-9 per group) were 
single housed for at least 2 weeks prior to ORX to control for a group housed setting, which may 
alter testosterone levels in male mice (57).  
 
For female serum testosterone, Δ-4 steroids analysis via LC/MS/MS was performed at the 
Michigan Regional Comprehensive Metabolomics Resource Core at the University of Michigan. 
Mouse serum samples were processed using 30 µL of serum to 100 µL of internal standard and 
were reconstituted with 100 µL of 40% methanol in water for a sample dilution of 3.33x. This was 
done to keep processing consistent with sample volume being limited. Samples were extracted 
using SLE and injection volume was 20 µL. Serum samples with remaining volume were pooled 
and then processed in 3200 µL aliquots of serum with 100 µL of internal standard and were 
reconstituted with 100 µL of 40% methanol in water for a sample dilution of 0.5 (2x 
concentration). This was done because previous lower volume samples showed very few 
measurable signals. Samples were extracted using SLE and injection volume was 20 µL. Variation 
was fairly high as signal strength, while quantifiable, was still quite low. This was to be expected 




Serum IGF1 assay 
To assess serum insulin-like growth factor 1 (IGF1) levels in females at 20 weeks of age, trunk 
blood was collected and serum processed as described above. Serum IGF1 was quantified using a 
mouse/rat IGF1 Quantikine ELISA Kit (R&D Systems, Cat# MG100, RRID#: AB_884569, assay 
range = 31.2 - 2,000 pg/mL, assay sensitivity = 8.4 pg/mL, intra-assay %CV = 3.3 - 5.6, inter-
assay %CV 4.3 – 9.1) following manufacturer’s instructions. Samples were assayed in duplicate.  
 
Quantitative PCR (qPCR) 
Pituitary gland and whole hypothalamus from adult, gonad intact, group housed male ARflox (n = 
3-4) and LepRbΔAR (n = 4) mice were homogenized with Qiazol reagent (Qiagen), and total RNA 
was isolated using the RNeasy Plus Mini kit (Qiagen), including genomic DNA elimination, 
following manufacturer’s instructions. First-strand cDNA was synthesized using SuperScript® II 
reverse transcriptase and oligo(dT). Gene expression was quantified in triplicate samples using 
qPCR with a CFX-384 Bio-Rad Real-Time PCR detection system with SYBR Green® 
(ThermoFisher) reaction for Kiss1, Tac2, and Pdyn, and TaqMan Gene Expression MasterMix 
(Applied Biosystems) for Ar. Transcript levels were normalized to the housekeeping gene β-actin 
(Actb). mRNA expression of target genes in male ARflox and LepRbΔAR mice was determined by a 
comparative cycle threshold (Ct) and relative (to Actb) gene copy number was calculated as 2-ΔΔCt, 
and is presented as the percentage of relative mRNA expression of ARflox mice. Primers used are 





Table 3.3: qPCR Primers 
 
Analysis of Data and Image Production 
Digital images were acquired using an Axio Imager M2 (Carl Zeiss) with a digital camera 
(AxioCam, Zeiss) using Zen Pro 2 software (Zeiss). Colocalization of neurons that express AR-ir 
and eGFP-L10a was quantified in one section on one side of each animal (n = 4-5 mice/sex) in 
specific hypothalamic nuclei (medial pre-optic area, MPO, rostral (rARH), mid (mARH), and 
caudal (cARH) arcuate, dorsomedial nucleus of the hypothalamus, DMH, PMv, nucleus of the 
solitary tract, NTS). Colocalization of neurons that express ERα-ir and eGFP-L10a was quantified 
in one section on one side of each animal (n = 4/genotype) in mARH and PMv. Cell counts were 
performed on images taken at 20× magnification using Photoshop software (Adobe Creative 
Cloud) Analysis Count Tool. Adobe Photoshop and Illustrator software were used to crop, scale, 
label, and assemble images into figures.  
 
Statistics 
Gene Primer Sequence Company Reference 
Ar 
FOR 5’ CTG CCT TGT TAT CTA GCC TCA 3’ 
REV 5’ ATA CTG AAT GAC CGC CAT CTG 3’ 
Probe:  /56-FAM/ACC ACA TGC /ZEN/ACA AGC TGC 
CTC T/3IABkFQ/ 
IDT Mm.PT.47.17416675 
Kiss1 FOR 5’ GCT GCT GCT TCT CCT CTG TG 3’ REV 5’ TCT GCA TAC CGC GAT TCC TT 3’ IDT Custom 
Tac2 FOR 5’ TCT GTG TGG GAT GTA AAG GAG GG 3’  REV 5’ GAC AGC GCG AAA CAG CAT GG 3’ IDT Custom 
Pdyn FOR 5’ CGT TGC TGT CAA GAT CTG TTG 3’  REV 5’ AGG CAG TCC GCC ATA ACA TT 3’ IDT Custom 
Actb 
FOR 5’ GAT TAC TGC TCT GGC TCC TAG 3’ 
 REV 5’ GAC TCA TCG TAC TCC TGC TTG 3’ 
Probe: 5’ CTG GCC TCA /ZEN/CTG TCC ACC TTC C 3’ 
IDT Mm.PT.39a.22214843.g 
Actb FOR 5’ CAG CCT TCC TTC TTG GGT ATG G 3’ REV 5’ AGC TCA GTA ACA GTC CGC CT 3’ IDT Custom 
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Data are reported as mean ± standard error of the mean (SEM). Data analysis was performed using 
GraphPad Prism software (Version 8). Data was analyzed for normal distribution using Shapiro-
Wilk test (significance level alpha 0.05). Unpaired t-test with Welch’s correction was used for day 
of VO, latency to birth for males, number of pups per litter, percentage of days in diestrus and 
estrus, femur length, serum IGF1, female serum testosterone, single housed male serum 
testosterone, female fat mass, female body length, food intake, energy expenditure (male and 
female, dark, light and 24h), ambulatory activity (male, dark and light phase, female, dark, light, 
and 24h), fasting blood glucose, area under the curve for GTT, pituitary Ar and hypothalamic 
Kiss1, Tac2, and Pdyn relative gene expression. Non-normal data was analyzed using Mann-
Whitney non-parametric test (first estrus, female latency to birth, day of BPS, percentage of days 
in proestrus, cycle length, number of cycles, testes and seminal vesicle mass, male fat mass, male 
and female lean mass, male body length, and male 24 h activity). Male serum testosterone values 
were log transformed prior to analysis by Mann-Whitney non-parametric test for group housed 
males and unpaired t-test with Welch’s correction for single housed males. Analysis for potential 
outliers was performed using the ROUT method (Q = 1%). Two-way ANOVA with repeated 
measures and Holm-Sidak correction was used to analyze glucose tolerance test and body weight 
data. Serum LH and FSH values were analyzed by two-way ANOVA with multiple comparisons 
and Holm-Sidak correction. Exact P values are reported and statistical significance is defined as P 




High colocalization of AR and LepRb in the arcuate and PMv nuclei 
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Several populations of LepRb neurons have been described in brain sites that also contain AR. 
These include the medial pre-optic area (MPO), arcuate nucleus (ARH), dorsomedial nucleus of 
the hypothalamus (DMH), ventral premammillary nucleus (PMv), and nucleus of the solitary tract 
(NTS) (43,58,59). Expression of AR in LepRb neurons was observed primarily in the ARH and 
PMv of both males and females (Figure 3.1A-D), which is consistent with previous studies (60).  
Table 3.4: Colocalization quantification of LepRb neurons with AR 
 
In the mid-ARH, approximately 30% of LepRb cells express AR in both sexes (Figure 3.1K). Most 
colocalization of AR and LepRb was observed at the mid/tuberal region of the ARH, with fewer 
LepRb cells co-expressing AR in the caudal and rostral ARH (rARH, ~24%, cARH, ~10-12%, 
Table 3.4). The PMv has the highest degree of colocalization, with approximately 49% of male 
and 35% of female LepRb cells expressing AR. Other nuclei, including the MPO (Figure 3.1E-F), 
DMH (Figure 3.1G-H), and NTS (Figure 3.1I-J) contained less than 15% of LepRb cells co-
expressing AR in both sexes.  
 Control Mice 
 Male: LepRbCre Female: LepRbCre 
Nucleus #LepRb #LepRb+AR %LepRb+AR #LepRb #LepRb+AR %LepRb+AR 
rARH 138.4 ± 
6.80 
32.2 ± 5.78 23.44 ± 4.07 124 ± 8.90 30.5 ± 6.69 24.28 ± 4.34 
mARH 187.4 ± 
15.39 
54.6 ± 11.61 28.24 ± 4.09 164.0 ± 
17.57 
49.75 ± 7.75 30.30 ± 3.65  
cARH 135.4 ± 
8.41  
13.4 ± 6.32 10.05 ± 4.55 155.0 ± 
14.53 
19.0 ± 4.38 11.91 ± 1.76 
PMv 228.6 ± 
25.05 
114 ± 16.65 49.76 ± 3.44 233.0 ± 
24.27 
84.5 ± 22.05 35.78 ± 7.61 
MPO 54.4 ± 
7.45 
7.6 ± 2.42 13.98 ± 3.49 57.25 ± 6.14 3.5 ± 0.87 6.03 ± 1.02 
DMH 221.8 ± 
51.78 
24.4 ± 5.47 11.92 ± 2.64 253.25 ± 
5.92 
12.0 ± 0.91 4.76 ± 0.45 
NTS 27.0 ± 
6.35 





In the pituitary gland, very few cells express LepRbCre;eGFPL10a (Figure 3.2A-C), and expression 
was sporadic and dispersed. qPCR was used to validate that Ar transcript levels were not affected 
in the pituitary gland. Ar gene expression levels relative to the housekeeper Actb were not 
significantly different in the pituitary gland of LepRbΔAR mice (ARflox relative expression = 100%, 
SEM = 28.59, LepRbΔAR relative expression = 162%, SEM = 19.86, t-test with Welch’s correction, 
P = 0.12).  In the testis, LepRbCre;eGFPL10a and AR co-expression was observed in few Leydig cells. 
Sertoli cells strongly express AR, but do not express LepRbCre;eGFPL10a (Figure 3.2D-F). 
LepRbCre;eGFPL10a cells were virtually absent in ovarian granulosa cells and theca cells, but were 
observed sporadically in ovarian parenchyma (Figure 3.2G-L). Liver, bone, and muscle were 
examined for LepRbCre;eGFPL10a, but reporter gene expression was very low or absent in these 
tissues. This pattern of co-localization between LepRb and AR indicate that the observed 
phenotype of LepRbΔAR mice are primarily due to deletion of AR in LepRb cells in the ARH and 
PMv. In LepRbΔAR mice, less than 4% (approximately 5-6 cells per mouse) of LepRb neurons 
express AR in the ARH and PMv of LepRbΔAR mice, indicating efficient deletion of AR in LepRb 
cells (Figure 3.3A-E and Table 3.5). 
Table 3.5: Colocalization quantification of LepRb neurons with AR in knockout mice (LepRbΔAR) 
 Knockout Mice 
 Male: LepRbΔAR Female: LepRbΔAR 
Nucleus #LepRb #LepRb+AR %LepRb+AR #LepRb #LepRb+AR %LepRb+AR 
rARH 120 ± 
13.85 
2.2 ± 0.58 1.75 ± 0.35 139.25 
± 20.17 
1.50 ± 0.65 0.99 ± 0.36 
mARH 162.8 ± 
21.85 
5.8 ± 1.36 3.60 ± 0.70 169.25 
± 14.01 
1.75 ± 0.85 1.03 ± 0.53 
cARH 140 ± 
8.44 
1.8 ± 0.49 1.34 ± 0.35 144.75 
± 17.38 
0.75 ± 0.25 0.58 ± 0.22 
PMv 238.4 ± 
30.29 
6.6 ± 1.72 2.95 ± 0.68 289.5 ± 
12.65 




No increase in ERα expression in the ARH and PMv of LepRbΔAR mice  
Fewer than 20% of LepRb cells in the ARH and PMv have been described to coexpress ERα in 
male and female mice (61). Neuronal deletion of AR in male mice results in increased ERα 
expression in the lateral septum and MPO (19). If LepRb cells in the ARH and PMv require 
androgenic signaling for proper function, we hypothesized that ERα expression would increase in 
order to compensate for loss of AR. Consistent with previous studies (61), approximately 17% of 
LepRb cells in the mARH and 5% of LepRb cells in the PMv co-express ERα in LepRbCre males 
(Figure 3.3F, H, J). With loss of AR, ERα expression in LepRb cells did not change (Table 3.6). 
In LepRbΔAR males, approximately 10% of LepRb cells coexpress ERα in the mARH and PMv 
(Figure 3.3G, I, J).   
Table 3.6: Colocalization quantification of ERα in LepRb neurons   
 Control Mice Knockout Mice 
 Male: LepRbCre Male: LepRbΔAR 
Nucleus #LepRb #LepRb+ERα %LepRb+ERα #LepRb #LepRb+ERα %LepRb+ERα 
mARH 104.5 ± 
4.87 
18.25 ± 3.52 17.48 ± 3.3 96 ± 
18.24 
10.25 ± 3.07 12.23 ± 4.60 
PMv 209.25 
± 26.41 
9.33 ± 2.12 5.40 ± 1.0 191.75 ± 
17.92 
10 ± 5.74 6.32 ± 4.29 
 
LepRbΔAR mice show typical sexual maturation and fertility 
To assess if lack of AR in LepRb cells disrupts sexual maturation, we evaluated external markers 
of puberty onset (VO) and puberty completion (first estrus) beginning at weaning. Female 
LepRbΔAR and control mice had similar day of VO (Figure 3.4A). No difference was seen in the 
day of first estrus between LepRbΔAR and control females (Figure 3.4B). LepRbΔAR and control 
females showed typical estrous cycles (Figure 3.4C), with a similar amount of time in each cycle 
stage (Figure 3.4D), estrous cycle length (Figure 3.4E), and number of cycles (Figure 3.4F).  
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LepRbΔAR and control females had a similar latency to birth (Figure 3.4G) and number of pups per 
litter (Figure 3.4H) for two consecutive pregnancies. Male LepRbΔAR and control mice had similar 
day of complete BPS (Figure 3.4I), and showed no difference in the latency to impregnate a female 
(time from start of mating to birth of pups) when mated with wild-type females (Figure 3.4J). 
 
LepRbΔAR male mice show exaggerated response to negative feedback actions of sex steroids 
Male LepRbΔAR mice display increased serum testosterone (T) compared to control males (ARflox 
mean T = 90.05 ng/dL, LepRbΔAR mean T = 297.5 ng/dL, Mann-Whitney non-parametric test, P = 
0.02, Figure 3.5A). Despite increased serum T, male LepRbΔAR mice had similar gonadal mass 
(mass of both testes, ARflox mean = 0.42 g, SEM = 0.04, LepRbΔAR mean = 0.47 g, SEM = 0.03, 
Mann-Whitney non-parametric test, P = 0.45) and seminal vesicle mass (ARflox mean = 0.38 g, 
SEM = 0.05, LepRbΔAR mean = 0.42 g, SEM = 0.04, Mann-Whitney non-parametric test, P = 0.56) 
compared to control males. Serum LH and FSH were no different between intact LepRbΔAR and 
ARflox male mice (Figure 3.5B-C).  Additionally, hypothalamic gene expression of Kiss1, Tac2, 
and Pdyn relative to the housekeeper Actb were not different in gonad intact LepRbΔAR  and ARflox 
male mice (Kiss1 relative expression: ARflox = 100%, SEM = 8.17, LepRbΔAR = 81.69%, SEM = 
22.09, t-test with Welch’s correction, P = 0.48, Tac2 relative expression: ARflox = 100%, SEM = 
8.24, LepRbΔAR = 101.7%, SEM = 9.30, t-test with Welch’s correction, P = 0.89, Pdyn relative 
expression: ARflox = 100%, SEM = 6.42, LepRbΔAR = 85.78%, SEM = 19.78, t-test with Welch’s 
correction, P = 0.53).   
 
LepRbΔAR and control mice were orchidectomized (ORX) to remove the predominant source of 
androgens (testes), resulting in loss of negative feedback to the hypothalamus and pituitary gland. 
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One week after ORX, ARflox control males showed an expected rise in serum LH, whereas 
LepRbΔAR males showed an exaggerated rise in serum LH (ORX ARflox mean LH = 1.242 ng/mL 
vs ORX LepRbΔAR = 3.265 ng/mL, two-way ANOVA, P = 0.04, Figure 3.5B). No difference in 
FSH levels were detected in ORX between ARflox and LepRbΔAR males (Figure 3.5C).  
 
Male mouse social hierarchy may result in differing levels of T among group housed cage mates 
(57,62). A separate cohort of LepRbΔAR and control males were single housed for up to 2 weeks 
to control for group housed status prior to ORX. Single housed LepRbΔAR and control males 
showed similar intact T levels (ARflox mean T = 303.8 ng/dL, SEM = 107.9, LepRbΔAR mean T = 
283.5 ng/dL, SEM = 65.66, t-test with Welch’s correction, P = 0.77, Figure 3.5D). Levels of T in 
LepRbΔAR males were similar between group and single housed mice, whereas T in single housed 
ARflox males increased to levels comparable to LepRbΔAR males. Single housed LepRbΔAR and 
ARflox ORX mice showed elevated gonadotropins, but there was no effect of genotype on LH or 
FSH. Single housed ARflox males show an increase in LH comparable to LepRbΔAR males (ORX 
ARflox mean LH = 4.26 ng/mL, SEM = 0.83, ORX LepRbΔAR mean LH = 4.91 ng/mL, SEM = 
1.07, two-way ANOVA with multiple comparisons and Holm-Sidak correction, P = 0.75, Figure 
3.5E). FSH was no different between ORX males, and FSH levels were comparable to group 
housed males (ORX ARflox mean FSH = 243.4 ng/mL, SEM = 17.99, ORX LepRbΔAR mean FSH 
= 261.6 ng/mL, SEM = 14.47, two-way ANOVA with multiple comparisons and Holm-Sidak 
correction, P = 0.67, Figure 3.5F).  
 
Serum T did not differ between ARflox and LepRbΔAR females (ARflox mean T = 1.95 ng/dL, 
LepRbΔAR mean T = 1.65 ng/dL, t-test with Welch’s correction, P = 0.49, Figure 3.5G). Levels of 
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LH in females were mostly below the detectable limit of the LH assay, as samples were collected 
during diestrus. No differences were detected between intact ARflox and LepRbΔAR female FSH. 
One week after ovariectomy (OVX), serum LH did not differ between OVX ARflox and OVX 
LepRbΔAR females (Figure 3.5H). However, OVX LepRbΔAR females display increased FSH 
compared with OVX ARflox females (OVX ARflox mean FSH =187.75 ng/mL, OVX LepRbΔAR 
mean FSH = 243.59 ng/mL, two-way ANOVA, P = 0.02, Figure 3.5I).  
 
LepRbΔAR mice show changes in ambulatory activity, lean mass, and body length in a 
sexually dimorphic manner 
To determine whether loss of AR from LepRb cells impacts regulation of energy homeostasis, 
mice underwent a comprehensive metabolic assessment. Male and female LepRbΔAR mice did not 
display a significant difference in body weight compared to control mice through 14 weeks of age 
(Figure 3.6A). No difference was observed in fat mass or lean mass in LepRbΔAR males compared 
to control males at 15 weeks of age (Figure 3.6B). LepRbΔAR females showed increased lean mass 
(about 2.5 g), but no change in percentage of lean or fat mass (Figure 3.6C), indicating that 
LepRbΔAR females are larger in size compared to control females. Body length was not different 
between LepRbΔAR males and females compared to controls at 15 weeks of age (males at 15 weeks 
of age, Figure 3.6D), but showed a trend in females at 15 weeks of age (P = 0.07, data not shown). 
A follow-up assessment showed increase in body length in LepRbΔAR females at 20 weeks of age 
(Figure 3.6D). Despite increased body length, femur length (mean femur length ARflox = 15.90 
mm, SEM = 0.11, LepRbΔAR = 15.68 mm, SEM = 0.21, t-test with Welch’s correction, P = 0.39) 
and serum IGF1 (mean serum IGF1 ARflox = 334.7 ng/mL, SEM = 33.32, LepRbΔAR = 258.1 
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ng/mL, SEM = 50.37, t-test with Welch’s correction, P = 0.23) were not different between ARflox 
and LepRbΔAR females at 20 weeks of age.  
 
Male and female LepRbΔAR mice show similar food intake (Figure 3.6E) and fasting blood glucose 
(mean male fasting blood glucose ARflox = 110 mg/dL, SEM = 7.30, LepRbΔAR = 106 mg/dL, SEM 
= 5.67, t-test with Welch’s correction, P = 0.70, mean female fasting blood glucose ARflox = 106 
mg/dL, SEM = 7.54, LepRbΔAR = 96.8 mg/dL, SEM = 10.3, t-test with Welch’s correction, P = 
0.47). GTT of both LepRbΔAR males and females on normal chow diet were similar compared with 
controls (Figure 3.6F). Area under the curve was used to compare GTT, and was not different 
between genotypes on same diet (AUC male ARflox = 3.2 x 104 mg/dL*min, SEM = 3.2 x 103, 
LepRbΔAR = 3.0 x 104 mg/dL*min, SEM = 1.9 x 103 , t-test with Welch’s correction, P = 0.62, 
AUC female ARflox = 2.8 x 104 mg/dL*min, SEM = 1.8 x 103, LepRbΔAR = 2.7 x 104 mg/dl*min, 
SEM = 3.1 x 103, t-test with Welch’s correction, P = 0.89).  
 
To determine if latent differences in body weight regulation would be uncovered with nutrient 
excess, we challenged LepRbΔAR and control mice with HFD. Previous studies have demonstrated 
that ARKO mice on HFD show increase in fat mass (17,63). After 12 weeks of HFD, LepRbΔAR 
and control male and female mice gained a similar amount of weight (Figure 3.6G) and displayed 
similar levels of fasting blood glucose (mean male HFD fasting blood glucose ARflox =  156 mg/dL, 
SEM = 13.74, LepRbΔAR = 126 mg/dL, SEM = 11.53, t-test with Welch’s correction, P = 0.10, 
mean female HFD fasting blood glucose ARflox = 126 mg/dL, SEM = 7.66, LepRbΔAR = 113.4 
mg/dL, SEM = 5.24, t-test with Welch’s correction, P = 0.18).  LepRbΔAR males and females 
displayed similar glucose tolerance after 12 weeks HFD compared with control mice (Figure 
3.6H). Area under the curve was used to compare GTT, and was not different between genotypes 
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on same diet (AUC HFD male ARflox = 4.6 x 104 mg/dL*min, SEM = 4.3 x 103, LepRbΔAR = 4.3 
x 104 mg/dL*min, SEM = 3.1 x 103, t-test with Welch’s correction, P = 0.56, AUC HFD female 
ARflox = 3.3 x 104 mg/dL*min, SEM = 2.5 x 103, LepRbΔAR = 3.2 x 104 mg/dL*min, SEM = 3.4 x 
103, t-test with Welch’s correction, P = 0.79). The GTT data of mice on different diets are not 
directly comparable because the experiments were done in different cohorts. Males on HFD, 
however, showed impairment of glucose intolerance compared to normal chow diet, validating the 
procedure. Due to lack of any difference between genotypes on HFD in both sexes, potential 
changes in energy homeostasis were not assessed further. Ambulatory activity in male, not female, 
LepRbΔAR mice was increased, specifically during the light phase (Figure 3.7A-D). Despite 
increased activity, energy expenditure in 24 h, and during light and dark phases was not different 
in male or female mice (Figure 3.7E-H). 
 
Discussion 
In this study we assessed the impact of lack of androgen signaling via AR on LepRb cells, which 
are a critical population of neurons relevant for both metabolism and reproduction. Consistent with 
previous studies of AR and LepRb expression (60), we show here that approximately 40-50% of 
LepRb neurons in the PMv co-express AR, the highest level of co-localization seen in the brain, 
followed by ~30% colocalization in the mARH. Furthermore, LepRb and AR cells in the pituitary 
gland and gonads show little to no co-expression, highlighting that androgenic input to LepRb 
cells occurs primarily in the mARH and PMv. We found that LepRbΔAR male mice show increased 
ambulatory activity, increased serum testosterone, and an exaggerated rise in serum LH in the 
absence of negative feedback. Female LepRbΔAR mice show instead an increased in linear growth, 
and a greater rise in FSH with OVX. Additionally, lack of AR does not result in upregulation of 
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ERα in LepRb mARH and PMv neurons, indicating that these populations of neurons are 
preferentially responsive to androgens rather than estrogens.  
LepRb and AR are expressed in many tissues of the HPG axis, including the pituitary gland and 
gonads (64-69). However, the degree of co-expression of LepRb and AR in the same cells is low, 
and few cells express LepRbCre in pituitary and gonads (70). While LepRbCre and AR coexpression 
is seen in some Leydig cells, deletion of AR via LepRbCre in Leydig cells is not likely responsible 
for increased serum testosterone observed in LepRbΔAR male mice. LepRbΔAR males show 
increased serum testosterone when group housed, unchanged testes mass, and are fertile, which 
does not phenocopy the low testosterone, testicular atrophy, elevated LH and FSH, and infertility 
seen in Leydig-cell specific ARKO (71). Likewise, female LepRbΔAR mice do not mimic ovary-
cell specific ARKO mice (72,73), as LepRbΔAR females do not show any difference in puberty 
onset, estrous cyclicity, or fertility. Additionally, pituitary deletion of AR results in reduced FSH 
with OVX in females (65), which is contrary to the elevation in FSH in OVX female LepRbΔAR 
mice. Therefore, it is unlikely that LepRb specific deletion of AR in the pituitary or gonads would 
result in the increased LH seen in ORX males or FSH in OVX females. The change in serum 
testosterone and gonadotropins with gonadectomy may reveal a change in hypothalamic sensitivity 
to androgens with deletion of AR in LepRb cells, or a different set point for androgenic negative 
feedback.  
 
Androgens exert negative feedback to the hypothalamus and pituitary gland via AR and ERα (74-
76). AR plays a greater role in male negative feedback to the hypothalamus, as males typically 
have higher levels of circulating androgens compared to females (77). Kisspeptin neurons in the 
ARH and anteroventral periventricular nucleus stimulate release of gonadotropin releasing 
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hormone (GnRH) and express sex steroid receptors, including ERα and AR (78,79). Androgenic 
actions on ARH kisspeptin/neurokinin/dynorphin (KNDy) expressing neurons are important for 
mediating negative feedback to the HPG axis, and may be indirectly impacted with LepRb-specific 
deletion of AR. A small population of Kiss1 neurons co-express LepRb or leptin-inducted pSTAT3 
in female mice (36,80,81), and up to 42% of Kiss1 neurons co-express Lepr mRNA in castrated 
male mice (82). However, LepRb in Kiss1 neurons is not required for leptin’s action in puberty or 
reproduction in mice (36), and LepRb signaling in Kiss1 neurons only arises in adult life, post-
sexual maturation (83). Taken together, this small sub-population of LepRb expressing Kiss1 
neurons in the hypothalamus may be indirectly responsible for the changes in LH with ORX and 
testosterone seen in LepRbΔAR males. We observed no changes in Kiss1, Tac2, or Pdyn 
hypothalamic gene expression in group housed, gonad intact males, further indicating that actions 
of androgens on LepRb are independent from KNDy neurons.   
 
Alternatively, neurons of the melanocortin system (NPY/AgRP and POMC/CART) have been 
shown to influence both reproduction and metabolism (39,40,84-87). Leptin promotes an 
anorexigenic state by stimulating ARH POMC neurons and inhibiting NPY/AgRP neurons (88-
90). Androgens have been shown to influence neurons of the melanocortin system, including 
masculinization of POMC mRNA expression and projections (91,92). However, while most 
POMC and AgRP/NPY neurons express LepRb (35,88,89,93,94), few POMC neurons express AR 
in rats (95), and AgRP/NPY neurons are not observed to coexpress AR in post-natal day 10 mice 
(96). The mechanism by which androgens impact POMC and AgRP/NPY neurons may be indirect 
and mediated via other populations of AR expressing LepRb neurons. With deletion of AR in 
LepRb cells, overall food intake and energy expenditure were not changed. Therefore, androgens 
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may act on additional populations of cells at the level of the hypothalamus to influence the 
regulation of metabolism and reproduction. 
 
LepRb are expressed in many metabolically relevant tissues, including liver and adipose (97). The 
degree of co-localization between LepRb and AR, however, is low in these peripheral tissues and 
the metabolic phenotype of LepRbΔAR does not phenocopy metabolic tissue-specific ARKO 
models, including liver (15) or adipocyte-specific ARKO (17). Both male and female LepRbΔAR 
mice showed no differences in global body fat mass, and glucose homeostasis was not altered on 
either normal chow or HFD, so it is unlikely that deletion of AR via LepRbCre in off-target tissues 
impacted our observed phenotype. Interestingly, female LepRbΔAR mice display increased lean 
mass, while male LepRbΔAR mice do not. Neuronal AR have been shown to positively regulate 
lean muscle mass, as male mice with loss of neuronal AR display decreased hindlimb muscle mass 
despite increased serum testosterone (98). LepRbΔAR females display increased body length, but 
not increased limb length, indicating an overall increase in axial rather than appendicular skeleton 
growth.  
 
LepRbΔAR male mice show increased ambulatory activity, mainly due to increased activity during 
the light phase when rodents are typically less active. Male mice with global deletion of AR DNA-
binding domain (mimics exon 2 deletion) show decreased activity (99) that is consistent with 
decreased running wheel activity seen in castrated wild-type males (100,101). However, neuronal-
specific AR knockout models provide contrasting results. CaMKIIα-iCre driven ARKO results in 
decreased activity (98), whereas nestin-Cre driven ARKO males show increased activity, which is 
correlated with an increase in E2 (19). The differences in activity seen in ARKO mouse models 
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highlights how the extent, timing, and sites of AR deletion can impact phenotype. In the absence 
of AR in certain populations of cells, such as LepRb expressing cells, estrogenic signaling is 
unopposed by androgens, and estrogens are known to increase ambulatory activity (102,103). 
Leptin increases locomotor activity via hypothalamic targets (104,105), and it is possible that sex 
steroids may modulate leptin’s effect on activity. LepRbΔAR males show elevated serum 
testosterone, which when aromatized to estradiol, can act to increase activity (106). However, this 
effect is not likely via ARH or PMv LepRb cells, as aromatase expression in these nuclei is low 
(107) and few LepRb cells express ERα in the ARH and PMv. Activity was increased in LepRbΔAR 
males particularly during the light-phase, which highlights the circadian component of activity 
which is influenced by gonadal hormones.  
 
Elevated testosterone in LepRbΔAR males was only observed in group housed males. This effect 
was not related to gonadal mass, as testes size was similar compared to control males. The impact 
of group housing highlights the role of male social hierarchy in rodents. A population of dopamine 
transporter (DAT)-expressing neurons in the PMv has been implicated in male-male aggression 
and establishment of male social hierarchy in mice (108). It is possible that AR expression in the 
PMv could play a role in the establishment of male social hierarchy. Pheromones are known to 
play a key role in social interaction and behavior in rodents, and exposure to both conspecific and 
opposite-sex odors result in Fos expression in the PMv of male and female rodents (109,110). PMv 
LepRb neurons are activated by opposite-sex odors and directly project to GnRH neurons in the 
pre-optic area (111). A sub-population of PMv LepRb neurons that co-expresses AR is therefore 
well situated to integrate gonadal signals, pheromone cues, and energy status to regulate the timing 




In summary, our findings demonstrate that deletion of AR from LepRb cells results in sex-specific 
differences in ambulatory activity, linear growth, testosterone, and gonadotropin levels. Deletion 
of AR in PMv and ARH neurons may explain this phenotype, revealing a key sexually dimorphic 
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Figure 3.1: Androgen receptor (AR) and leptin receptor (LepRb) are highly colocalized in the mid-
arcuate (mARH) and ventral premammillary (PMv) nuclei in male and female brain. A-J, fluorescent 
images showing colocalization of LepRbCre (eGFP-L10a, green) and AR immunoreactivity (AR-ir, purple) 
in the mARH (A-B), PMv (C-D), medial pre-optic area (MPO, E-F), dorsomedial nucleus of the 
hypothalamus (DMH, G-H), and nucleus of the solitary tract (NTS, I-J). Insets are higher magnification of 
A-J. K, Scatter plot graph showing percentage of LepRbCre neurons co-expressing AR (mean ± SEM, n = 5 
males and n = 4 females). Three levels of ARH were quantified (rostal, mid/tuberal, and caudal), and images 
for mARH are presented (A-B). Solid white arrows indicate LepRb cells which co-express AR. Arrows 
with black center indicate LepRb cells which do not co-express AR. Abbreviations: 3v, third ventricle, AP, 
area postrema, cARH, caudal arcuate, c, central canal of the medulla, DMX, dorsal motor nucleus of the 
vagus nerve, fx, fornix, OV, vascular organ of the lamina terminalis, rARH, rostral arcuate, VMH, 





Figure 3.2: Co-expression of androgen receptor (AR) and leptin receptor (LepRb) in the pituitary 
gland and gonads is very low. A-I, fluorescent images showing LepRbCre (eGFP-L10a, green, A, D, G) 
and AR immunoreactivity (AR-ir, purple, B, E, H) expression in the pituitary gland (A-C), testis (D-F), and 
ovary (G-I). C, F, I, merged images. LepRbCre expression was low in the pituitary gland (A-C). Female 
pituitary gland is shown in A-C. LepRbCre expression in the testes (D-F) was limited to few Leydig cells 
and virtually absent from Sertoli cells. Ovarian (G-I) LepRbCre expression was sporadic in ovarian 
parenchyma, and absent in granulosa and theca cells. Solid white arrows indicate LepRb cells which co-
express AR. Arrows with black center indicate LepRb cells which do not co-express AR. Abbreviations: 
CL, corpus luteum, GC, granulosa cell, LC, Leydig cell, oo, oocyte, SC, Sertoli cell, TC, theca cell. Scale 




Figure 3.3: Deletion of androgen receptor (AR) in LepRbΔAR mice induces no change in estrogen 
receptor alpha (ERα) expression in leptin receptor (LepRb) expressing cells. A-D, fluorescent images 
showing AR immunoreactivity (AR-ir, purple) and LepRbΔAR (eGFP-L10a, green) expression in mid-
arcuate nucleus (mARH, A-B) and ventral pre-mammillary nucleus (PMv, C-D) of a LepRbΔAR male (A, 
C) and female (B, D) hypothalamus. Inset is higher magnification of A-D. E, scatter plot graphs of 
percentage of LepRbΔAR neurons co-expressing AR (mean ± SEM, n = 5 males and n = 4 females, E). Three 
levels of ARH were quantified (rostal, mid/tuberal, and caudal), and images for mARH shown (A-B). Less 
than 4% of LepRbΔAR express AR in the mARH and PMv in both sexes. Arrows with black center indicate 
LepRb cells which do not co-express AR. F-I, fluorescent images showing colocalization of LepRbCre (F, 
H) and LepRbΔAR (G, I) (eGFP-L10a, green) and ERα immunoreactivity (ERα-ir, purple) in mARH (F-G), 
and PMv (H-I). J, scatter plot graph showing percentage of LepRbCre neurons co-expressing ERα (mean ± 
SEM, n = 5 males). Insets are higher magnification of F-I. Solid white arrows indicate LepRb cells which 
co-express ERα. Arrows with black center indicate LepRb cells which do not co-express ERα. 
Abbreviations: 3v, third ventricle, fx, fornix, VMH, ventromedial hypothalamus. Abbreviations based on 




Figure 3.4: Deletion of androgen receptor (AR) in leptin receptor (LepRb) cells does not impact 
puberty timing and fertility in males and females. A-B, scatter plot graphs of age at vaginal opening 
(VO), and age at first estrus (B), between ARflox female (n = 11-12) and LepRbΔAR (n = 7-10) mice. C, 
representative cycles shown for ARflox (left panel) and LepRbΔAR (right panel). Abbreviations: E, estrus, P, 
proestrus, M, metestrus, D, diestrus. ARflox and LepRbΔAR females show similar percentage of time in each 
cycle stage (D), typical estrous cycle length (E), and number of cycles per 35 days (F).  G-H, LepRbΔAR 
females show typical latency to birth and number of pups per litter when mated with wild-type males (ARflox 
n = 6, LepRbΔAR n = 6). I, day of complete balanopreputial separation (BPS) was not different between 
ARflox males (n = 17) and LepRbΔAR (n = 14). J, latency to birth did not differ in wild-type females mated 




Figure 3.5: LepRbΔAR mice display higher testosterone and altered gonadotropin levels in a sexually 
dimorphic manner. A, scatter plot graph showing serum testosterone (T) in group housed intact ARflox and 
LepRbΔAR males. Serum T levels for males are plotted on a log scale to better illustrate distribution of 
individual data points. B, serum luteinizing hormone (LH) was significantly different for treatment (intact 
vs ORX) and genotype (ARflox intact n = 11, ORX n = 7, LepRbΔAR intact n = 15, ORX n = 11-12), with 
LepRbΔAR showing higher LH with ORX vs ARflox males. C, serum follicle stimulating hormone (FSH) was 
not different between genotype or treatment. D-F, scatter plot graphs showing T, LH, and FSH in singled 
housed intact and ORX males (ARflox intact n = 9, ORX n = 8, LepRbΔAR intact n = 8, ORX n = 8). Single-
housed male mice did not show significantly different levels of T, LH, or FSH, either intact or ORX. G, 
serum T was not different between ARflox and LepRbΔAR and females. H, serum LH was not different with 
treatment or genotype in female LepRbΔAR compared to ARflox females. I, serum FSH was significantly 
different for treatment (intact vs OVX), with LepRbΔAR females showing elevated FSH with OVX compared 
to OVX ARflox females. Intact (squares, male) and orchidectomized (ORX, circles, male) male ARflox 
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(white) and LepRbΔAR (blue). ARflox females (white circles intact, grey circles OVX), LepRbΔAR (pink 














Figure 3.6: Deletion of androgen receptor (AR) in leptin receptor (LepRb) cells results in increased 
body length in females. A, Scatter plot graphs showing body weight of male ARflox (n =13) and LepRbΔAR 
(n = 11), female ARflox (n = 13) and LepRbΔAR (n = 12) mice. B-C, scatter plot graphs showing body 
composition of male and female ARflox and LepRbΔAR mice in total grams of lean and fat mass and percent 
lean and fat mass. Female LepRbΔAR show increased total lean mass but no difference in percentage of lean 
mass compared to ARflox females. D, scatter plot graph of body length of ARflox and LepRbΔAR male and 
female mice. Female LepRbΔAR display greater body length than ARflox females. E, scatter plot graph of 
average food intake, which was not different in male or female ARflox and LepRbΔAR mice. Glucose tolerance 
test (GTT) for male and female ARflox and LepRbΔAR in normal chow (F) and high-fat diet (HFD, H). Body 
weight of male ARflox (n = 10), LepRbΔAR (n = 9), and female ARflox (n = 8), LepRbΔAR (n = 7) mice on 
HFD (G). Male ARflox = white squares, male LepRbΔAR = blue squares, female ARflox = white circles, female 





Figure 3.7: Male LepRbΔAR mice show increased ambulatory activity in the light phase. A,C, 
ambulatory activity measured in hourly mean ± SEM over 72 h (males, A, females, C). LepRbΔAR males 
show increased ambulatory activity compared to controls (light phase, mean ± SEM, B). Female ambulatory 
activity was not different (D). E, G, energy expenditure hourly mean ± SEM over 72 h (males, E, females, 
G). Energy expenditure was not significantly different in male or female LepRbΔAR mice compared to 















Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in people with ovaries 
who are of reproductive age, and is characterized by hyperandrogenism, oligo/anovulation, and/or 
polycystic ovaries. Many patients with PCOS also show adverse metabolic phenotypes, including 
central adiposity, insulin resistance, and glucose intolerance, which can exacerbate reproductive 
dysfunction. The elevated androgens in PCOS can act upon androgen receptors (AR), which are 
expressed in many reproductive and metabolic tissues, including the neuroendocrine hypothalamic 
sites that regulate the hypothalamic-pituitary-gonadal (HPG) axis and energy homeostasis. Yet it 
is not known which specific populations of neurons are impacted by female androgen excess. We 
and others have previously shown that AR is highly expressed in LepRb neurons, particularly in 
the arcuate (ARH) and ventral premammillary nuclei (PMv) of female mice. We hypothesize that 
leptin-receptor (LepRb) neurons participate in the pathogenesis of PCOS, as LepRb neurons are 
critical in the central regulation of energy homeostasis, and exert permissive actions on puberty 
and fertility. We have pre-natally androgenized (PNA) a mouse model of AR deletion specifically 
in LepRb cells (LepRbΔAR) and have conducted reproductive and metabolic phenotyping. As 
previously demonstrated, control PNA females show long periods of acyclicity, whereas 
LepRbΔAR PNA female mice show improved estrous cyclicity. Our findings indicate that a 
subpopulation of AR/LepRb cells mediate the effects of prenatal androgen excess on female 




Androgens at physiologic levels are crucial for the adequate functioning of female reproductive 
and metabolic physiology. Females typically have lower levels of androgens than males, but 
disorders of androgen excess can lead to reproductive and metabolic dysfunction. Polycystic ovary 
syndrome (PCOS) is one example of a disorder caused by pathogenic androgen excess. PCOS the 
most prevalent endocrine disorder among reproductive aged people with ovaries, with a prevalence 
ranging from 5-20% (1,2). PCOS is a heterogeneous disorder, with diagnostic criteria including 
oligo/anovulation, polycystic ovarian morphology, and/or hyperandrogenism (3,4). Elevated 
androgens are key in driving the reproductive, metabolic, and neuroendocrine abnormalities in 
PCOS patients, that include infertility, increased gonadotropin releasing hormone secretion, 
abdominal obesity, and insulin resistance (5,6).  
 
Androgens can act on steroid hormone receptors in many tissues via androgen receptors (AR), or 
estrogen receptors (ERα/β) after conversion to estradiol via aromatase. Androgens acting via AR, 
however, are critical in driving the pathophysiologic changes seen with female hyperandrogenism. 
Experimentally, treatment of female animal models with the non-aromatizable androgen 
dihydrotestosterone (DHT) either prenatally during late embryonic development (7-10), or 
prepubertally (11-14) leads to a phenotype in adults which mimics that of PCOS. While androgens 
acting via AR can impact different tissues to cause pathologic change, neuronal AR are key in 
driving reproductive dysfunction of hyperandrogenic females (15). Mice with neuronal deletion of 
AR exposed to androgen excess are protected from development of anovulation, polycystic 
ovaries, and metabolic abnormalities (16). However, it is not clear which population of AR-deleted 




We hypothesize that leptin-receptor (LepRb)-expressing neurons participate in the pathogenesis 
of female hyperandrogenism-induced reproductive dysfunction. Leptin is a hormone produced by 
white adipose tissue in proportion to the amount of adipose mass, and signals centrally via LepRb. 
Leptin confers status of peripheral energy stores to hypothalamic sites, permitting energetically 
demanding processes such as pregnancy and lactation to occur (17). Lack of either leptin or its 
receptor leads to obesity, diabetes, and infertility. We have previously shown that a subset of 
LepRb neurons coexpress AR in hypothalamic areas involved in the control of reproduction, and 
that loss of AR from LepRb neurons has minimal effects in typical female fertility (18). In this 
study, we examined whether LepRb-specific deletion of AR protects from the development of 




All research animals were acquired, used, and maintained in accordance with the National 
Research Council Guide for the Care and Use of Laboratory Animals (19), the US Public Health 
Service’s Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use 
of Laboratory Animals, as well as federal, state, and local laws. Procedures and protocols were 
approved by the University of Michigan Committee on Use and Care of Animals (IACUC, Animal 





LepRb-Cre (LepRbCre, JAX®  mice, B6.129-Leprtm3(cre)Mgmj/J, stock #032457 (20,21)), AR-flox 
(ARflox, 129-Artm1Verh/Sv, provided by Dr. S. Marc Breedlove, Michigan State University, with 
permission from Dr. Karel De Gendt, Catholic University of Leuven, Belgium, UFA ID: 16-
UFA03327 (22)), ROSA26-loxSTOPlox-eGFP-L10a (JAX® mice, B6;129S4-
Gt(ROSA)26Sortm9(EGFP/Rpl10aAmc/J, stock #024750 (23)), ROSA26-loxSTOPlox-ChR2-EYFP 
(JAX® mice, B6.Cg-Gt(ROSA)26Sortm32(CAG-COP4*H134R/EYFP)Hze/J, stock #024109 (24) ), and CD-1® 
IGS (Charles River Laboratories, Crl;CD1(ICR), stock #022) mice were housed in an Association 
for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited facility at 
the University of Michigan Medical School. Mice were housed in a 12:12 light/dark cycle 
environment with controlled temperature (21-23°C) and humidity (30-70%). Mice were provided 
water ad libitum and were fed a phytoestrogen-reduced diet (16% protein, 4.0% fat, 48.5% 
carbohydrate, Teklad 2916 irradiated global rodent diet, Envigo) or a phytoestrogen-reduced, 
higher protein and fat diet (19% protein, 9% fat, 44.9% carbohydrate, Teklad 2919 irradiated 
global rodent diet, Envigo) for breeding and lactating females. Phytoestrogen-reduced diets were 
used to avoid effects of exogenous dietary estrogens on reproductive or metabolic physiology of 
experimental mice. Genotyping was performed on DNA extracted from ear samples or tail tips 
obtained prior to weaning and at termination of experiments (RED Extract-N-Amp Tissue PCR 








Table 4.1: Primers used for genotyping 
Mice Primer Sequence Size (bp) 
LepRbCre 
Comm FOR 5’ TCC AAG AAG CCT CAA GGT TCC A 3’ 
Wt REV 5’ TCG TGT TGA AAT TTC TTC TTT CCA GA 3’ 
Cre REV 5’ ACG CAC ACC GGC CTT ATT CC 3’ 
Wt: 300 
Mutant: 200 





FOR 1 5’ GAG GGG AGT GTT GCA ATA CC 3’ 
FOR 2 5’ TCT ACA AAT GTG GTA GAT CCA GGC 3’ 





Wt FOR 5’AAG GGA GCT GCA GTG GAG TA 3’ 
Wt REV 5’CCG AAA ATC TGT GGG AAG TC 3’ 
Mut FOR 5’ ACA TGG TCC TGC TGG AGT TC 3’ 
Mut REV 5’ GGC ATT AAA GCA GCG TAT CC 3’ 
Wt: 297 
Mutant: 253  
 
LepRb-specific deletion of AR (LepRbΔAR) 
As previously described (18), mice with deletion of Ar specific to LepRb expressing neurons were 
generated by crossing LeprCre mice with ARflox mice (Arfl/fl females and Arfl/Y males). LepRbCre and 
LepRbΔAR mice were bred with Cre-dependent reporter mice (eGFP-L10a or ChR2-EYFP) to 
visualize LepRbCre expressing cells. For scientific rigor and reproducibility, and to generate 
adequate number of experimental and control mice from the same litter, we performed the same 
experiment in at least four independent cohorts of animals. Experimental animals were derived 
from multiple breeding pairs (a minimum of 5, but up to 15 breeding pairs per data set). Each 
graph shown includes animals derived from different pairs of breeders to account for differences 
in vivarium conditions. 
 
Prenatal androgenization 
To generate PNA female offspring, a LepRb(Cre/Wt);AR(fl/fl) female and a CD1 female were paired 
with a LepRb(Cre/Wt);AR(fl/Y) male. Mice that were heterozygous for Cre were mated to generate 
offspring homozygous for Cre, or wild-type for the Lepr gene in order to generate littermate 
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controls in experimental mice (Figure 4.1A). Timed pregnancy was established by monitoring of 
vaginal plugs the morning after introduction, and presence of a plug was considered gestational 
day 1. Males were removed from breeding cages by gestational day 15. On gestational days 16 
through 18, pregnant LepRb(Cre/Wt);AR(fl/fl) dams were injected subcutaneously with 225 µg of 
dihydrotestosterone (DHT, 5α-androstan-17β-ol-3-one) in 50 µL of sesame oil. Control dams were 
injected with sesame oil (vehicle, VEH). All breeding cages included a CD1 dam throughout 
pregnancy and lactation to provide maternal and nutritional support, in order to increase survival 
of PNA offspring. Combined litter size was adjusted to 8-10 pups per cage by postnatal day (PND) 
10, by culling CD1 offspring or male pups. Androgenization of PNA female offspring was 
assessed by measurement of anogenital distance (distance from base of the clitoris to midpoint of 
the anus) with digital calipers at PND 60 (Figure 4.1B). PNA treatment resulted in a significant 
increase in AGD in both genotypes (two-way ANOVA with Holm-Sidak correction, effect of 
treatment, P = 0.001, F = 11.57, DFn = 1, DFd = 59).  
 
Reproductive Phenotyping 
Pubertal onset was monitored daily beginning at PND 14, as advancement in vaginal opening (VO) 
has been reported with PNA treatment (9,25). Day of VO for PNA females was considered as a 
reddening of the narrowed and constricted vaginal opening at the base of the clitoris. Body weight 
was recorded at the time of VO. After VO, females were monitored daily for first estrus via vaginal 
lavage. First estrus was defined as the presence of predominantly keratinized epithelial cells for 
two consecutive days following the presence of predominantly leukocytes, or one day preceded by 




Adult estrous cyclicity was evaluated for 35 consecutive days beginning at 10 weeks of age by 
performing daily vaginal lavage. Estrous cycle stage was based on the proportion of leukocytes, 
epithelial, and keratinized epithelial cells (29). Evaluation of daily vaginal cytology was performed 
blinded. Estrous cycle length was determined by counting the number of days between the first 
day of estrous in each cycle, averaged per mouse. Number of cycles completed was considered as 
the number of complete estrous cycles completed in 35 days. Percentage of time spent in each 
cycle stage was calculated as the number of days in each stage (diestrus/metestrus, proestrus, or 
estrus), divided by 35 days.  
 
Metabolic Phenotyping  
Body weight of experimental and control mice was measured weekly beginning at weaning 
(postnatal day 21). Glucose levels were measured in blood samples obtained from tail-tip bleeding 
in female (n = 7-15 mice/group, 16-17 weeks of age) PNA and VEH LepRbΔAR and ARflox mice 
after an overnight fast (approximately 16 h) using a glucometer (OneTouch Ultra, LifeScan Inc). 
After fasting blood glucose was measured, mice received an intraperitoneal bolus of D-glucose in 
sterile saline (2 mg D-glucose/g body weight) at 0 min, and tail tip blood was collected for glucose 
levels at 15 min intervals for the first hour, and 30 min intervals for the second hour (2 h total). 
Body composition (fat and lean mass) was quantified in 19-week old female (n = 8-15 mice/group) 
PNA and VEH LepRbΔAR and ARflox mice using an NMR-based device (Minispec LF 90II, Bruker 
Optics). Body composition measurements were performed at the Michigan Mouse Metabolic 





Adult female mice were euthanized during diestrus (morning, 0900-1130 h), as determined by a 
vaginal lavage with predominately leukocytes (29) and confirmed by uterine weight below 100 
mg (30). Mice were deeply anesthetized with isoflurane and euthanized via decapitation. Trunk 
blood was collected and allowed to clot for 45 mins at room temperature, then centrifuged at 4°C 
for 20 mins at 3,000 x g, followed by collection of serum which was stored at -20°C. Pituitary 
glands were quickly collected, frozen on dry ice, and stored at -80°C until RNA extraction. 
 
A separate cohort of mice were deeply anesthetized with isoflurane and transcardially perfused 
with 0.1M PBS until liver and lungs cleared (about 1 minute), followed by 10% neutral buffered 
formalin (NBF) for 10 minutes. Perfused ovaries (n = 6-8/group) were transferred to 10% NBF 
and stored at 4°C until paraffin embedding at the University of Michigan Unit for Laboratory 
Animal Medicine In-Vivo Animal Core. Ovaries were sectioned at 4 µm in three series, 
deparaffinized and dehydrated, then stained with hematoxylin and eosin (H&E). 
 
Serum hormone assays 
Serum samples (n = 5-6/group) were sent to the University of Virginia Ligand Core for the 
following assays: ultra-sensitive mouse LH ELISA and mouse anti-Mullerian hormone (AMH) 
ELISA. LH was measured using an in-house method as previously described(31). The capture 
monoclonal antibody (anti-bovine LH beta subunit, 518B7, RRID: AB_2665514) was provided 
by Janet Roser, University of California, and the detection polyclonal antibody (rabbit LH 
antiserum, AFP240580Rb, RRID: AB_2665533) was provided by A.F. Parlow, National Hormone 
Peptide Program (NHPP). The HRP-conjugated goat anti-rabbit polyclonal antibody was 
purchased from DakoCytomation (Glostrup, Denmark; D048701-2). The assay standard was 
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mouse LH reference prep AFP5306A (NHPP). The limit of quantification (LoQ, lowest 
concentration that demonstrates accuracy within 20% of expected values) or functional sensitivity 
= 0.016 ng/mL, intra-assay %CV = 2.2%, inter-assay %CV 7.3% (low QC, 0.13 ng/ml), 5.0% 
(medium QC, 0.8 ng/ml) and 6.5% (high QC, 2.3 ng/ml). Antibodies used for assays are listed in 
Table 4.2.  
Table 4.2: Antibodies 
Peptide/Protein 
Target 
Antibody Name Cat # Species Raised In RRID 








LH Rabbit Anti-LH 
antiserum 
A.F. Parlow, National 
Hormone and Peptide 
Program, 
AFP240580Rb 






Aglient, P0448 Goat, polyclonal AB_2617138 
 
Quantitative PCR 
Pituitary from adult ARflox and LepRbΔAR (n = 3/group) mice were homogenized with Qiazol 
reagent (Qiagen), then total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen), including 
genomic DNA elimination, according to manufacturer’s protocol. First-strand cDNA was 
synthesized using SuperScript II reverse transcriptase (Invitrogen), oligo(dT), and 1000 ng of 
RNA. Gene expression was quantified in triplicate samples using quantitative real-time PCR 
(qPCR) with a CFX-384 Bio-Rad Real-Time PCR detection system. TaqMan Gene Expression 
MasterMix (Applied Biosystems) was used with primer/probes listed in Table 4.3. Transcript 
levels were normalized to the housekeeping gene Actb. and mRNA expression levels of target 
genes were determined by comparative cycle threshold (Ct) values, and relative to Actb gene copy 
number was calculated as 2-ΔΔCt. No differences were observed in relative expression of Actb 
between experimental groups.  
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Microscopy and Image Acquisition  
Digital images were acquired using an Axio Imager M2 (Carl Zeiss) with a digital camera 
(AxioCam, Zeiss) using Zen Pro 2 software (Zeiss), using the same magnification, illumination, 
and exposure time for each image of the same experiment.  
 
Illustration 
Adobe Photoshop and Illustrator software (Adobe Creative Cloud) were used to prepare digital 
images, including adjusting resolution to 300 dpi, adjustment of image size, addition of annotation 
and labels. Uniform adjustments were made to every image. Abbreviations are based on the Allen 
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Mouse Brain Atlas (postnatal day 56, coronal reference atlas, Allen Institute for Brain Science, 
Allen Mouse Brain Atlas, http://mouse.brain-map.org/static/atlas). 
 
Data Analysis 
Ovary sections from one series of H&E-stained slides were imaged at 5× magnification, and every 
fifth section was imaged for quantification of corpora lutea. All imaging, quantification, and 
analysis was performed blinded to genotype and treatment.  
 
Statistics 
Data are reported as mean ± standard error of the mean (SEM). Analysis was performed using 
GraphPad Prism software (Version 9). Data is presented as individual values with mean ± standard 
error of the mean (SEM). Data was analyzed for normal distribution using a Shapiro-Wilk test 
(significance level alpha 0.05). Non-normal data was log transformed prior to analysis. Two-way 
ANOVA with multiple comparisons and Holm-Sidak correction was used to analyze data, except 
for body weight and glucose tolerance test data which two-way ANOVA with repeated measures 
and Holm-Sidak correction was used. Exact post-hoc P values are reported and statistical 
significance is defined as P < 0.05. 
 
Results 
LepRbΔAR female mice show mild changes in body weight and glucose tolerance 
PNA treatment results in mild metabolic changes in female mice (8). We observed that all 
experimental groups had similar body weight at weaning (Figure 4.2A), and gained similar 
amounts of weight until 7 weeks of age (Figure 4.2B). At 7 weeks of age, there was a significant 
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difference in body weight between PNA groups, with LepRbΔAR PNA females weighing less than 
ARflox PNA mice (mean body weight ARflox PNA = 19.71 g, LepRbΔAR PNA = 17.82 g, P = 0.01, 
mean difference 1.90 g, SEM 0.53 g, t = 3.51, DF = 16.57, two-way ANOVA, repeated measures, 
with Holm-Sidak correction). Additionally, at 8 and 9 weeks of age, LepRbΔAR PNA females 
weighed significantly less than ARflox VEH mice (8 weeks, mean body weight ARflox PNA = 20.73 
g, LepRbΔAR PNA = 18.40 g, P = 0.04, mean difference 2.3 g, SEM 0.68 g, t =3.42, DF = 9.42, 9 
weeks, mean body weight ARflox PNA = 21.21 g, LepRbΔAR PNA = 19.01 g, P = 0.02, mean 
difference 2.2 g, SEM 0.62 g, t =3.53, DF = 11.44, two-way ANOVA, repeated measures, with 
Holm-Sidak correction). Body weight was not significantly different between groups before or 
after 7-9 weeks of age. Body composition, including fat and lean mass, was no different between 
groups at 19 weeks of age (Figure 4.3C). LepRbΔAR PNA mice displayed increased blood glucose 
at15 minutes post-injection during glucose tolerance testing compared to ARflox PNA mice (mean 
blood glucose ARflox PNA = 295 mg/dL, LepRbΔAR PNA = 410 mg/dL, P = 0.01, mean difference 
= 114 mg/dL, SEM 30 mg/dL, t = 3.75, DF = 16.37, Figure 4.3D). However, area under the curve 
of GTT was no different between groups (Figure 4.3E).  
 
Knockout of AR from LepRb neurons does not improve delay in sexual maturation with prenatal 
androgen excess 
Previous reports have described an advance in the day of VO in PNA mice. We did not observe a 
significant difference in day of VO in either PNA or VEH ARflox or LepRbΔAR females (Figure 
4.3A). Day of VO was similar in all groups (Figure 4.3B). While we did not observe differences 
in VO, day of first estrus was delayed in both ARflox or LepRbΔAR PNA groups compared to ARflox 
VEH controls (Figure 4.3C). Day of first estrus was also delayed by 8 days in LepRbΔAR VEH 
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females (Figure 4.3D), including the day at which half of LepRbΔAR VEH females reached first 
estrus (delayed by approximately 7 days). Despite this delay, almost all (94%) of LepRbΔAR VEH 
females reached first estrus by PND60. Only 45-50% of females in the PNA groups reached first 
estrus by PND60, indicating that deletion of AR from LepRb cells was not sufficient in preventing 
PNA-induced delays in sexual maturity.  
 
Estrous cycles are improved in PNA females with knockout of AR in LepRb neurons 
Consistent with our previous findings, VEH LepRbΔAR female mice display typical estrous cycles 
compared to ARflox controls, including similar cycle length, number of cycles, and percentage of 
time spent in each cycle stage (Figure 4.4A-D). PNA treatment induced acyclicity in ARflox mice, 
characterized by long periods of anestrus. Compared to VEH, ARflox PNA mice displayed 
increased cycle length, fewer number of cycles, a greater percentage of days in diestrus, and fewer 
percentage in estrus. In PNA LepRbΔAR mice, cycle length was similar to VEH treated mice, and 
was significantly different compared to ARflox PNA mice (average cycle length PNA ARflox 9.3 
days, PNA LepRbΔAR 6.2 days, P = 0.01, t = 3.2, DF = 37, Figure 4.4B). PNA LepRbΔAR mice also 
had a similar number of cycles as VEH treated mice, and displayed a significant improvement in 
number of cycles compared to PNA ARflox (mean number of cycles/35 days PNA ARflox = 3.5, 
PNA LepRbΔAR = 6, P = 0.005, t = 3.43, DF = 37, Figure 4.4C). Percentage of days spent in diestrus 
was significantly improved in PNA LepRbΔAR (percentage of days diestrus PNA ARflox = 84.7%, 
LepRbΔAR 69.7%, P = 0.03, t = 3.2, DF = 111). Likewise, PNA LepRbΔAR mice displayed 
improvements in percentage of days spent in estrus compared to PNA ARflox mice (percentage of 
days estrus PNA ARflox = 13.3%, LepRbΔAR = 24.2%, P = 0.03, t = 2.3, DF = 111). No differences 




Pituitary gene expression of gonadotropin subunits and sex steroid receptors  
To determine whether changes in pituitary gland gene expression could in part explain the 
improvement in PNA LepRbΔAR estrous cycles, we examined expression of selected genes 
associated with reproductive neuroendocrine control. No significant differences were observed in 
gonadotropin subunits Lhb, Fshb, or Cga among experimental groups relative to VEH ARflox mice 
(Figure 4.5A-C). Relative expression of Ar was increased in PNA LepRbΔAR compared to both 
ARflox VEH and PNA mice (mean difference relative expression PNA LepRbΔAR vs PNA ARflox = 
138%, SEM = 40%, P = 0.04, mean difference relative expression PNA LepRbΔAR vs VEH ARflox 
= 152%, SEM = 40%, P = 0.03, two-way ANOVA with Holm-Sidak correction, Figure 4.5D). 
Additionally, sex steroid receptors Esr1, and Pgr were unchanged (Figure 4.5E-F).  
 
Ovary histology 
Ovarian histology was examined for number of corpora lutea (Figure 4.6A-D), an endocrine 
structure that forms from follicular cells post-ovulation. Ovaries from all experimental groups 
displayed similar number of corpora lutea per ovary (Figure 4.6E).  
 
Serum LH concentrations 
Blood collected at time of sacrifice during the morning of diestrus was analyzed for concentration 







Disorders of androgen imbalance are common, particularly PCOS which is characterized by 
female androgen excess. Androgens acting via AR can exert significant effects on the central 
regulation of the neuroendocrine reproductive axis, and have been implicated in the pathogenesis 
of DHT-induced reproductive and metabolic changes in animal models. However, the specific 
neuronal populations impacted by androgen excess have not been fully examined. In this study, 
we have assessed the effect of deletion of AR in LepRb cells in the context of prenatal androgen 
excess. LepRb expressing neurons represent a metabolically and reproductively relevant 
hypothalamic population which are also sensitive to androgens, especially those in the ARH and 
PMv. We have shown that PNA LepRbΔAR female mice have improved estrous cycles compared 
to littermate controls.  
 
LepRbΔAR female mice also show mild metabolic changes, including decreased body weight 
between 7-9 weeks of age. The cause of this temporary difference in body weight is not known, 
but this is also the period where we observed differences in reproductive maturation. Yet, body 
weight gain did not differ outside of this period, which is consistent with previous descriptions of 
PNA female mice that show no difference in adult body weight (8,12). PNA treatment also has 
been shown to result in glucose intolerance and impairments in pancreatic islet function. While we 
did not observe glucose intolerance with PNA treatment in our studies, PNA LepRbΔAR mice did 
show increased blood glucose 15 min post-injection during glucose tolerance testing. These 
differences may represent changes in acute insulin response, and warrant future studies examining 




The PNA mouse model is useful in representing lean PCOS patients, who may develop mild 
metabolic impairments. However, many people with PCOS are obese (32), and obesity can 
exacerbate reproductive dysfunction. Therefore, it will be important to study the effects of 
androgen excess on LepRb neurons in a PCOS-like mouse model that develops a stronger 
metabolic phenotype. Prepubertal androgen excess (PPA) leads to increased body weight, 
adiposity, dyslipidemia, and glucose intolerance, in addition to the reproductive PCOS-like 
features observed in PNA treated mice (12,13). Additional studies involving LepRbΔAR and PPA 
treatment will further elucidate the role of LepRb cells in disorders of female hyperandrogenism.  
 
Previous reports found that PNA female mice have advanced age of VO (9). In our studies, 
however, we observed uniformly advanced day of VO in all experimental groups. This 
advancement was likely due to body weight at day of VO, as body weight is a known factor in the 
initiation of puberty (33). Since our experimental design involved rearing litters with dual dams, 
offspring were provided with greater nutrition which could explain the advancement of VO. While 
day of VO was no different, PNA treated mice show a clear delay in day of first estrus, which was 
not improved in LepRbΔAR mice. This suggests that AR in LepRb cells does not play a role in the 
pubertal deficits with prenatal exposure androgen excess, but may be relevant for adult fertility.  
  
Our ARflox control mice replicate the reported anestrus phenotype seen with PNA treatment, 
including long periods of diestrus, and fewer completed cycles. PNA LepRbΔAR mice displayed 
improved estrous cycles, although not fully restored to typical cycles observed in VEH treated 
mice. Since evaluation of estrous cycles via examination of vaginal cytology only indicates relative 
exposure of vaginal epithelium to fluctuating levels of estradiol, we examined additional markers 
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of reproductive axis function. Number of corpora lutea, a marker of post-ovulatory ovarian 
follicles, are either decreased (12,34,35), or unchanged in PNA rodents (9). We did not observe a 
difference in the number of corpora lutea with PNA treatment. However, other aspect of ovarian 
health may be affected. For example, increased follicular atresia and greater amount of unhealthy 
antral follicles are found in PNA ovaries. Prenatal androgen excess has also been shown to deplete 
the pool of primordial follicles in sheep (36). Therefore, further examination of follicle numbers 
and markers of morphological health are warranted.  
 
In addition to altered ovarian morphology, PCOS patients and PCOS-like animal models show 
abnormal neuroendocrine function. Prenatal or peripubertal exposure to androgen excess results 
in persistently elevated GnRH pulse frequency and impaired hypothalamic sensitivity to the 
negative feedback effects of progesterone (7,25,37,38). Increased GnRH neuron activity is driven 
by increased excitatory GABAergic inputs (10,39), particularly by ARH GABAergic neurons 
which also show reduced progesterone receptor expression (40). Furthermore, the increase in 
GABAergic inputs to GnRH neurons is AR dependent, and is prevented by treatment with the AR-
antagonist flutamide (35). It is possible that AR-expressing LepRb neurons are part of the ARH 
GABAergic population innervating GnRH neurons. However, a greater portion of LepRb neurons 
express AR in the female PMv. As opposed to the ARH, the PMv is highly glutamatergic, and 
PMv LepRb neurons directly innervate GnRH neurons (41). However, glutamatergic inputs to 
GnRH neurons are not changed with PNA treatment (40). Further studies will be needed to 
evaluate the impact of PNA on LepRb neuron projections, and whether GABAergic and/or 
glutamatergic projections are differently affected. Additionally, it will be important to determine 
if direct projections to GnRH neurons, or indirect projections to upstream reproductively-relevant 
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neurons (i.e., kisspeptin/neurokinin/dynorphin, and/or agouti-related peptide/neuropeptide Y) are 
changed in PNA LepRb female mice. 
 
As a consequence of increased GnRH pulse frequency, PCOS patients display altered patterns of 
gonadotropin release (42,43). LH hypersecretion is present in a majority of people with PCOS 
(44), and is elevated relative to FSH. However, LH levels in PNA mice show conflicting results. 
An increase in mean LH at time of sacrifice and increased LH pulses (10,40), or no changes in LH 
have been described in PNA mice (12,45). In our studies, we did not observe a difference in mean 
LH at time of sacrifice in gonadally intact diestrus mice. Additionally, we did not observe changes 
in pituitary gland Lhb or Fshb transcript levels. It will be interesting to assess pattern of LH pulses 
and/or LH surge profiles in PNA LepRbΔAR mice to determine whether deletion of AR in LepRb 
cells prevents elevated LH pulse frequency with PNA.  
 
In summary, these studies demonstrate that androgen action via AR in LepRb cells is important 
for the development of some of the reproductive features of female hyperandrogenism, including 
anestrus. Future studies will be needed to determine the mechanism of AR action in LepRb 
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Figure 4.1: Experimental design and validation of prenatal androgenization. A, illustration of 
experimental setup. A sire and a dam heterozygous for LeprCre and hemizygous or homozygous for Arflox 
were mated to generate littermate controls with two copies of LeprCre (LepRb-specific AR deletion, 
LepRbΔAR) and two LeprWt alleles (ARflox). Dams were treated with dihydrotestosterone (DHT) or oil 
(vehicle, VEH) on embryonic day (E)16, 17, and 18, and prenatally androgenized (PNA) and control VEH 
female offspring were used for experiments. B, scatter plot graph showing anogenital distance (AGD) of 
adult postnatal day 60 mice (mean ± SEM, ARflox VEH n = 11, ARflox PNA n = 11, LepRbΔAR VEH n = 24, 
LepRbΔAR PNA n = 17). Effect of treatment was statistically significant (two-way ANOVA with Holm-










Figure 4.2: Mild changes in body weight and glucose tolerance were observed in LepRΔAR PNA mice. 
A, scatter plot graph of body weight of experimental mice at weaning day/postnatal day 21 (mean ± SEM, 
ARflox VEH n = 10, ARflox PNA n = 12, LepRbΔAR VEH n = 18, LepRbΔAR PNA n = 13). B, line graph of 
weekly body weight from 3 to 15 weeks of age (mean ± SEM, ARflox VEH n = 7, ARflox PNA n = 9, 
LepRbΔAR VEH n = 15, LepRbΔAR PNA n = 10). LepRΔAR PNA mice weighed significantly less than ARflox 
PNA mice at 7 weeks (mean difference 1.9 g, SEM = 0.53 g, P = 0.01), and less than ARflox VEH mice at 
8 weeks (mean difference 2.3 g, SEM = 0.68 g, P = 0.04), and 9 weeks (mean difference 2.2 g, SEM = 0.62 
g, P = 0.02). Body weight gain analyzed by two-way ANOVA with repeated measures and Holm-Sidak 
correction. C, scatter plot graph of fat and lean mass of 19 week old mice (mean ± SEM, ARflox VEH n = 
8, ARflox PNA n = 8, LepRbΔAR VEH n = 15, LepRbΔAR PNA n = 10). D, line graph showing levels of blood 
glucose during glucose tolerance testing of 16-17 week old mice (mean ± SEM, ARflox VEH n = 7, ARflox 
PNA n = 9, LepRbΔAR VEH n = 15, LepRbΔAR PNA n = 10). LepRbΔAR PNA mice show greater blood 
glucose compared to ARflox PNA mice 15 mins after i.p. injection of glucose (mean difference 114 mg/dL, 
SEM = 30 mg/dL, P = 0.01, two-way ANOVA with repeated measures and Holm-Sidak correction). D, 











Figure 4.3: LepRb-specific deletion of AR does not impact pubertal timing and does not rescue 
delayed sexual maturity of PNA mice. A-B, scatter plot graphs of day of vaginal opening (VO) and body 
weight at day of VO (mean ± SEM, ARflox VEH n = 7, ARflox PNA n = 11, LepRbΔAR VEH n = 19, LepRbΔAR 
PNA n = 12). C, scatter plot graph of day of first estrus (mean ± SEM, ARflox VEH n = 7, ARflox PNA n = 
5, LepRbΔAR VEH n = 18, LepRbΔAR PNA n = 6). First estrus was monitored up until postnatal day 60 
(dotted line). Day of first estrus was delayed in VEH LepRbΔAR vs ARflox mice (mean difference = 8 days, 
SEM = 1.7 days, P = 0.04, two-way ANOVA with Holm-Sidak correction). First estrus was also delayed 
in ARflox PNA compared to ARflox VEH (mean difference = 15.5 days, SEM = 4.5 days, P = 0.007, two-
way ANOVA with Holm-Sidak correction), and in LepRbΔAR PNA compared to LepRbΔAR (mean difference 
= 11.4 days, SEM = 3.6 days, P = 0.01, two-way ANOVA with Holm-Sidak correction). D, percentage of 
females who had first estrus plotted by postnatal day. Dotted line indicates when 50% of each group had 
first estrus. 50% of LepRbΔAR VEH mice reached first estrus 7 days later than ARflox VEH mice (ARflox 
VEH 50% reached first estrus = 32.5 days, LepRbΔAR VEH 50% reached first estrus = 39.5 days). Note that 





Figure 4.4: Deletion of AR from LepRb cells improves estrous cycles of PNA mice. A, representative 
cycles shown for experimental and control groups. Littermate controls are shown side by side. M/D = 
metestrus/diestrus, P = proestrus, E = estrus. B, scatter plot graph of average cycle length (mean ± SEM, 
ARflox VEH n = 7, ARflox PNA n = 9, LepRbΔAR VEH n = 15, LepRbΔAR PNA n = 10). ARflox PNA mice had 
longer cycle length compared to ARflox VEH (mean difference = 4.1 days, SEM = 1.0 days, P = 0.002, two-
way ANOVA with Holm-Sidak correction). LepRbΔAR PNA mice showed improved cycle length compared 
to ARflox PNA (mean difference = 3.1 days, SEM = 0.9 days, P = 0.01, two-way ANOVA with Holm-Sidak 
correction). C, scatter plot graph of average number of cycles completed in 35 days. ARflox PNA mice 
completed fewer cycles than ARflox VEH (mean difference = 3.1 cycles, SEM = 0.77 cycles, P = 0.001, 
two-way ANOVA with Holm-Sidak correction). LepRbΔAR PNA mice showed improved number of cycles 
compared to ARflox PNA (mean difference = 2.4 cycles, SEM = 0.71 cycles, P = 0.005, two-way ANOVA 
with Holm-Sidak correction). D, scatter plot graph of percentage of days spent in each cycle stage (mean ± 
SEM of %metestrus/diestrus, %proestrus, and %estrus). ARflox PNA mice spent greater percentage of days 
in diestrus and fewer percentage of days in estrus compared to ARflox VEH (%diestrus mean difference = 
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32%, SEM = 5.0%, P < 0.0001, %estrus mean difference = 27%, SEM = 5.0%, two-way ANOVA with 
Holm-Sidak correction). LepRbΔAR PNA mice showed improvements in percentage of days in diestrus and 
estrus compared to ARflox PNA (%diestrus mean difference = 15%, SEM = 4.6%, P = 0.03, %estrus mean 























Figure 4.5: Expression of pituitary gland genes in control and experimental mice. A-F, scatter plot 
graphs of gene expression normalized to housekeeping gene beta-actin (Actb), and relative to ARflox VEH. 
Select genes shown include A, luteinizing hormone, beta subunit (Lhb), B, follicle stimulating hormone, 
beta subunit (Fshb), C, glycoprotein hormones alpha chain (Cga), D, androgen receptor (Ar), E, estrogen 
receptor α (Esr1), and F, progesterone receptor (Pgr). Data presented as mean ± SEM and analyzed by two-










Figure 4.6: Ovarian histology and corpora lutea quantification. A-D, images of histologic hematoxylin 
and eosin-stained sections of ovaries from VEH ARflox (A), VEH LepRbΔAR (B), PNA ARflox (C), and PNA 
LepRbΔAR (D) mice. CL, corpus luteum. Scale bar = 500 µm. E, scatter plot graph of number of corpora 
lutea per ovary. Data presented as mean ± SEM and analyzed by two-way ANOVA with Holm-Sidak 
























Figure 4.7: Serum LH concentrations. Scatter plot graph of serum levels of luteinizing hormone (LH) at 
time of sacrifice during the morning of diestrus. Data presented as mean ± SEM and analyzed by two-way 



































Androgens are essential hormones in both male and female physiology, with effects on multiple 
systems. Imbalance of androgens outside the homeostatic range has both reproductive and 
metabolic consequences for both sexes. In the second chapter, we show that the brain is a highly 
androgen-responsive organ, and expresses the androgen receptor (AR) during a critical window of 
prepubertal development in male and female mice. We further describe brain regions that may 
preferentially respond to androgens, rather than estrogens. For example, the ventral 
premammillary nucleus (PMv) shows dense expression of AR in both sexes, yet it is relatively low 
in ERs, and the enzyme aromatase. Since AR was heavily expressed in areas with known 
contribution to the regulation of metabolism and reproduction, particularly nuclei that densely 
express the leptin receptor (LepRb), we conducted a thorough characterization of the expression 
of AR in LepRb cells in mice. Major coexpression of LepRb and AR was observed in the arcuate 
(ARH) and PMv of both sexes. Deletion of AR from LepRb cells, causes sex-specific changes in 
the neuroendocrine reproductive axis, locomotor activity, and body composition. We further 
evaluated if deletion of AR from LepRb neurons protects female mice from hyperandrogenism-
induced reproductive deficits in a model of prenatal androgen excess. We found that deletion of 
AR from metabolic and reproductively relevant LepRb neurons improved estrous cycles in 
prenatally androgenized female mice. Our findings highlight that LepRb neurons represent an 
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important target of androgen action in the brain, particularly with regards to regulation of the 
hypothalamic-pituitary-gonadal axis and some aspects of metabolic regulation. In previous 
chapters, I discussed the relevance of all the specific findings of my studies and the contribution 
to the field. In this chapter, I will focus on the limitations of our studies, propose alternatives and 
future directions 
 
Limitations of Animal Models and Proposed Alternative Approaches 
The Cre/loxP mouse model used in these studies was effective in reducing AR expression in 
LepRb-Cre cells. However, since LepRb is expressed during embryonic development (1,2), Cre-
induced deletion of AR occurred during active periods of neurogenesis and organization of the 
nervous system. We did not observe a difference in the number of LepRb neurons in LepRbΔAR 
mice, although it is possible other receptors could compensate for the loss of AR (i.e., ERα/β, 
GPER). Therefore, it is possible that deletion of AR in LepRb neurons in adulthood may induce a 
stronger phenotype as observed in other hypothalamic systems. For example, mice with embryonic 
deletion of AgRP only show minor differences in feeding behavior, yet mice with adult deletion 
of AgRP show drastically reduced food intake, leading to starvation (3). Furthermore, deletion of 
AR during embryonic development does not allow for the examination of the effects of androgens 
during different periods of development and maturation. This deficiency became clear when we 
compared results from distinct experiments. In chapter 3, we observed that LepRbΔAR female mice 
only developed changes in lean mass later in adult life, whereas in chapter 4, LepRbΔAR female 
mice exposed to androgen excess during embryonic development showed improvements in estrous 
cycles during adulthood. It will be important to determine if AR is deleted from LepRb neurons 




Additionally, with deletion of AR from all LepRb-expressing cells, it is difficult to determine the 
specific nucleus and/or neurons that are responsible for the observed phenotype of LepRbΔAR mice. 
To overcome the limitations of a conditional Cre model, CRISPR (clustered regularly interspaced 
short palindromic repeats)-Cas9 technology can be used to temporally and spatially refine the 
deletion of AR. The endonuclease CRISPR-associated protein 9 (Cas9) in the presence of a guide 
RNA, recognizes the corresponding sequence of target DNA, inducing double-stranded breaks 
which, when repaired by nonhomologous end-joining, results in genomic insertions or deletions, 
frame-shift mutations, and knockout of a target sequence (4). Stereotactic delivery of an AAV 
vector containing guide RNA targeting AR injected into specific hypothalamic nuclei (i.e., ARH 
or PMv) of LepRbCre;lox-STOP-lox-Cas9 mice (5) will result in excision of AR from only Cas9-
expressing LepRb neurons. This approach will restrict deletion of AR to LepRb neurons of specific 
nuclei in prepubertal or adult mice, allowing for a more precise interpretation of the role of AR in 
distinct hypothalamic nuclei and their individual contribution to the regulation of metabolism and 
reproduction. This approach will not allow, however, evaluation of the effects of AR deletion in 
developing mice.  
 
In our studies, we have used a mouse model with deletion of exon 2 of Ar, resulting in a premature 
stop codon and severely truncated protein. Theoretically, expression of only exon 1 and the N-
terminal it encodes, could result in a fragment of AR capable of interacting with other signaling 
pathways. Ligand-independent activation of AR through the N-terminal domain is possible via 
MAPK and JAK/STAT3 (6). However, it is unlikely that the AR N-terminal remains in LepRbΔAR 
mice, because the anti-AR antibody used to validate deletion of AR in LepRb-Cre cells targets the 
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N-terminal of AR (7). We observed a very low percentage of cells expressing Cre-induced reporter 
gene and AR-ir in LepRΔAR mice. While well-defined AR genomic and membrane signaling via 
alternative pathways is reduced in exon 2 knockouts, novel non-AR receptors that are activated by 
androgens (i.e., TRPM8, OXER1, GPRC6A, and/or ZIP9) may still allow for androgenic effects. 
Further work is needed to characterize the multiple pathways by which androgens can modulate 
intracellular signal transduction, and the specific consequences of each pathway.  
 
Impacts of Androgen Excess in Females 
The PNA mouse model replicates many of the reproductive characteristics experienced by patients 
with polycystic ovary syndrome (PCOS), including acyclicity and altered neuroendocrine output 
from the HPG axis. Reduced fertility has also been reported in PNA female mice (8,9). However, 
PNA mice display a narrowed vaginal opening due to timing of androgen excess on development 
of the external genitalia. The narrowed vaginal opening in PNA females may impact copulation 
and hinders parturition, preventing analysis of fertility in our model.  
 
A significant portion of PCOS patients also exhibit metabolic abnormalities, including obesity, 
insulin resistance, and type 2 diabetes. However, these metabolic changes are not replicated with 
exposure to androgen excess during late fetal development in rodents. Treatment of female mice 
at PND21 with the non-aromatizable androgen DHT also induces a PCOS-like phenotype in mice 
(10). These pre-pubertal androgenized (PPA) female mice exhibit acyclicity, anovulation, a 
polycystic ovary phenotype, and show changes in metabolic physiology, including body mass, 
adiposity impaired glucose tolerance and dyslipidemia (10-14). The PPA mouse model is useful 
for studies focused on a subpopulation of PCOS patients with metabolic dysfunction, and may be 
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more relevant in studies focused on LepRb neurons that are critical in regulation of body mass and 
adiposity. Determining if LepRbΔAR female mice exposed to androgen excess peripubertally show 
a similar protection in estrous cycles as PNA LepRbΔAR mice would be informative and warrants 
further investigation. Additionally, it would be important to evaluate if deletion of AR from LepRb 
neurons protects from the increases in body mass and adiposity seen in PPA mice. The PPA mouse 
model would also allow for evaluation of fertility.  
 
The effects of androgen excess during critical fetal and pubertal windows of development on 
female reproductive physiology have been well described. However, there are few animal models 
used to investigate the effects of androgen excess in adult females. Treatment of adult female mice 
with DHT will allow for the further distinction between the roles of androgens acting during 
critical windows of permanent developmental organization and pubertal activation compared to 
actions on adult reproductive and metabolic physiology. This strategy will more closely mimic 
those who experience androgen excess during adult life, and can distinguish which changes are 
permanent or reversible.  
 
Potential Mechanisms of AR Action in LepRb-Expressing Cells 
While we have shown that deletion of AR from LepRb cells impacts typical physiology, the 
intracellular mechanism underlying the AR and LepRb interaction has yet to be determined. The 
LepRb contains an intracellular signaling domain, capable of activating different signaling 
pathways, including JAK/STAT3 or STAT5, PI3K/AKT, MAPK, and AMPK (15). It has been 
indicated that T can interact with tyrosine residue 985 of LepRb, which facilitates inhibitory 
actions through SHP2 and SOCS3 (16). Additionally, AR has the ability to enhance LepRb-
176 
 
induced STAT3 signaling in vitro (17). Further studies are needed to evaluate if the regulatory 
mechanisms that exist between AR and LepRb are also observed in vivo. 
 
Final Conclusions 
I have shown here that LepRb neurons are an important target of androgen action in the 
hypothalamic control of the reproductive neuroendocrine axis and some aspects of metabolic 
regulation, and that AR in LepRb neurons may play a role in the pathogenesis of PCOS. Additional 
work will be needed to characterize the different neurochemical phenotypes of AR-expressing 
neurons, and to delineate their role in reproductive and metabolic physiology. A complete 
understanding of the cell-, tissue-, and organ-specific effects of androgens is fundamental for 
developing better treatments for those experiencing hypo or hyperandrogenism, as well as for 
gender-affirming hormone therapy designed for transmen taking T, or transwomen taking AR 
antagonists. Further defining the targets of androgen action via AR in the brain will contribute to 
a better understanding of the neuroendocrine control of reproduction and metabolism, and will 
open opportunities for development of therapeutic interventions to overcome disorders of 
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LIST OF ABBREVIATIONS 
 
Name Abbreviation 
Androgen receptor AR 
Androgen receptor knockout ARKO 
Balanopreputial separation BPS 
Corpus luteum/corpora lutea CL 
Dopamine transporter DAT 
Estrus E 
Enhanced green fluorescent protein eGFP 
Estrogen receptor, alpha ERα 
Estrogen receptor, beta ERβ 
Granulosa cell GC 
Hypothalamic-pituitary-gonadal  HPG 
Leydig cell LC 




Polycystic ovary syndrome PCOS 
Prenatal androgenization PNA 
Postnatal day PND 
Sertoli cell SC 
Theca cell TC 
Testicular feminization Tfm 
Vehicle treated VEH 
Vaginal opening VO 
    
Brain Regions Abbreviation 
Anterior cingulate cortex, dorsal ACAd 
Anterior cingulate cortex, ventral ACAv 
Nucleus accumbens ACB 
Anterodorsal nucleus of the thalamus AD 
Anterior hypothalamic nucleus AHN 
Alveus alv 
Nucleus ambiguus  AMB 
Olfactory nucleus, anterior AON 
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Area postrema AP 
Cerebral aqueduct AQ 
Arcuate hypothalamic nucleus  ARH 
Anteroventral nucleus of the thalamus AV 
Anteroventral periventricular nucleus AVPV 
Bed nucleus of stria terminalis, principal nucleus  BSTpr 
Central canal of the medulla c 
Field CA1 CA1 
Field CA2  CA2 
Field CA3  CA3 
Arcuate hypothalamic nucleus, caudal cARH 
Corpus callosum cc  
Genu of corpus callosum ccg 
Cochlear nuclei  CN 
Cortical amygdalar area  COA 
Cerebral peduncle cpd 
Dentate gyrus DG 
Dorsomedial nucleus of the hypothalamus  DMH 
Dorsal motor nucleus of vagus nerve  DMX 
Dorsal nucleus raphe  DR 
Dorsal tegmental nucleus  DTN 
External medullary lamina of the thalamus em 
Entorhinal area  ENT 
Endopiriform  EP 
Fasiculus retroflexus fr 
Fornix fx 
Induseum griseum  IG 
Intermediate reticular nucleus IRN 
Lateral hypothalamic area  LHA 
Lateral olfactory tract lot 
Lateral reticular nucleus LRN 
Lateral septal nucleus, caudodorsal  LSc 
Lateral septal nucleus, rostroventral  LSr 
Arcuate hypothalamic nucleus, mid/tuberal mARH 
Magnocellular reticular nucleus MARN 
Medial amygdalar nucleus, posterodorsal MEApd 
Medial geniculate complex MG 
Medial lemniscus ml 
Motor cortex MO 
Secondary motor area MOs  
Medial preoptic nucleus MPN 
Medial preoptic area, anterior  MPOa 
Medial preoptic area, posterior  MPOp 
Medial septal nucleus MS 
Medial vestibular nucleus MV 
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Nucleus of the solitary tract  NTS 
Optic tract opt 
Olfactory tubercle OT 
Vascular organ of the lamina terminalis OVLT 
Posterior amygdala  PA 
Periaqueductal gray, ventrolateral  PAGvl 
Parabrachial nucleus  PB 
Parafasicular nucleus PF 
Piriform  PIR 
Dorsal premammillary nucleus  PMd 
Ventral premammillary nucleus  PMv 
Presubiculum / Subiculum  PRE/SUB 
Pontine reticular nucleus  PRN 
Nucleus prepositus PRP 
Principal sensory nucleus of the trigeminal  PSV 
Parataenial nucleus PT 
Periventricular hypothalamic nucleus  PV  
Paraventricular hypothalamic nucleus  PVH 
Paraventricular nucleus of the thalamus  PVT 
Pyramid pyr 
Arcuate hypothalamic nucleus, rostral rARH 
Nucleus of reuniens  RE 
Rhomboid nucleus RH 
Red nucleus  RN 
Subparaventricular zone  SBPV 
Suprachiasmatic nucleus  SCH 
Ventral spinocerebellar tract sctv 
Subfornical organ  SFO 
Septohippocampal nucleus  SH 
Stria medullaris sm 
Spinal nucleus of the bulbocavernosus SNB 
Superior olivary complex  SOC 
Stria terminalis st  
Subthalamic/ Parasubthalamic, caudal  STN/PSTN 
Supramammillary nucleus  SUM 
Taenia tecta  TT 
Tuberal nucleus  TU 
Third ventricle V3 
Fourth ventricle  V4 
Facial motor nucleus  VII 
Facial nerve VIIn 
Lateral ventricle VL 
Ventromedial hypothalamic nucleus, central VMHc  
Ventromedial hypothalamic nucleus, dorsomedial VMHdm 
Ventromedial hypothalamic nucleus, ventrolateral  VMHvl 
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Ventral medial nucleus of the thalamus VMHvl 
Vestibular Nucleus  VNC 
Ventral posterior complex of the thalamus VP 
Ventral tegmental area  VTA 
Hypoglossal nucleus  XII 
Zona incerta ZI 
    
Hormones/Peptides  Abbreviation 
Agouti-related peptide AgRP 
Anti-Mullerian Hormone AMH 
Cocaine- and amphetamine-regulated transcript CART 
Dihydrotestosterone DHT 
Follicle stimulating hormone FSH 
Gonadotropin releasing hormone GnRH 
Insulin-like growth factor 1 IGF1 
Kisspeptin/neurokinin/dynorphin KNDy 
Luteinizing hormone LH 
Neuropeptide Y NPY 
Pro-opiomelanocortin POMC 
Testosterone T 
    
Methods Related Abbreviation 
Association for Assessment and Accreditation of Laboratory Animal Care  AAALAC 
Avidin-biotin AB 
Analysis of variance ANOVA 
Area under the curve AUC 
Comprehensive Laboratory Monitoring System  CLAMS 
Diethyl pyrocarbonate DEPC 
Dithiothreitol DTT 
Energy expenditure EE 
Enzyme-linked immunosorbent assay ELISA 
Gonadectomy GDX 
Glucose tolerance test GTT 
Haematoxylin and eosin stain H&E 
High fat diet HFD 
Institutional Animal Care and Use Committee  IACUC 
Integrated optical density IOD 
Immunoreactivity ir 
Lean body mass LBM 
Liquid chromatography–mass spectrometry  LC/MS 
Neutral buffered formalin NBF 
Optimal cutting temperature compound OCT 
Orchidectomy ORX 
Ovariectomy OVX 
Phosphate-buffered saline PBC 
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Quantitative polymerase chain reaction qPCR 
Region of interest ROI 
Real-time polymerase chain reaction RT-PCR 
Standard error of the mean SEM 
Sodium chloride-sodium citrate buffer SSC 
Tyramide signal amplification TSA 
Volume carbon dioxide produced VCO2 
Volume oxygen consumed VO2 
 
 
 
 
 
 
 
